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Chapter 1
Improvements in kidney transplantation
Kidney transplant patients are no longer balancing on the edge of life and death, 
residing in a plastic bubble for weeks after their transplantation in order to protect them from 
infections under their heavy immunosuppression. This intensive immunosuppression was deemed 
necessary to prevent them from losing their graft to hyper acute antibody-mediated or acute 
T-cell mediated rejection.(1, 2) Nowadays, quality of life and outcomes of kidney transplant 
patients are significantly improved by the implementation of pre-emptive transplantation and 
careful human leukocyte antigen (HLA)-matching(3-5), but mostly by the development of a 
greater therapeutic arsenal, including calcineurin inhibitors (CNIs).(6-8) The downside of potent 
immunosuppressive reagents like CNIs is the increased risk of infections and malignancies.(9, 
10) In addition, CNIs are known for their nephrotoxicity, which can cause kidney graft failure.
(11, 12) Another problem of CNI-based regimens is the insufficient prevention of the formation 
of donor-specific anti-HLA antibodies (DSA) and therefore antibody-mediated rejection, which 
also decreases kidney graft survival.(13-15) Clearly, there is still room for improvements in the 
treatment of kidney transplant patients. The development of immunosuppressive drugs that 
have less adverse effects, but are more potent in preventing the development of DSA could 
contribute to improved long-term outcomes in kidney transplantation.
The immune reaction of T cells
Understanding the basic principles of the immune reaction of T cells is important to 
comprehend alloreactive processes in kidney transplantation, because the current most widely-
used immunosuppressive regimen targets predominantly this cell population, but not its interaction 
with other immune cells. This regimen consists of anti-CD25 (anti-IL-2 receptor) induction therapy 
with basiliximab, and maintenance therapy with the CNI tacrolimus, the cell cycle inhibitor 
mycophenolate mofetil (active compound = mycophenolic acid) and glucocorticoids. This 
combination intervenes on different points in the hereafter described immune cascade in T cells 
(Figure 1)(16) and effectively blocks the functions of aggressive cytotoxic T cells,(17) one of the 
key mediators in a classical T-cell mediated rejection response. 
The immune reaction in T cells comprises 3 signals (Figure 1): 1) T-cell activation via 
the T-cell receptor, 2) costimulation, and 3) cytokine receptor up-regulation and cytokine 
production. In detail, the T-cell receptor is activated by antigen bound to an HLA molecule on 
the antigen-presenting cell (APC), the first signal. In case of transplantation, this APC can be from 
the recipient that presents antigen in an indirect manner or from the allograft donor in the case 
of direct antigen presentation.(18) For proper T-cell activation, a second signal, the so-called 
costimulatory signal, is required. This second signal is provided when multiple costimulatory 
molecules expressed on APCs interact with their specific receptors on the surface of T cells. 
Important costimulatory molecules are CD80 and CD86 (also named B7-1 and B7-2, respectively) 
expressed by APCs, which activate T cells by binding their CD28. This T-cell activation leads to the 
third signal in the immune cascade: production of soluble activation proteins called interleukins 
(IL). Mainly the production of IL-2 and the up regulation of the IL-2 receptor, resulting in abundant 
IL-2 production, are important for the positive feedback loop that augments the T-cell response. 
After T-cell activation, the co-inhibitory molecule CTLA-4 is up regulated on the surface of T-cells 
to control this augmented activation. The CTLA-4 molecule has a much stronger interaction 
11
C
ha
pt
er
1
General introduction and outline of the thesis
with CD80/86 than CD28 and has an inhibitory effect on activated T cells. Subsequently, T-cell 
activation will be dampened through this CD80/86–CTLA-4 pathway. 
CD80/86
CD28
HLA
TCR
T cell
Antigen presenting cell
2+Ca
2+Ca
Calcineurin
NFAT P
P
P
G1
G2
M
S Cell
cycle
IL-2R (CD25)
IL-2
IL-2 mRNA
MTOR
Apoptotic signals
Transcription
NFkB NFkB
P
NFATP
P
Stabilize
mRNA IL-2
Glucocorticoids
GC-receptor
Tacrolimus Basiliximab
Mycophenolic acid
mTOR inhibitor
Belatacept
2
1
3
CD80/86
CD28
Belatacept
T cell 
anergy
T cellAPC
HLA TCR
Figure 1. Immune reaction by T cells and different interference points of immunosuppressive drugs. 
The immune reaction comprises 3 signals: 1) T-cell activation via the T-cell receptor, 2) costimulation, and 3) 
cytokine receptor upregulation and cytokine production. The current most widely used immunosuppressive 
regimen in kidney transplantation consists of anti-CD25 induction therapy with basiliximab, the calcineurin 
inhibitor  tacrolimus, the cell cycle inhibitor mycophenolate mofetil (active compound = mycophenolic acid) 
and glucocorticoid maintenance therapy, and intervenes on different points in above described immune 
cascade. Belatacept, an alternative immunosuppressant for tacrolimus, binds CD80 and CD86 on antigen-
presenting cells, and consequently prevents signal 2 necessary for T-cell activation, leading to T-cell anergy.
APC, antigen-presenting cells; Ca2+, calcium ion; CD, cluster of differentiation; G, Gap phase; HLA, human 
leukocyte antigen; IL, interleukin; M, mitosis phase; mRNA, messenger ribonucleic acid; mTOR, mammalian 
target of rapamycin; NFAT, nuclear factor of activated T cells; NFkB, nuclear factor kappa B; P, phosphor; S, 
synthesis phase; TCR, T-cell receptor
12
Chapter 1
Follicular T helper cells, a recently discovered T helper cell subset
As previously mentioned, the current most widely-used immunosuppressive regimen in 
kidney transplantation is less effective against DSA formation resulting from T-B cell interactions 
(19-21) than in suppressing cytotoxic T cells. Over the last decade, the importance of B cells is 
recognized in acute alloreactivity after transplantation.(15, 22-28) B cells are present in biopsies 
of apparent T cell-mediated rejections, probably functioning as APCs.(23-28) Furthermore, B 
cells produce important interleukins for T-cell activation, proliferation and differentiation, like IL-6 
and TNFα.(29, 30)
Important mediators in B-cell activation and differentiation are follicular T helper (Tfh) 
cells. These specialized cells support differentiation and immunoglobulin production when 
co-cultured with B cells (Figure 2), and express high levels of CXCR5, which, in conjunction 
with the loss of CCR7, enables them to localize to B-cell follicles and germinal centers of 
secondary lymphoid organs during T-cell-dependent immune responses.(31, 32) The capacity 
of Tfh cells to provide B cell-help depends upon the acquisition of molecules that are known 
to play functional roles in T–B cell interactions, like the costimulatory molecules CD40 ligand, 
inducible costimulator (ICOS), programmed death 1 (PD-1), and the cytokine interleukin (IL)-21 
(Figure 2). The transcriptional suppressor B cell lymphoma-6 (Bcl-6) is the master regulator for 
Tfh-cell differentiation.(32-34) Recent identification of these Tfh cells in the circulation created 
the possibility to study the immunological functions and molecular composition of antigen-
activated Tfh cells in detail.(32, 33) In contrast to Tfh cells present in the secondary lymphoid 
tissues, their peripheral counterparts, characterized as CXCR5+CD4+ T cells, do not express Bcl-6 
and express lower levels of ICOS and PD-1.(31, 33) Both Tfh and peripheral Tfh cells secrete IL-
21 upon stimulation, which has an essential role in activation and expansion of  B cells, plasma 
cell generation and immunoglobulin production, including DSA. An immunosuppressive agent 
specifically targeting Tfh-B cell interaction would be a useful contribution to the improvement of 
outcomes in kidney transplantation. Studies on peripheral Tfh cells could be very helpful in this 
aspect. 
Belatacept, the latest approved immunosuppressant in kidney transplantation
An immunosuppressive agent that might effectively inhibit Tfh-B cell interaction is the 
costimulatory signal inhibitor belatacept (Nulojix®, formerly known by its study name LEA29Y and 
produced by Bristol-Myers Squibb).(35) This inhibitor of the CD28-CD80/86 pathway is the first 
drug in its class approved for the prevention of kidney allograft rejection. Belatacept binds CD80 
and CD86 on APCs, and consequently prevents signal 2 necessary for T cell activation, leading 
to T cell anergy (Figure 1).  In June 2011, this compound was approved by the Food and Drug 
Administration of the Unites States of America and the European Medicines Agency. The drug 
is also marketed in several countries in South America. Belatacept is prescribed in combination 
with mycophenolate mofetil and glucocorticoids and allows for CNI-free immunosuppression. 
Because belatacept is not nephrotoxic and lacks many of the other troublesome side effects 
of the CNIs tacrolimus and cyclosporine, the drug has great potential for transplantation 
medicine. Belatacept is a fusion-protein that consists of the modified Fc-fragment of the human 
immunoglobulin G1 linked to the extracellular domain of human cytotoxic T-lymphocyte antigen 
(CTLA)-4 (Figure 3).(35) The latter binds CD80 and CD86 with high affinity, i.e., the strength of 
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Chapter 1
interaction between belatacept and CD80/86 is high. By changing the 2 amino acids L104E and 
A29Y, the belatacept fusion-protein is a higher affinity variant of CTLA4-immunoglobulin (Ig) or 
abatacept, that is used to treat rheumatoid arthritis.(35) Belatacept was developed because 
CTLA4-Ig was not effective enough in inhibiting alloreactivity in a pancreatic islet and kidney 
transplantation model in nonhuman primates.(36, 37) Belatacept inhibits T-cell activation by 
blocking costimulatory signals from antigen-presenting cells (APCs), which include dendritic 
cells, but also monocytes and B cells. This costimulatory inhibitor therefore has the potential 
to efficiently interfere with Tfh-B cell interaction. In animal studies, combination therapy with 
belatacept effectively prevented germinal center and Tfh-cell formation, IL-21 production, 
clonal B-cell expansion and DSA production.(20, 21) In line with this, belatacept-treated patients 
had significantly lower DSA levels than patients treated with the CNI cyclosporine A seven years 
after kidney transplantation.(19, 38) So far, belatacept has not been compared to the most 
widely-used CNI, tacrolimus, in this aspect.
CH
3 CH3
CH2 CH
2
Human IgG1
(Fc) part
CD86
CD80
CTLA-4
Belatacept
Figure 3. Structure of the costimulatory inhibitor, belatacept. 
Belatacept is a fusion-protein that consists of the modified Fc-fragment of the human immunoglobulin G1 
linked to the extracellular domain of human cytotoxic T lymphocyte antigen (CTLA)-4. The latter binds to CD80 
and CD86 with high affinity.
CH, constant domain heavy chain; CTLA-4, cytotoxic T lymphocyte antigen 4; Fc, fragment crystallizable 
region; IgG, immunoglobulin G
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Aim and outline of this thesis
Despite the promising results in the large randomized controlled trials comparing 
belatacept vs. cyclosporine A, treatment with this costimulatory inhibitor has downsides, e.g. 
a higher acute rejection rate.(19, 38) At present, no reliable immunological biomarkers are 
available that can predict who is at risk for allograft rejection under belatacept treatment. 
In this thesis, we aimed to learn more about the immune mechanisms involved in 
alloreactivity in patients treated with belatacept or tacrolimus after kidney transplantation. 
Particularly, we focused on the effects of belatacept on effector T cells and Tfh-B cell interaction, 
and on the question which cell types are less susceptible to the effects of belatacept. In detail, 
the following aims were investigated:
•	 To determine if Tfh cells still mediate humoral alloreactivity shortly after kidney 
transplantation in a tacrolimus-based regimen – Chapter 2
•	 To study whether belatacept more efficiently inhibits alloreactive Tfh-B cell interaction 
than tacrolimus in kidney transplantation – Chapter 3
•	 To assess if belatacept effectively suppresses its indirect targets, CD28-positive T cells 
– Chapter 4
•	 To identify a biomarker for belatacept-resistant rejection and to compare clinical 
outcomes of belatacept- and tacrolimus-treated kidney transplant patients in a 
randomized controlled trial – Chapter 5
•	 To immunologically analyze a severe steroid-resistant rejection under belatacept-
treatment, leading to graft loss – Chapter 6
In Chapter 7 and Chapter 8 the findings of abovementioned studies are summarized and 
put into perspective of the clinical practice in kidney transplantation.
16
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Summary
Memory B cells play a pivotal role in alloreactivity in kidney transplantation. Follicular 
T-helper (Tfh) cells play an important role in the differentiation of B cells into immunoglobulin-
producing plasmablasts (through IL-21). It is unclear to what extent this T cell subset regulates 
humoral alloreactivity in kidney-transplant patients. Therefore we investigated the absolute 
numbers and function of peripheral Tfh cells (CD4POSCXCR5POS T cells) in patients before and after 
transplantation. In addition, we studied their relationship with the presence of donor specific anti-
HLA antibodies (DSA), and the presence of Tfh cells in rejection biopsies. After transplantation, 
peripheral TFH-cell numbers remained stable, while their IL-21-producing capacity decreased 
under immunosuppression. When isolated after transplantation, peripheral Tfh cells still had 
the capacity to induce B-cell differentiation and immunoglobulin production, which could be 
inhibited by an IL-21-receptor-antagonist. After transplantation the quantity of Tfh cells was the 
highest in patients with pre-existent DSA. In kidney biopsies taken during rejection, Tfh cells co-
localized with B cells and immunoglobulins in follicular-like structures. Our data on Tfh cells in 
kidney transplantation demonstrate that Tfh cells may mediate humoral alloreactivity, which is 
also seen in the immunosuppressed milieu.
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Introduction
Memory B cells are important in alloreactivity in kidney transplantation. During the last 
decade it has become clear that acute T cell mediated rejection biopsies contain numerous B 
cells as well as conventional T cells.(1) A significant proportion of acute rejections can therefore 
be classified as a mixed rejection, rather than a pure, T-cell mediated rejection.(2, 3) Hence, B 
cells are also involved in acute T-cell mediated rejection next to chronic antibody-mediated 
rejection, which involves donor-specific anti-human leucocyte antigen (HLA) antibodies 
(DSA) produced by B cells that differentiated into plasmablasts or plasma cells.(4) The latter 
are formed after the differentiation of donor-specific memory B cells. Follicular T helper (Tfh) 
cells are of importance for the survival of memory B cells and the differentiation of B cells into 
immunoglobulin-producing plasmablasts or plasma cells.(5) These Tfh cells are a heterogeneous 
population of CD4POS T helper cells, which are active in secondary lymphoid organs(6) and may 
be present in tertiary lymphoid structures formed in kidney allografts.(7) Tfh cells also produce 
interleukin (IL)-21, which is an important cytokine for B cell stimulation and differentiation.(5, 8, 
9) The transcription factor for the formation of Tfh cells, B cell lymphoma 6 (Bcl-6), suppresses 
the transcription factors required for formation of other T helper subsets.(5, 9, 10) Chemokine 
Receptor 5 (CXCR5) allows migration of Tfh cells towards the germinal center. (11-13) Peripheral 
CD4POSCXCR5POS T cells are the counterparts of Tfh cells in blood and express low levels of ICOS 
and PD1, and lack Bcl-6. (5, 14) 
 Recent studies revealed the pivotal role of Tfh cells in B-cell mediated immune 
responses in auto-immunity(15-17) and chronic viral infections(18-23) in humans. In autoimmunity, 
frequencies of Tfh cells are positively correlated with the peripheral blood levels of disease-
specific auto-antibodies(16, 17) and with disease-activity.(15) Accordingly, the percentage of 
circulating Tfh cells decreased in patients with autoimmune thyroiditis after treatment.(17) IL-
21 is an important disease mediator in these autoimmune disorders.(15-17) Also in chronic viral 
infections, such as hepatitis B and HIV, Tfh cells are expanded in peripheral blood(21-23) or in 
lymph nodes,(18, 19) and they can function as markers for the response to anti-viral treatment. 
No studies have been conducted which define the role of Tfh cells in B cell activation and 
humoral alloreactivity in immunosuppressed kidney transplant patients.(24) In CD4-reconstituted 
rodents, Tfh cells induce long-lasting immunoglobulin (Ig)G alloantibody responses after heart 
transplantation,(25) which are potentially dangerous for the graft. These cells also mediated 
humoral responses towards the kidney allograft in an immunosuppressed non-human primate 
model.(26) In addition, Tfh cells from intestinal transplant patients maintain germinal centers in 
isolated lymphoid follicles in the transplanted intestines and subsequently ensure IgA synthesis 
to control commensal micro flora, despite the immunosuppressed milieu.(27) As B cells play a 
pivotal role in both cellular and humoral alloreactivity, the interaction between Tfh cells and B 
cells is an important target for immunosuppression. We hypothesize that in immunosuppressed 
kidney transplant patients Tfh cells can still stimulate B cells, which leads to their differentiation 
into immunoglobulin-producing plasmablasts and plasma cells. The frequency and function 
of peripheral Tfh cells were therefore examined before and after kidney transplantation, as 
well as their relationship with the presence of donor specific antibodies (DSA). In addition, we 
stained acute rejection biopsies to examine the presence of intragraft Tfh cells, B cells and 
immunoglobulins.
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Material and methods
Study population in which peripheral Tfh cells were studied
Thirty consecutive renal transplant recipients were included and followed for one 
year post-transplantation. Sixteen age and gender-matched controls (healthy volunteers) were 
also included. Patients receiving a kidney transplant from a living donor all participated in a 
randomized controlled clinical trial with the primary aim to study the efficacy of a genotype-
based approach to tacrolimus dosing (Dutch trial registry number NTR 2226; http://www.
trialregister.nl/trialreg/admin/rctview.asp?TC=2226). All patients received induction therapy with 
basiliximab (Simulect®, Novartis; 20 mg i.v. on day 0 and day 4), tacrolimus (Prograf®, Astellas 
Pharma; aiming for predose concentrations of 10 - 15 ng/mL in weeks 1 - 2, 8 - 12 ng/mL in 
weeks 3 - 4, and 5 - 10 ng/mL, thereafter), mycophenolate mofetil (Cellcept®, Roche; starting 
dose of 1 g b.i.d., aiming for predose concentrations of 1.5 – 3.0 mg/L), and glucocorticoids. 
Prednisolone was tapered to 5 mg at month 3 and withdrawn at month 4 - 5. For inclusion in the 
study, as well as the current substudy, written informed consent was required from the patient. 
The study was approved by the Medical Ethical Committee of the Erasmus MC (MEC number 
2010-080, EudraCT 2010-018917-30). Rejections were defined as biopsy-proven acute rejection 
(BPAR) according to the Banff-classification 2009.(28) 
Numbers of peripheral Tfh cells and cytokine production capacity
Peripheral Tfh cells were defined as CD3POSCD4POSCXCR5POS lymphocytes and measured 
in fresh whole blood samples obtained 1 day before and 3 months after transplantation. In 
these cells the intracellular IL-21 production-capacity was determined ex vivo after 4 hours of 
stimulation with PMA 0.5 µg/ml and Ionomycine 10 µg/ml (Sigma-Aldrich, St. Louis, MO) at 37°C. 
The following monoclonal antibodies (mAbs) were used: CD3 AmCyan; CD4 Pacific Blue; CXCR5 
AF647; IL-21 phycoeryhtrin (PE); and the IL-21 isotope mouse IgG1-PE (all from BD Biosciences, 
San José, CA). To measure absolute numbers of CD3 and CD4, BD multi-test 6-color® was used 
in BD TruCount Tubes® (San Jose, CA). Absolute numbers of the subsets were calculated using 
the percentages of these subsets within the total CD3 and CD4 populations.    
Co-culture experiments of peripheral Tfh cells and memory B cells
To determine the function of peripheral Tfh cells, co-culture experiments with memory B 
cells were conducted. First, peripheral Tfh cells, i.e. CD3POSCD4POSCXCR5POS T cells, and memory B 
cells, i.e. CD19POSCD27POS cells, were isolated by sorting with BD-FACSAria II SORPTM (purities≥95%) 
from defrosted peripheral blood mononuclear cells (PBMCs). These PBMCs were obtained from 
patients one day before transplantation and three months after transplantation (thus isolated 
from an immunosuppressed milieu). As a control, PBMCs of healthy volunteers were used. 
mAbs were used as described above, including viability staining solution 7-aminoactinomycin 
(7-AAD) peridinin chlorophyll (PerCP) (BD Biosciences). Secondly, memory B cells were 
co-cultured for 7 days with CD4POSCXCR5POS Tfh cells in the presence of the superantigen 
Staphylococcus Aureus Antigen B (SEB, Sigma-Aldrich). Subsequently, differentiation of B cells 
into plasmablasts after 7 days was determined with flow cytometry. Plasmablasts were defined 
as CD3NULLCD4NULLCD19POSCD20NULLCD27POSCD38HIGH cells(14, 29) using the following mAbs: CD3 
AmCyan (BD Biosciences); CD4 Pacific Blue (Becton Dickinson, BD, Frankin Lakes, NJ); CD19 
fluorescein isothiocyanate (FITC) (BD); CD20 PerCP (BD); CD27 PE-Cy7 (eBioscience, San Diego, 
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CA); and CD38 PE (eBioscience). Finally, after 7 days, IgM and IgG production were measured 
with a sandwich ELISA in the supernatants of the co-cultures.
To determine the role of IL-21 in the interaction of Tfh cells with memory B cells, 5 µg/
mL of IL-21-receptor blocking antibody (IL-21-R-Fc R&D Systems, Minneapolis, MN) was added 
to the co-cultures of four patients (pretransplantation samples) and three healthy volunteers 
according to the concentration used for blocking immunoglobulin production by 50-75% in cells 
of healthy controls,(14) thus sufficiently blocking the IL-21-receptor without completely inhibiting 
plasmablast formation and immunoglobulin production. An isotype-matched control (IgG1-
Fc R&D Systems) was used. Thereafter, differentiation into plasmablasts and immunoglobulin 
production were measured after 7 days. 
Donor-specific anti-HLA antibodies (DSA)
DSA, including C1q-binding capacity, were determined in thawed heparin plasma 
samples before and 3, 6 and 12 months after kidney transplantation. For all patients the 
complement-dependent cytotoxicity (CDC) cross-match before transplantation was negative 
for both current and historic sera. DSA presence before transplantation was considered as pre-
existent DSA, and DSA developing after transplantation as de novo DSA. Plasma samples were 
centrifuged for 10 minutes at 14 170 rpm. Thirty µL of the plasma was incubated with 100 µl/mL 
Adsorb Out microbeads (One Lambda®) to minimize false positive staining. Subsequently, 20 µl 
plasma was incubated for 30 minutes with 2 µl Single Antigen beads mix from LABScreen (One 
Lambda®) Single Antigen class I and class II kits. After protocol washing procedures, plasma 
samples were incubated with 1 µl goat anti-human IgG-PE per well (One Lambda®). Microbeads 
were analyzed with a Luminex LabscanTM 100 analyzer using both Luminex 100IS and HLA Fusion 
3.0 software. All samples fulfilled the quality criteria for reactivity of the control beads.
Immunohistochemistry
 Kidney biopsies, diagnosed as type I acute rejection (three of type 1A and two of type 
1B), were paraffin-embedded, formalin-fixed and cut into 4 µm sections. Immunohistochemistry 
was performed by routine diagnostics on the Benchmark Ultra Stainer (Ventana, Basel), using 
the following mAbs: CD3 (1:150 dilution, DAKO, Denmark) was used to detect pan-T cells; CD4 
(undiluted, Ventana, Arizona) for T helper cells; CD8 (1:50, DAKO) for cytotoxic T cells; CD20 
(1:400 dilution, DAKO) for B cells; C4d (1:60 dilution, Biomedica Gruppa, Vienna, Austria) for 
complement factor C4d; Bcl-6 (1:15 dilution, Novocastra/Leica, Solms, Germany) for the 
transcription factor of Tfh cells; IgM (1:80 dilution, Biogenex, Fremont, CA) and IgG (1:200 dilution, 
DAKO) for the immunoglobulin production. 
Incubation with antibodies was done for 30 minutes and anti-rabbit or anti-mouse 
amplifiers were used. As positive control for Bcl-6, tonsillar sections obtained from a pediatric 
tonsillectomy were used.
To identify intragraft Tfh cells, sections were double-labeled with CD3 (polyclonal 
rabbit; DAKO; 1:200) and Bcl-6 (mouse monoclonal, Novocastra; 1:50). After incubation 
overnight at 4°C with the primary antibody Bcl-6, sections were subsequently incubated with a 
biotinylated horse-anti-mouse Ab (1:500) and Dyelight®594 (red) conjugated with streptavidin 
(Vector Laboratories, Burlingame, CA; 1:500) to visualize the Bcl-6 expression. Next, sections were 
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incubated for 1 hour with the CD3-antibody and subsequently with the Dyelight®488 (green) 
goat-anti-rabbit Ab (Vector Laboratories; 1:200). 
Table 1: Baseline characteristics and outcomes
 Study Group (n=30)
Recipient age in years (median, range) 52 (19-75)
Recipient Gender (%M) 67%
HLA-A Mismatches (mean±SD) 0.9 (±0.8)
HLA-B Mismatches (mean±SD) 1.1 (±0.8)
HLA-DR Mismatches (mean±SD) 1.0 (±0.6)
Cause of end-stage renal disease
•	 Hypertensive nephropathy 23.3% (7)
•	 Glomerulonephritis 16.7% (5)
•	 Polycystic kidney disease 13.3% (4)
•	 Focal segmental 
glomerulosclerosis 10% (3)
•	 Diabetic nephropathy 6.7% (2)
•	 Congenital dysplasia 6.7% (2)
•	 Miscellaneous 23.3% (7)
Previous kidney transplantation 20% (6)
•	 Third kidney transplantation 6.7% (2)
•	 Second kidney transplantation 13.3% (4)
Renal replacement therapy before 
transplantation 53.3% (16)
•	 Hemodialysis 26.7% (8)
•	 Peritoneal dialysis 26.7% (8)
Rejection within 12 months of 
transplantation 36.7% (11)
•	 Type I T-cell mediated rejection 54.5% (6)
•	 Type II T-cell mediated rejection 27.3%(3)
•	 Antibody-mediated rejection 0% (0)
•	 Mixed rejection 18.2% (2)
Time to rejection in days (median, range) 99 (7-261)
One-year death-censored graft survival 100%
One-year patient survival 96.7%
Patient number is depicted between brackets unless otherwise specified.
C4d, complement factor 4d; M, male; SD, standard deviation
Statistical analyses
Differences between measurements before and after transplantation were analyzed 
using the Wilcoxon-signed-rank test. Using the Mann-Whitney U-test, the differences were 
analyzed between transplant patients and healthy controls; and between patients with pre-
existent DSA and patients without pre-existent DSA. For comparing dichotomous outcomes, we 
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used Fisher’s exact test.  
IBM SPSS 20 (New York, NY) was used for statistical analysis. P-values with a 2-sided α 
of 0.05 were considered statistically significant. When not otherwise specified, medians [+range] 
are presented.
Results 
Study population  
Table 1 depicts the baseline characteristics of the patients from whom we studied the 
peripheral Tfh cells. Two patients discontinued tacrolimus within three months of transplantation. 
In one case this was necessitated by tacrolimus-induced thrombotic micro-angiopathy and 
in the other because of severe acute nephrotoxicity. One patient underwent a complicated 
transplantation with small bowel perforation and subsequently did not receive mycophenolate 
mofetil (MMF). The remaining 27 patients were all on a tacrolimus/MMF/prednisolone regimen 
for the first 3 months after transplantation. Eleven patients (36.7%) suffered from rejection within 
twelve months of transplantation. Median time to rejection was 99 days, ranging from 7 to 261 
days. Six patients had an early BPAR, i.e. within the first three months of transplantation. One-year 
dead-censored graft survival was 100% and one-year patient survival was 96.7%. One patient 
died from gastric adenocarcinoma 9 months after transplantation.
Numbers of peripheral Tfh cells remain stable after kidney transplantation, while their IL-21 
production capacity decreases 
We studied the number of peripheral Tfh cells before and 3 months after kidney 
transplantation. Absolute numbers of CD4POSCXCR5POS T cells were lower in patients before and 
after transplantation compared to the healthy controls (p<0.01), but remained stable after 
transplantation (Figure 1A and 1B).
  To confirm that IL-21 is produced by CD4POSCXCR5POS T cells, their IL-21 production 
capacity upon PMA/Ionomycin stimulation was compared with that of CD4POSCXCR5NULL T cells. 
A representive example of the IL-21-production by CD4POSCXCR5POS and CD4POSCXCR5NULL T cells 
is illustrated (Figure 1C). A higher percentage of CD4POSCXCR5POS T cells produced IL-21 than 
CD4POSCXCR5NULL T cells (6.9% [1.5-12.6%] vs. 3.2% [0.4-8.5%], p<0.0001).
The numbers of IL-21-producing Tfh cells after stimulation were comparable between 
healthy controls and patients before transplantation (Figure 1D). After transplantation, a 
decrease in IL-21 production capacity of CD4POSCXCR5POS T cells was observed, p<0.05. (Figure 
1D). Patients (n=6) with a BPAR within 3 months after transplantation, which consequently 
received high doses of pulse steroids, had similar numbers of CD4POSCXCR5POS T cells. However, a 
lower IL-21 production capacity was observed compared to patients who did not reject within 
the first three months after transplantation (n=24), p<0.05 (Supplementary figure 1).
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Figure 1. Numbers of peripheral (CD4POSCXCR5POS) follicular T helper (Tfh) cells remained equal after 
transplantation, while interleukin (IL)-21-production capacity decreased after transplantation. 
(A) CD4POSCXCR5POS were gated from CD3-positive cells within the lymphocytes, which were defined by 
forward- and sided-scatter. A typical example of CXCR5-expression within CD4-positive T cells is shown for a 
patient before and 3 months after kidney transplantation.
(B) Absolute numbers of CD4POSCXCR5POS T cells were compared between before and 3 months after 
transplantation (n=30), and between patients and healthy controls (n=16).
(C) The proportion of IL-21-producing cells is shown upon 4 hours phorbol myrisate acetate (PMA)/ionomycine 
stimulation in typical examples for CD4POSCXCR5POS T cells and CD4POSCXCR5NULL T cells (total measured in 
n=30). An unstimulated (i.e. negative) control for CD4POSCXCR5POS T cells is depicted. 
(D) Absolute numbers of IL-21-producing CD4POSCXCR5POS T cells upon 4 hours PMA/ionomycine stimulation 
are depicted before and after transplantation (n=30), and in healthy controls (n=16).
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Table 2: Baseline characteristics of patients with pre-existent DSA and without pre-existent DSA when a cut-off 
of an MFI≥4000 is used
No Pre-existent 
DSA (n=16)
Pre-existent DSA 
(n=7) p-value (two-sided)
Recipient age in years (median+range) 58 (19-75) 51 (22-58) 0.02
Donor age in years (median+range) 55 (26-86) 48 (25-54) 0.08
Recipient Gender (%M) 31% (5) 57% (4) 0.36
HLA-A Mismatches (mean±SD) 1.1 (±0.7) 0.9 (±0.9) 0.56
HLA-B Mismatches (mean±SD) 1.3 (±0.8) 1.1 (±0.9) 0.86
HLA-DR Mismatches (mean±SD) 1.1 (±0.6) 1.1 (±0.4) 0.97
Cause of end-stage renal disease 0.02
•	 Hypertensive nephropathy 31.2% (5) 14.3% (1)
•	 Glomerulonephritis 0% (0) 28.6% (2)
•	 Polycystic kidney disease 18.8% (3) 0% (0)
•	 Focal segmental 
glomerulosclerosis 0.0% (0) 28.6% (2)
•	 Diabetic nephropathy 12.5% (2) 0% (0)
•	 Congenital dysplasia 12.5% (2) 0% (0)
•	 Miscellaneous 25% (4) 28.6% (2)
Previous kidney transplantation1 0% (0) 43% (3) 0.02
•	 Third kidney transplantation - 14.3% (1)
•	 Second kidney transplantation - 28.6% (2)
Replacement therapy before 
transplantation 43.8% (7) 71.4% (5) 0.37
•	 Hemodialysis 31.2% (5) 14.3% (1)
•	 Peritoneal dialysis 12.5% (2) 57.1% (4)
Rejection within 12 months of 
transplantation 31.3% (5) 42.9% (3) 0.47
Time to rejection in days (median+range) 78 (7-261) 129 (8-216) 0.71
Patient number is depicted between brackets unless otherwise specified.1Two patients received two previous 
grafts: one received a graft from a post-mortal donor and from a living donor; the other one received both 
previous grafts from a post-mortal donor. Four patients received one previous graft, all from a living donor. 
DSA, donor-specific anti-human leukocyte antigen antibody; HLA, human leukocyte antigen; M, male; SD, 
standard deviation
The in-vitro function of peripheral Tfh cells is conserved in patients after transplantation
 To determine the functionality of peripheral (CD4POSCXCR5POS) Tfh cells, we performed 
co-culture experiments of pure, isolated Tfh cells and memory B cells from patients from whom 
materials were available before and after transplantation (n=11). For gating strategies see Figure 
2A-2C. After transplantation, less Tfh-cell dependent B-cell differentiation into plasmablasts was 
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observed than before transplantation (Figure 2D, p<0.05). Nevertheless, this did not lead to 
altered IgM and IgG production levels: among samples obtained before and 3 months after 
transplantation, comparable levels of IgM and IgG were measured in the co-cultures with 
CD4POSCXCR5POS T cells (Figure 2E-2F). Tfh-cell dependent IgM production was lower in co-
cultures of patient-derived cells than in co-cultures of healthy control-derived cells (Figure 2E, 
p<0.01). This difference was not observed for the Tfh-cell dependent IgG production (Figure 2F).
Plasmablast formation and immunoglobulin production regulated by peripheral Tfh cells are 
dependent on IL-21
 The importance of IL-21 in the functional interaction between Tfh cells and B cells was 
established by adding an anti-IL-21-R antibody to co-cultures containing CD4POSCXCR5POS T cells 
and memory B cells from healthy controls or patients before transplantation. Differentiation of 
memory B cells into plasmablasts was inhibited by 48.4% (ranging from 11.3 to 89.9%, p<0.05, 
Figure 2G). Subsequently, both IgM and IgG production were inhibited by 89.2% [27.4-97.5%[, 
p<0.05 (Figure 2H) and 80.4% [3.6-99.8%], p<0.05 (Figure 2I). 
After transplantation, numbers of peripheral Tfh cells are higher in patients with pre-existent DSA 
than in patients without pre-existent DSA    
To study whether Tfh cells may induce the B cell differentiation in vivo, we determined 
the relation between peripheral Tfh (CD4POSCXCR5POS) cell numbers and the presence of DSA. For 
this purpose the absolute numbers of CD4POSCXCR5POS T cells, before and after transplantation, 
were compared between patients with pre-existent DSA and patients without pre-existent 
DSA (Figure 3). To cover the different definitions for DSA-positivity, different mean fluorescence 
intensity (MFI) cut-offs were used to determine DSA-positivity or negativity. No differences were 
found at MFI cut-offs ≥1000, ≥2000 or ≥3000 (data not shown). When cut-offs for the MFI of 
≥4000 or ≥5000 were used, patients with pre-existent DSA had more peripheral Tfh cells after 
transplantation than patients without pre-existent DSA (Figure 3A and 3B, p<0.05 and p<0.001). 
See Table 2 for baseline characteristics in patients with and without pre-existent DSA at an MFI 
cut-off ≥4000. All pre-existent DSA (MFI≥4000) were initially C1q-negative and were persistent 
after transplantation. In two patients the pre-existent DSA converted into C1q-positive, i.e. 
complement-binding DSA, after transplantation. In the other patients the DSA remained C1q-
negative after transplantation. Five patients developed de-novo DSA after transplantation. In 
three of these patients DSA de novo were C1q-positive, two of whom suffered from an acute 
rejection within the first year after transplantation. Despite the limited numbers of patients with 
de-novo DSA, we compared them with patients without de-novo DSA and found no differences 
among the numbers of peripheral Tfh cells (data not shown). 
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Table 3: Immunofluorescence on 5 biopsies of kidney-transplants undergoing acute T cell mediated rejection 
 PA diagnosis CD3 CD4 CD20 BCL6 IgM IgG
1 TCMR I ++ ++ ++ + ++ ++
2 TCMR I ++ ++ ++ ++ not enough material
not enough 
material
3 TCMR I ++ ++ ++ ++ - -
4 TCMR I ++ ++ ++ + + +++
5 TCMR I ++ ++ +++ + ++ ++
+++, very strongly positive; ++, strongly positive; +, positive; +/-, weakly positive; -/+, very weakly positive; -, 
negative; TCMR I, T cell (cellular) mediated rejection type I
Tfh cells are present in follicular-like structures in acute T cell-mediated rejection kidney biopsies 
Acute T-cell mediated rejection biopsies (n=5) were stained to determine the 
presence of Tfh cells (representative example in Figure 4). Semi-quantitative analyses of the 
immunohistochemistry are depicted in Table 3. Follicular-like structures containing CD4POS T cells 
and CD20POS B cells were observed. Simultaneous staining of CD3 and Bcl-6 revealed Bcl-6-
expressing T cells on the T-B cell border of the follicular-like structures, suggesting that these cells 
physically interact at the graft site to regulate B-cell function (Figure 4F-4G). Confirming this, 
the immunohistochemistry data showed that these biopsies were also positive for IgM and IgG 
(Figure 4I-4J). All biopsies were C4d-negative (data not shown). 
Discussion
 We have studied the involvement of Tfh cells in B-cell mediated immune responses 
after kidney transplantation in vitro and in vivo. Several new insights were gained: (i) despite the 
decreased capacity of peripheral Tfh cells to stimulate B-cell differentiation after transplantation, 
the levels of IgM and IgG production capacity by plasmablasts in co-cultures were not affected 
by the immunosuppressive drugs in vivo; (ii) Tfh cells numbers post-transplantation were associated 
with high DSA titers before transplantation; (iii) graft infiltrating Tfh cells co-localized with B cells in 
follicular like structures; and (iv) locally-produced immunoglobulins were present in transplanted 
kidneys during rejection. Overall, the combination of in-vitro and in-vivo measurements in 
samples of patients before and after transplantation emphasize the importance of Tfh cells in 
humoral alloreactivity.
Even though the immunoglobulin production remained intact after transplantation, 
Tfh-cell dependent B-cell differentiation into plasmablasts was reduced, which suggests that 
either the Tfh cells or the B cells are partially influenced by immunosuppressive drugs. As IgM 
and IgG levels were comparable after transplantation, this indicates that at the single cell level, 
differentiated B cells produced higher amounts of IgM and IgG. (30, 31) The sustained Tfh-cell 
mediated immunoglobulin production after transplantation by differentiated B cells in vitro 
indicates that peripheral Tfh cells are capable to support B cells. Meier et al. also concluded 
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that Tfh cells are present and functional in the immunosuppressed milieu of intestinal transplant 
patients.(27) IgM-production capacity of the cells isolated from pre-transplant patients was lower 
than in healthy controls (Figure 2E), which may be explained by an impaired immune response 
caused by uremia in end-stage renal disease patients,(32) resulting in a lower antibody response 
towards new antigen.(33) IgG production by plasma cells represents a memory response, which 
was not impaired in our study cohort, suggesting that memory B cell or plasmablast functions 
are not susceptible to the devastating effects of end-stage kidney disease. Because in our study 
the function of peripheral Tfh cells was demonstrated by the differentiation of memory B cells 
into IgM and IgG producing plasmablasts in the presence of a super-antigen, further studies 
will have to establish whether these peripheral Tfh cells are fully capable to provide B cell help 
during allogeneic stimulation. 
In vivo, the peripheral Tfh cells were also linked to humoral reactivity. The numbers of 
peripheral Tfh cells were associated with the presence of pretransplantation DSA measured by 
Luminex (Figure 3A-D). When cut-offs at MFIs ≥4000 or ≥5000 were used, identifying DSA with a 
low prevalence for false-positivity (34), patients with pre-existent DSA had more peripheral Tfh 
cells after transplantation than patients without pre-existent DSA. This can be explained by the 
fact that peripheral Tfh cells, including other CXCR5POS T cells, are memory T cells, which are less 
susceptible for the given immunosuppressive medication.(5, 35-37) As patients with pre-existent 
DSA were mostly patients with previous kidney transplants (Table 2), it is expected that HLA-specific 
memory T cells are present in these patients’ circulations. Another explanation could be that pre-
existent DSA indicates the presence of antigen-specific memory B cells, which can present donor 
antigen to naive T cells. These naive T cells consequently differentiate into antigen-specific Tfh 
cells and other subtypes of matured T cells.(5) Finally, the higher numbers of peripheral Tfh cells 
in patients with pre-existent DSA might be related to an underlying autoimmune disease. Two 
patients in the pre-existent DSA group suffered from glomerulonephritis before transplantation, 
which could have led to higher numbers of circulating Tfh cells.(38) The remaining five patients, 
however, did not have an autoimmune disease and still had higher numbers of circulating Tfh 
cell. Larger patient cohorts are needed to determine other confounders for the numbers of 
circulating Tfh cells. 
All pre-existent DSA were non-complement binding, i.e. C1q-negative. The clinical 
relevance of non-complement binding C1q-negative DSA is under debate, and conflicting results 
are reported. C1q-negative DSA are often dismissed as clinically irrelevant(39, 40); however, 
patients with C1q-negative DSA have a more severe Banff-score during rejection(4) as well as a 
worse graft survival compared to patients without DSA.(4, 41) Hence, C1q-negative DSA cannot 
be labeled automatically as clinically irrelevant. C1q-positive DSA are known to predict graft 
loss.(4, 41) Despite these ongoing discussions we observed an association between peripheral 
Tfh cells and DSA, which suggests the involvement of Tfh cells in anti-donor B-cell mediated 
alloreactivity in kidney transplant patients. Interference of the Tfh-B cell interaction may be 
an approach to block B-cell differentiation into immunoglobulin-producing plasmablasts and 
plasma cells. One method of interfering in this interaction is the blockade of the IL-21 pathway, as 
demonstrated in our in-vitro studies (Figure 2G, 2H and 2I). The immunosuppressed regimen in this 
cohort probably partially interferes with this interaction.(29,30) The IL-21 production capacity by 
peripheral Tfh cells as measured in whole blood was decreased after transplantation. However, 
the presence of circulating DSA and the support by peripheral Tfh cells to humoral reactivity 
in vitro indicate that the interference by the current calcineurin-based immunosuppressive 
regimen is only partially effective.
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In addition to pure humoral alloreactivity, Tfh cells are involved in B-cell alloreactivity 
classified as T-cell mediated rejection.(2, 3) The presence of Bcl-6 expressing Tfh cells was 
demonstrated in C4d-negative acute T-cell mediated rejection biopsies of kidney grafts. These 
findings strengthen our observations that Tfh cells contribute actively to the anti-donor response 
and that rejection is the result of T and B cell interactions, even when the rejection is not classified 
as mixed or antibody-mediated.(3, 28) As well as their effector functions, B cells still could exhibit 
their well-known antigen-presenting function during rejection. The Bcl-6 expressing T cells were, 
however, located on the T-B cell border, which is the same localization pattern of Tfh cells in lymph 
nodes to provide B cell help.(5) Furthermore, the presence of IgM and IgG in these follicular-
like structures reflects humoral alloreactivity and thus effector function of differentiated B cells. 
Tfh cells may be the link between cellular and humoral reactivity in acute rejection in kidney 
transplantation. Whether these Tfh cells are always present in transplanted kidneys, such as their 
presence in stable allografts from intestinal transplant patients,(27) is yet unknown. In contrast to 
Tfh-cell function in the intestines, the B-cell supporting function of Tfh cells in transplanted kidneys 
is not desirable.
In conclusion, our blood and biopsy data on Tfh cells in kidney transplantation 
demonstrate that Tfh cells may mediate humoral alloreactivity, also in the immunosuppressed 
milieu of tacrolimus combined with MMF and steroids. 
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Supplementary figure 1. Absolute numbers of CD4POSCXCR5POS T –lymphocytes (A) and IL21+CD4POSCXCR5POS 
T-lymphocytes (B) in patients who rejected within the first three months after transplantatie (R<M3) and patients 
who did not (NR).
KT, kidney transplantation; , p<0.05
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Abstract 
Humoral alloreactivity has been recognized as a common cause of kidney transplant 
dysfunction. B-cell activation, differentiation and antibody production are dependent on IL-21+ 
CXCR5+ follicular T-helper (Tfh) cells. Here, we studied whether belatacept, an inhibitor of the 
co-stimulatory CD28-CD80/86-pathway, interrupts the crosstalk between Tfh- and B-cells more 
efficiently than the calcineurin inhibitor tacrolimus.
The suppressive effects of belatacept and tacrolimus on donor antigen-driven Tfh-B-
cell interaction were functionally studied in peripheral blood mononuclear cells from 40 kidney 
transplant patients randomized to a belatacept- or tacrolimus-based immunosuppressive 
regimen. 
No significant differences in uncultured cells or donor antigen-stimulated cells were 
found between belatacept and tacrolimus-treated patients in the CXCR5+ Tfh cell generation and 
activation (upregulation of PD-1). Belatacept and tacrolimus in vitro minimally inhibited Tfh-cell 
generation (by ~6-7%) and partially prevented Tfh cell activation (by ~30-50%). The proportion of 
IL-21+ activated Tfh-cells was partially decreased by in vitro addition of belatacept or tacrolimus 
(by ~60%). Baseline expressions and proportions of activated CD86+ B-cells, plasmablasts and 
transitional B-cells after donor antigen-stimulation did not differ between belatacept and 
tacrolimus-treated patients. Donor antigen-driven CD86 upregulation on memory B-cells was 
not fully prevented by adding belatacept in vitro  (~35%), even in supra-therapeutic doses. In 
contrast to tacrolimus, belatacept failed to inhibit donor antigen-driven plasmablast formation 
(~50% inhibition vs. no inhibition, respectively, p<0.0001).
In summary, donor antigen-driven Tfh-B-cell crosstalk is similar in cells obtained from 
belatacept and tacrolimus-treated patients. Belatacept is, however, less potent in vitro than 
tacrolimus in inhibiting Tfh-cell-dependent plasmablast formation. 
Key words: belatacept, costimulatory blockade, follicular T-helper cells, immunoglobulins, 
plasmablasts, tacrolimus, transitional B-cells 
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Introduction
B-cells and antibodies against the allograft are increasingly recognized to contribute to 
alloreactivity and subsequent graft failure after kidney transplantation under the currently used 
calcineurin inhibitor (CNI)-based immunosuppressive regimen.(1-7) CD4+CXCR5+ follicular T-helper 
(Tfh) cells are key mediators in B-cell activation, differentiation and antibody production.(8-12) 
Moreover, these cells infiltrate the allograft and co-localize with B-cells during acute rejection 
after kidney transplantation.(13, 14) In alloreactivity, both Tfh and B-cells are activated by the 
same antigen via their T and B-cell receptor, respectively.(15) The CD40-40L, CD28-CD80/86 and 
ICOS-ICOSL costimulatory pathways, and the cytokines IL-6 and IL-21, are important in this Tfh-B-
cell interaction, and for B-cell differentiation into immunoglobulin-producing plasma cells.(16-21)
Belatacept is a selective inhibitor of the CD28-CD80/86 pathway and subsequently 
interrupts Tfh-B-cell interaction.(21, 22) In animal transplant models, belatacept, or the lower 
affinity version abatacept (CTLA4 Immunoglobulin), inhibited germinal center formation, 
clonal B-cell expansion, IL-21 production and the development of donor-specific anti-human 
leukocyte antigen antibodies (DSA).(14, 23) These findings were in line with observations from 
a large randomized, controlled trial in kidney transplant patients where the belatacept-based 
regimen resulted in a significantly lower prevalence of DSA than the cyclosporine A (CsA)-based 
regimen at 7 years after transplantation: 4.6% vs. 17.8%, respectively.(24) However, in all these 
clinical studies, belatacept was combined with other immunosuppressive drugs: in the BENEFIT 
and BENEFIT-EXT trials belatacept was combined with MMF and prednisone, and in the animal 
studies belatacept was combined with either sirolimus or T-cell depleting antibodies.(14, 23-25) 
Contradictory effects of tacrolimus on B-cell activation, proliferation and differentiation 
have been reported (26-28) because tacrolimus only inhibits calcium-influx dependent, and 
not calcium-independent, B- and T-cell activation.(27, 29) This calcineurin-mediated activation 
is dependent on the type of stimulus.(26, 28, 29) B-cell activation can thus be prevented by 
calcineurin-inhibition in an antigen-dependent manner. The effect of tacrolimus on donor 
antigen-stimulated Tfh-B-cell interaction is unknown in kidney transplantation.
In addition to the in vivo animal studies and clinical data that suggest belatacept 
effectively inhibits the humoral immune response specific for donor antigen,(14, 23, 24), this class 
of immunosuppressive agents may also favor a more regulatory rather than effector alloreactive 
B-cell activity by enhancing the survival of transitional B-cells over memory B-cells in the long 
term.(30) Theoretically, this may reduce rejection risk.(15, 30-34) 
So far no studies have been conducted which compared the effects of belatacept to 
tacrolimus, on Tfh-B-cell interaction in kidney transplantation. We hypothesized that belatacept 
more efficiently interrupts Tfh-B-cell crosstalk than tacrolimus. Therefore, we compared i) the 
frequencies of Tfh and B-cell subsets between belatacept- and tacrolimus-treated patients; ii) 
the in vitro donor antigen-driven Tfh-B-cell interaction in peripheral blood mononuclear cells 
(PBMCs) obtained from belatacept- and tacrolimus-treated kidney transplant patients; and iii) 
the isolated the effects of additional belatacept and tacrolimus in vitro on donor antigen-driven 
Tfh-B cell interaction in PBMCs obtained from the same patients. 
Material and Methods
Study population and materials
 Materials were collected from 40 kidney transplant patients and their donors who 
participated in a prospective, randomized-controlled trial (approved by the Medical Ethical 
Committee of the Erasmus MC, University Medical Centre Rotterdam; MEC-2012-42, EUDRACT CT 
# 2012-003169-16). After written informed consent, patients were included and randomized to 
a tacrolimus-based (control) or belatacept-based (experimental) immunosuppressive regimen. 
For in- and exclusion criteria, refer to Supplementary Table 1. All procedures were in accordance 
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with the ethical standards of the Declaration of Istanbul.(35) In short, both groups received 
basiliximab induction therapy (Simulect®, Novartis, Basel, Switzerland), followed by maintenance 
therapy with mycophenolate mofetil (MMF) and prednisolone, which was tapered to 5 mg by 
month 3 after transplantation. Maintenance therapy with tacrolimus (Prograf®, Astellas Pharma, 
Tokyo, Japan) was adjusted to pre-dose levels of 5-10 ng/mL, while belatacept (Nulojix®, Bristol-
Meyers Squibb, NYC, NY) was dosed according to bodyweight (Less-Intensive regimen of the 
BENEFIT trials).(36) 
 Lithium heparin blood was collected from patients one day before transplantation, 
and 3 months after transplantation or during clinically suspected acute rejection before any 
additional anti-rejection therapy was given. All samples were processed within 24 hours of 
withdrawal. If patients had a biopsy-proven acute rejection (BPAR) (2) materials of that time 
point were used instead of their materials of 3 months after transplantation. Lithium heparinized 
blood from donors was collected one day before transplantation. Peripheral blood mononuclear 
cells (PBMCs) were isolated from blood using the Ficoll density isolation method.
Mixed lymphocyte reactions (MLRs)
 Patients PBMCs obtained after transplantation were thawed and used in MLRs. 
PBMCs were obtained 3 months after transplantation in stable, non-rejecting patients or before 
additional anti-rejection therapy was given in rejecting patients. Live cells were counted under 
a light microscope and distinguished from dead cells with Trypan Blue. Per patient ~5 x 105 
uncultured PBMCs were stained for phenotypical analyses. 5 x 104 patients’ PBMCs/well (in a 
96-wells plate) were stimulated for 7 days at 37°C with 5 x 104 CFSE-labeled, irradiated donor 
PBMCs (40 Gy) in RPMI 1640 + 10% heat-inactivated fetal bovine serum. Half of patients’ PBMCs 
were incubated for 1 hour with clinically therapeutic concentrations of belatacept (10 µg/mL)
(37) or tacrolimus (10 ng/mL), dependent on the randomization group, before donor antigen 
was added. After the donor antigen was added, these amounts of immunosuppressive drugs 
remained in the culture for the whole period of 7 days. At the end of day six 100 µL supernatant 
per well was harvested and stored at -20°C. Subsequently, Monensin and Brefeldin (GolgiStop 
and GolgiPlug, BD Biosciences, Franklin Lakes, NJ) were added for 16 hours over night in a 
concentration of 1:1500 and 1:1000, respectively, to allow the measurement of intracellularly 
accumulated cytokines in PBMCs. 
 Refer to Figure 1 for the different comparisons made in our study. Proportions of studied 
cell populations (see Flow Cytometry) were compared between: 
i) belatacept- and tacrolimus-treated patients in uncultured, 
unstimulated PBMCs;
ii) belatacept- and tacrolimus-treated patients in 7-day donor 
antigen-stimulated PBMCs;
iii) uncultured, unstimulated PBMCs and 7-day donor antigen-
stimulated PBMCs in belatacept-treated patients
iv) uncultured, unstimulated PBMCs and 7-day donor antigen-
stimulated PBMCs in tacrolimus-treated patients.
Patient PBMCs obtained one day before transplantation were also cultured with donor 
antigen in the same way to investigate whether PBMCs obtained from an immunosuppressed 
environment reacted differently on donor antigen compared to PBMCs before any 
immunosuppression was given.  
 Post-transplant PBMCs obtained from 3 belatacept-treated and 3 tacrolimus-treated 
patients were used in MLRs to study the CD40-CD40L, PD1-PDL1 and ICOS-ICOSL interaction 
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during costimulation blockade by belatacept 10 µg/mL or calcineurin-inhibition by tacrolimus 10 
ng/mL. MLRs were conducted as described above, only with 5 x 104 CD3 and CD19-depleted 
irradiated donor PBMCs instead of CFSE-labeled donor PBMCs. The same methods were used 
in 6 independent MLRs of healthy controls’ PBMCs to determine free CD80/86 expression after 
allo-antigen stimulation in the presence of various concentrations of belatacept (0-1000 µg/mL) 
or tacrolimus (0-100 ng/mL). 
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Figure 1. Different comparisons made in conducted studies (example figure).
In the left column (“in vivo drug”), the proportions of studied cell populations (see Flow Cytometry, Materials 
and Methods) were compared between i) belatacept- and tacrolimus-treated patients in uncultured, 
unstimulated PBMCs; ii) belatacept- and tacrolimus-treated patients in 7-day donor antigen-stimulated 
PBMCs; iii) uncultured, unstimulated PBMCs and 7-day donor antigen-stimulated PBMCs in belatacept-treated 
patients; and iv) uncultured, unstimulated PBMCs and 7-day donor antigen-stimulated PBMCs in tacrolimus-
treated patients. In the right column (“Additional in vitro drug”), the relative inhibition by additional in vitro 
belatacept or tacrolimus is depicted by “v” and “vi”, respectively, in this example figure. If the median relative 
inhibition is significantly smaller than zero, the in vitro drug significantly decreases the proportion of the studied 
cell type. Per cell type, the relative inhibitions were compared between belatacept and tacrolimus in vitro. 
This is depicted by “vii” in this example figure.
Carboxyfluorescein succinimidyl ester (CFSE) labeling of PBMCs
 To distinguish between patient and donor PBMCs in the MLRs, donor PBMCs were 
labeled with the cell-permeable, intracellular linker CFSE (Thermo Fisher Scientific, Waltham, MA), 
according to manufacturer’s manual. CFSE-labeled donors’ PBMCs expressed an MFI>104 on the 
FITC-channel. 
Co-cultures of isolated follicular T helper (Tfh) cells and memory B-cells(13, 38)
CD3+CD4+CXCR5+ T-cells and CD19+CD27+ B-cells from 3 healthy controls and 3 patients 
before transplantation were isolated using a FACSAria II 4L SORPTM (BD Biosciences). From both 
populations 2 x 104 cells/well were co-cultured for 7 days at 37°C with 4 x 104 40 Gy irradiated 
CD3/CD19-depleted, allogeneic PBMCs. Half of the wells were spiked with belatacept 10 µg/
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mL or tacrolimus 10 ng/mL. After 7 days co-culture, supernatants were collected and stored at 
-20 °C until analysis, and the proportion of memory B-cells that differentiated into CD27+CD38++ 
plasmablasts was measured.
Flow cytometry 
 For a complete overview of the monoclonal antibodies used, see Supplementary Table 
2. Follicular T helper (Tfh) cells were defined as CD3+CD4+CXCR5+ T lymphocytes, and classified 
as activated or resting by their expression of the activation marker and co-inhibitor PD-1.(39, 40) 
Tfh cell generation was defined as an increase in the proportion of CXCR5+ within CD4+ T-cells; 
Tfh cell activation comprised the increase in the proportion of PD-1+ within CD4+CXCR5+ T-cells; 
and the generation of activated Tfh-cells was equivalent to an increase in the proportion of 
CXCR5+PD-1+ within CD4+ T-cells. The characteristic Tfh-cell cytokine IL-21 was determined in 
donor antigen-stimulated PBMCs in the presence or absence of belatacept or tacrolimus. 
Within CD19+ B-cells, we distinguished CD27- naïve B-cells, CD27+ memory B-cells, 
CD24+CD38++ transitional B-cells, and CD27+CD38++ plasmablasts. Free CD86 expression on B-cells 
was measured on donor antigen-stimulated PBMCs by using an antibody that is competitive 
with belatacept for CD86, but binds with lower affinity.(41) Expressions of the immune regulatory 
cytokine IL-10 in transitional B-cells and of the aggressive effector cytokine TNFα in plasmablasts 
were also assessed after 7 days of donor antigen stimulation.
ELISA for IgM and IgG3 measurements
 IgM concentrations in supernatants from all cell cultures were determined by ELISA. A 
calibration curve using human IgM 1.6 – 100 ng/mL (Sigma-Aldrich, St. Louis, MO) was used to 
quantify results. All experiments were performed in duplo (medians were used for end result). 
Supernatants were diluted, if necessary, to fit within the measurements of the calibration curve. 
Measurements <1.6 ng/mL were considered negative. IgG3 concentrations were measured 
in the same way using an ELISA-kit with a calibration curve of 4.4 – 200 ng/mL (Affymetrix/
eBioscience, Santa Clara, CA). 
Single bead Luminex assay
 DSA were measured in (14-150x) concentrated culture supernatants using the Single 
Antigen beads mix from the LABScreen Single Antigen class II kit (Thermo Fisher, Waltham, MA).
(13) Microbeads were analyzed with a Luminex LabscanTM 100 analyzer using the Luminex 100IS 
software and analyzed using the HLA Fusion 3.0 software. All samples fulfilled the quality criteria 
for reactivity of the control beads.
Calculation of the relative inhibition
 The relative inhibition was used to account for inter-patient variability in the response 
to donor antigen (Figure 1, “additional in vitro” column). The relative inhibition by additional in 
vitro belatacept or tacrolimus was calculated for the donor antigen-driven Tfh cell generation, 
Tfh cell activation and the generation of activated Tfh-cells as well as for the donor antigen-
driven intracellular IL-21 by activated Tfh-cells and the formation of IL21+ activated Tfh-cells. The 
relative inhibition by the in vitro drugs was also assessed for the upregulation of CD86 on naïve 
and memory B-cells, the formation of plasmablasts and their IgM production, and the transitional 
B cell survival. For these calculations the proportions of aforementioned cell subsets after donor 
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antigen stimulation were set to 0 by using the following equation:
Relative inhibition (after donor antigen stimulation) = 
[(Proportion in the presence of in vitro drug)-(Proportion without in vitro drug added)] / [Proportion 
without in vitro drugs added]
If the median relative inhibition is significantly smaller than zero, the in vitro drug significantly 
decreases the proportion of the studied cell type (Figure 1, comparison “v” and “vi”). Per cell 
type, the relative inhibitions were compared between belatacept and tacrolimus in vitro (Figure 
1, comparison “vii”). 
Statistical analyses
 Proportions of cell subsets in uncultured or donor antigen-stimulated PBMCs were 
compared between the belatacept and tacrolimus group using the Mann-Whitney U test (Figure 
1, comparisons “i” and “ii”) as well as baseline characteristics that were continuous variables. 
Baseline characteristics that were categorical variables were compared with the Fisher’s Exact 
Test. Proportions of cell subsets between uncultured and donor antigen-stimulated PBMCs were 
compared using the Wilcoxon Signed Rank test (Figure 1, comparisons “iii” and “iv”). The median 
relative inhibition was compared to a theoretical mean of zero (=no inhibition) with the Wilcoxon 
Signed Rank test to determine if the inhibition by the in vitro drug was statistically significant 
(Figure 1, comparisons “v” and “vi”). The relative inhibitions by in vitro belatacept and in vitro 
tacrolimus were compared using the Mann-Whitney U test (Figure 1, comparison “vii”).
Multivariable linear regressions were used to examine the in vitro effects of belatacept 
compared to tacrolimus on donor antigen-activated Tfh and B-cell subsets, adjusted for 
confounders (presence of in vitro added drugs [present vs. absent], time point [after vs. before 
transplantation] and BPAR [PBMCs obtained during rejection vs. 3 months after transplantation). 
To avoid multiple testing errors, only cell subsets in which the relative inhibition significantly 
differed between belatacept and tacrolimus in vitro were included for these analyses. 
SPSS Statistics 21.0 (IBM, Armonk, NY) was used for statistical analyses. Unless mentioned 
otherwise, medians [+ range] are given for continuous variables, and numbers (+ proportions) are 
given for categorical variables. p-values with a 2-sided α of <0.05 were considered statistically 
significant. 
Results
1. Study population
 No significant differences were observed with regard to baseline characteristics 
between the two treatment groups (Supplementary Table 3). Seventeen (85%) patients in the 
belatacept and 19 (95%) in the tacrolimus group completed the 1-year follow-up period (last 
patient, last visit occurred on February 19th, 2016). The incidence of biopsy-proven acute rejection 
was higher among the belatacept-treated patients than in the tacrolimus-treated patients: n = 
11 (55%) vs. n = 2 (10%), respectively; p = 0.006 (unpublished, submitted data).
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Figure 2. No differences between belatacept and tacrolimus in vivo or in vitro on donor antigen-driven follicular 
T helper cell formation and activation in cultured PBMCs
Two typical examples are depicted for CXCR5 and PD-1 expression on T helper cells in uncultured PBMCs, 
and after 7 days of donor antigen-stimulation, in the presence or absence of belatacept and tacrolimus 
(A). Follicular T helper (Tfh)-cells were distinguished from non Tfh-cells by surface CXCR5-expression, while 
activated cells were defined by surface PD-1 expression. Donor PBMCs were discriminated by CFSE-labeling 
them prior to the mixed lymphocyte reaction and gating them out after.
The proportions are depicted of CXCR5+ within CD4+ T-cells (B); PD-1+ within CD4+CXCR5+ T-cells (C); and 
CXCR5+PD-1+ within CD4+ T-cells (D). 
In the graphs in the “in vivo drug” column, proportions of aforementioned cell populations were compared 
i) between belatacept- and tacrolimus-treated patients in uncultured, unstimulated PBMCs; ii) between 
belatacept- and tacrolimus-treated patients in 7-day donor antigen stimulated PBMCs; iii) between 
uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in belatacept-treated patients; 
and iv) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in tacrolimus-
treated patients. Every dot represents PBMCs of a single patient. 
In the graphs in the “additional in vitro drug” column the relative inhibitions by additional in vitro belatacept 
and tacrolimus are depicted for aforementioned cell populations in the same belatacept- and tacrolimus-
treated patients. The proportions of these cell populations after donor antigen-stimulation in the absence of 
in vitro drugs are set to zero. The median relative inhibitions by belatacept and tacrolimus were tested against 
a theoretical median of 0. Asterisks below the boxes depict the p-values of these tests. The relative inhibitions 
were compared between belatacept and tacrolimus in vitro. Lines in boxes represent medians, borders of 
boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box represents 
cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. 
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, NS = not significant
2. The effects of belatacept and tacrolimus on follicular T helper (Tfh) cells
2.1  Tfh cell generation and activation (CXCR5 and PD-1 upregulation)
The surface expression of the Tfh marker CXCR5 and the activation marker PD-1 were 
determined on CD4+ T-helper cells (Figure 2). 
Baseline expression of CXCR5 on CD4+ T-cells in uncultured PBMCs was comparable 
between belatacept- and tacrolimus-treated patients (Figure 2B, “in vivo drug” column). 
Following donor antigen-stimulation, Tfh-cell generation, defined by the expression of CXCR5 on 
CD4+ T-cells, increased ~3 to 4 fold in PBMCs obtained from belatacept- and tacrolimus-treated 
patients, p<0.001 and p<0.01, respectively (Figure 2B, “in vivo drug” column). This process was 
inhibited when the samples were spiked in vitro by adding tacrolimus and belatacept. The relative 
inhibition of Tfh-cell generation, however, was similar between belatacept and tacrolimus: -6.3% 
[-56.6 to +3.3%], p<0.001, by belatacept and -7.0% [-26.4 to +3.3%], p<0.01, by tacrolimus (Figure 
2B, “additional in vitro drug” column). 
The expression of PD-1 on CD4+CXCR5+ T-cells in uncultured PBMCs was similarly low in 
belatacept- and tacrolimus-treated patients (medians 1.3% and 1.5%, respectively; Figure 1C, “in 
vivo drug” column). Tfh-cells of belatacept- and tacrolimus-treated patients were significantly 
activated after donor antigen-stimulation, i.e. a significant increase of PD-1 expression on 
CXCR5+CD4+ T-cells was observed. The relative inhibition of Tfh cell activation was -27.5% [-74.0 
to +2.3%], p<0.001, by belatacept and -48.4% [-80.0 to 16.7%], p<0.001, by tacrolimus, inhibition 
by belatacept vs. tacrolimus; p=0.13 (Figure 2C, “additional in vitro drug” column). 
The proportion of CXCR5+PD-1+ double-positive CD4+ T-cells was negligible in uncultured 
PBMCs from belatacept- and tacrolimus-treated patients (Figure 2D, “in vivo drug” 
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Figure 3. IL-21 production by remaining activated follicular T helper cells was not inhibited by belatacept in 
vitro
A typical example is depicted for the intracellular IL-21 production after donor antigen-stimulation in non-
activated and activated Tfh-cells (CXCR5+PD-1- and CXCR5+PD-1+ CD4+ T-cells, respectively) in the 
presence and absence of belatacept (A). The proportions of IL-21+ cells within non-activated and activated 
Tfh-cells were compared after 7 days of donor antigen-stimulation of PBMCs obtained from both belatacept- 
and tacrolimus-treated patients (B). The proportions of IL21+ activated Tfh-cells within CD4+ T-cells (C) and 
the proportions of IL-21+ cells within activated Tfh-cells (D) were compared between 7-day donor antigen-
stimulated PBMCs obtained from the belatacept and tacrolimus group (“in vivo” column), as well as the 
relative inhibitions by in vitro addition of belatacept or tacrolimus (“additional in vitro” column). 
In the graphs in the “in vivo drug” columns, every dot represents PBMCs of a single patient. 
In the graphs in the “additional in vitro drug” columns the relative inhibitions by additional in vitro belatacept 
and tacrolimus are depicted for aforementioned cell populations in the same belatacept- and tacrolimus-
treated patients. The proportions of these cell populations after donor antigen-stimulation in the absence of 
in vitro drugs are set to zero. The median relative inhibitions by belatacept and tacrolimus were tested against 
a theoretical median of 0. Asterisks below the boxes depict the p-values of these tests. The relative inhibitions 
were compared between belatacept and tacrolimus in vitro. Lines in boxes represent medians, borders of 
boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box represents 
cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. 
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, NS = not significant
column). The generation of activated Tfh-cells (defined by an increase of the proportion of 
CXCR5+PD-1+ double-positive CD4+ T-cells) was 1.1% [0.4 to 18.1%] in donor antigen-stimulated 
PBMCs from belatacept-treated patients and 1.6% [0.6 to 4.1%] in those from tacrolimus-treated 
patients. These proportions were not significantly different. The generation of activated Tfh-cells 
was inhibited by both belatacept and tacrolimus in vitro (Figure 2D, “additional in vitro drug” 
column): the relative inhibition was -28.8% [-74.3 to -2.1%], p<0.001 by belatacept, and -32.9% 
[-79.4 to +17.5%] by tacrolimus, p<0.001.
2.2  Tfh cell function (intracellular IL-21 production)
As described previously, “activated Tfh-cells” were defined as Tfh-cells that upregulated 
PD-1 after donor antigen stimulation and “non-activated Tfh-cells” were defined as Tfh-cells 
that failed to upregulate PD-1 after donor antigen stimulation. IL-21, a key cytokine in Tfh-B-cell 
interaction, and subsequent B-cell differentiation into immunoglobulin-producing plasma cells, 
was assessed in Tfh-cells (Figure 3). The donor antigen-stimulated IL-21 production was highest 
in activated Tfh-cells (Figure 3B). The proportions of IL21+ activated Tfh-cells within CD4+ T-cells 
were similar between donor antigen-stimulated PBMCs from the belatacept and tacrolimus 
groups (Figure 3C, “in vivo drug” columns). The total proportion of IL21+ activated Tfh-cells was 
partially decreased by belatacept and tacrolimus in vitro. The relative inhibition was -55.0% [-79.0 
to +28.6%], p<0.01, in the presence of belatacept and -57.7% [-94.1 to +8.7%], p<0.001, in the 
presence of tacrolimus (Figure 3C, “in vivo drug” columns). No differences between the inhibition 
by belatacept and tacrolimus were observed (Figure 3C, “additional in vitro drug” column). 
When we focused on the remaining activated Tfh-cells in the presence of in vitro drugs, a 
substantial proportion could still produce IL-21. Even though the relative inhibitions of intracellular 
IL-21 production were not significantly different between belatacept and tacrolimus in vitro, only 
the latter (minimally) inhibited IL-21 production by activated Tfh-cells: relative inhibition -17.3% 
[-71.2 to +52.9%, p<0.05 (Figure 3D, “additional in vitro drug” column). 
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Figure 4. Donor antigen-stimulated CD86 upregulation on B-cells is only partially blocked by belatacept in vitro
Two typical examples are depicted for the free CD86 expression after 7 days of donor antigen-stimulation on 
naïve (CD27-) and memory (CD27+) CD19+ B-cells, in the presence and absence of belatacept or tacrolimus 
(A). The proportions are depicted of CD86+ cells within naïve and memory B-cells as well as the Median 
Fluorescence Intensities (MFIs) of CD86 within naïve and memory B-cells (B). 
In the graphs in the “in vivo drug” columns, proportions and MFIs of aforementioned cell populations were 
compared i) between belatacept- and tacrolimus-treated patients in uncultured, unstimulated PBMCs; ii) 
between belatacept- and tacrolimus-treated patients in 7-day donor antigen stimulated PBMCs; iii) between 
uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in belatacept-treated patients; 
and iv) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in tacrolimus-
treated patients. Every dot represents a single culture of PBMCs. 
In the graphs in the “additional in vitro drug” columns the relative inhibitions by additional in vitro belatacept 
and tacrolimus are depicted for aforementioned cell populations in the same belatacept- and tacrolimus-
treated patients. The proportions or MFIs of these cell populations after donor antigen-stimulation in the 
absence of in vitro drugs are set to zero. The median relative inhibitions by belatacept and tacrolimus were 
tested against a theoretical median of 0. Asterisks below the boxes depict the p-values of these tests. The 
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relative inhibitions were compared between belatacept and tacrolimus in vitro. Lines in boxes represent 
medians, borders of boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. 
Every box represents cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated 
patients. 
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, NS = not significant
2.3 Summary of the effects of belatacept and tacrolimus on Tfh-cells
 Belatacept and tacrolimus minimally inhibited Tfh-cell generation and partially 
prevented Tfh-cell activation. The proportion of IL-21+ activated Tfh-cells was not completely 
diminished by in vitro addition of belatacept or tacrolimus. Thus the remaining activated Tfh-
cells have the potential capacity to provide B-cell help. Next, we tested the immunosuppressive 
effects of both agents on B-cell activation and functional Tfh-B-cell crosstalk.
3. The effects of belatacept and tacrolimus on B-cells
3.1  B cell activation (CD86 upregulation)
Part of the activation of B-cells and their ability to proliferate, differentiate and function 
as antigen-presenting cells is reflected by their (free) CD86-expression, but also by the expression 
of CD40 and ICOS-L. Here, The efficacy of belatacept was determined by means of B-cell 
activation, i.e. the free expression of CD86, which was measured on naïve CD19+CD27- and 
memory CD19+CD27+B-cells (in proportions and Median Fluorescence Intensities [MFIs]), using 
tacrolimus as control (Figure 4). The expression of CD40 and ICOS-L on B cells in the presence of 
belatacept is described in paragraph 4.1. 
CD86 expression was almost absent on naïve B-cells and low on memory B-cells in 
unstimulated uncultured PBMCs (Figure 4B, “in vivo” columns). No differences were observed 
between belatacept- or tacrolimus-treated patients. After donor antigen-stimulation both the 
proportions of CD86+ B-cells, as well as the expression of CD86 (MFIs) significantly increased on 
both naïve and memory B-cells (Figure 4B, “in vivo” columns). These were not different between 
the belatacept and tacrolimus group. 
Despite the selective binding of belatacept to CD86,(22) the upregulation of CD86 was 
not completely blocked by the in vitro addition of belatacept. The relative inhibition of CD86 
upregulation (proportion) by belatacept was -55.2% [-85.7 to -18.8%], p<0.001, on naïve B-cells, 
and -35.5% [-63.9 to +0.2%], p<0.001, on memory B-cells (Figure 4B, “additional in vitro drug”). 
The relative inhibition of CD86 upregulation on naïve and memory B-cells was significantly more 
by belatacept than by tacrolimus in vitro, p<0.05. MFIs of CD86 on naïve and memory B-cells 
were significantly decreased by both belatacept and tacrolimus in vitro (Figure 4B, “additional 
in vitro drug”). The relative inhibitions of CD86 MFIs were comparable between belatacept and 
tacrolimus. 
To determine if the residual B-cell activation in the presence of immunosuppressive 
drugs was dose-dependent, the relative inhibitions by belatacept and tacrolimus were measured 
in the presence of supra-therapeutic concentrations. Even in the presence of supra-therapeutic 
concentrations of belatacept, membrane CD86 expression on allo-antigen-stimulated B-cells 
was still detectable (Supplementary Figure 1): The relative inhibition by 1000 µg/mL belatacept 
(100 x higher than the therapeutic concentration) was -72.4% [-86.5 to -19.7%], p<0.05, in naïve 
B-cells and -43.2% [-53.9 to -7.4%], p<0.05, in memory B-cells.
Since belatacept binds CD80 with much higher affinity than CD86,(22, 41) the residual 
surface expression of CD80 was low on activated naïve and memory B-cells in the presence of 
the different doses of belatacept (Supplementary Figure 1): The relative inhibition by 1000 µg/
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mL belatacept was -90.2% [-97.5 to -75.4%], p<0.05, in naïve B-cells and -85.0% [-95.1 to -57.3%], 
p<0.05, in memory B-cells. CD80 expression on B-cells was not significantly decreased in the 
presence of tacrolimus.
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Figure 5. Belatacept in vitro did not inhibit donor antigen-driven plasmablast formation or TNFα production in a 
PBMC-based assay, but suppressed IgM production 
The gating strategy is depicted for plasmablasts (CD19+CD27+CD38++) after 7 days of donor antigen-
stimulation, in the presence or absence of belatacept and tacrolimus (A). Donor PBMCs were discriminated 
by CFSE-labeling them prior to the mixed lymphocyte reaction and gating them out after. The proportions of 
plasmablasts are shown for 7-day donor antigen-stimulated PBMCs obtained from the belatacept or tacrolimus 
group (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept or tacrolimus 
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(“additional in vitro” column) (B). The IgM concentrations in the supernatants are shown for the same cultures 
as previously mentioned (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept 
or tacrolimus (“additional in vitro” column) (C). A typical example is depicted for intracellular TNFα-production 
by plasmablasts after 7 days of donor antigen-stimulation, in the presence or absence of belatacept (D). The 
proportions of TNFα+ cells within plasmablasts (E) and the proportions of TNFα+ plasmablasts within B-cells (F) 
are shown for 7-day donor antigen-stimulated PBMCs obtained from the belatacept or tacrolimus group (“in 
vivo” column), as well as the relative inhibitions by in vitro addition of belatacept (“additional in vitro” column). 
The proportions of TNFα+ plasmablasts could not be reliably determined in the presence of tacrolimus in vitro, 
because of the strong inhibition of plasmablast formation by tacrolimus. In the graphs in the “in vivo drug” 
columns, every dot represents PBMCs of a single patient. 
In the graphs in the “additional in vitro drug” columns the relative inhibitions by additional in vitro belatacept 
and tacrolimus are depicted for aforementioned cell populations in the same belatacept- and tacrolimus-
treated patients. The proportions of these cell populations after donor antigen-stimulation in the absence of in 
vitro drugs are set to zero. The median relative inhibitions by belatacept and tacrolimus were tested against a 
theoretical median of 0. Asterisks below boxes depict the p-values of these tests. The relative inhibitions were 
compared between in vitro belatacept and tacrolimus. Lines in boxes represent medians, borders of boxes 
represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box represents cultures 
of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. 
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, NS = not significant
3.2 B-cell differentiation (plasmablast formation)
To study the effect of belatacept and tacrolimus on the antigen dependent Tfh-B-cell 
interaction, differentiation of B-cells into plasmablasts was measured in donor antigen-activated 
PBMCs obtained after transplantation (Figure 5). 
The proportions of plasmablasts were equally low in PBMCs from belatacept- and 
tacrolimus-treated patients (Figure 4B, “in vivo drug” column). Plasmablast formation was 
significant after donor antigen-stimulation in PBMCs from the belatacept group (8.8% [1.0 to 
20.7%], p<0.001) and from the tacrolimus group (13.1% [1.9 to 37.6%], p<0.001), belatacept vs. 
tacrolimus group, p=0.10). Only tacrolimus significantly inhibited plasmablast formation with a 
relative inhibition of -50.5% [-89.7 to -8.2%], p<0.0001 (Figure 5B, “additional in vitro drug” column). 
Belatacept failed to inhibit this alloreactive process in PBMCs, and its relative inhibition (-28.1% 
[-69.1 to +54.8%]) was significantly less than the inhibition by tacrolimus, p<0.001. 
3.3 Plasmablast function (IgM production and intracellular TNFα production)
IgM production by donor antigen-stimulated PBMCs was not significantly different in 
PBMCs obtained from the belatacept-treated patients compared to the tacrolimus-treated 
patients (Figure 5C, “in vivo drug” column). The relative inhibitions of IgM production by 
belatacept and tacrolimus in vitro were -32.9% [-100.0 to +59.1%], p<0.01, and -54.9% [-100.0 
to +141.4%), p<0.05, respectively (Figure 4C, “additional in vitro drug” column). Even though 
tacrolimus more efficiently inhibited plasmablast formation than belatacept, the inhibition of 
IgM production did not significantly differ between these two drugs.
Since belatacept is a fusion protein consisting of the Fc-fragment of IgG1,(22) total 
human IgG could not be determined by ELISA. No IgG DSA were detected by Luminex in 
supernatants of the MLRs. Total IgG3 could be detected in 8 cultures with donor-antigen 
stimulated PBMCs (median 6.6 [4.8 -34.3] ng/mL; 5x from tacrolimus-treated and 3x from 
belatacept-treated patients), and was -12.3% [-79.3 to +33.5%] inhibited in these samples by 
tacrolimus or belatacept, p=0.01 (Supplementary Figure 2). Because of the limited amount of 
IgG3+ supernatants no subgroup analysis per treatment arm was performed.
Of the B-cells that differentiated into plasmablasts 19.4% [0.0 to 66.7%] expressed 
intracellular TNFα in the PBMCs obtained from belatacept-treated patients, and 12.7% [3.4 to 
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Figure 6. Transitional B-cells and their donor antigen-driven IL-10 production were conserved by belatacept in 
vitro, but inhibited by tacrolimus 
The gating strategy is depicted for transitional B-cells (CD24+CD38++) after donor antigen-stimulation (A). Cells 
were gated from CD19+ B-cells like depicted in Figure 4A. The proportions of transitional B-cells are shown for 
7-day donor antigen-stimulated PBMCs obtained from the belatacept or tacrolimus group (“in vivo” column), 
as well as the relative inhibitions by in vitro addition of belatacept or tacrolimus (“additional in vitro” column) 
(B). A typical example is depicted for intracellular IL-10 expression (Median Fluorescence Intensity [MFI]) by 
transitional B-cells after 7 days of donor antigen-stimulation, in the presence or absence of belatacept, including 
a Fluorescence-Minus-One control (FMO) (C). The MFIs of IL-10 within transitional B-cells are shown for 7-day 
donor antigen-stimulated PBMCs obtained from the belatacept or tacrolimus group (“in vivo” column), as well 
as the relative inhibitions by in vitro addition of belatacept (“additional in vitro” column) (D). The MFI of IL-10 
within transitional B-cells could not be reliably determined in the presence of tacrolimus in vitro, because of the 
decreased transitional B-cells survival in the presence of tacrolimus. In the graph in the “In vivo drug” column 
in (B), proportions of transitional B cell populations were compared i) between belatacept- and tacrolimus-
treated patients in uncultured, unstimulated PBMCs; ii) between belatacept- and tacrolimus-treated patients 
in 7-day donor antigen stimulated PBMCs; iii) between uncultured, unstimulated PBMCs and 7-day donor 
antigen stimulated PBMCs in belatacept-treated patients; and iv) between uncultured, unstimulated PBMCs 
and 7-day donor antigen stimulated PBMCs in tacrolimus-treated patients. Every dot represents PBMCs of a 
single patient. In the graphs in the “Additional in vitro drug” column the relative inhibitions by additional in vitro 
belatacept and tacrolimus are depicted for aforementioned cell populations in the same belatacept- and 
tacrolimus-treated patients. The proportions of these cell populations after donor antigen-stimulation in the 
absence of in vitro drugs are set to zero. The median relative inhibitions by belatacept and tacrolimus were 
tested against a theoretical median of 0. Asterisks below boxes depict the p-values of these tests. The relative 
inhibitions were compared between in vitro belatacept and tacrolimus. Lines in boxes represent medians, 
borders of boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box 
represents cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. 
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, NS = not significant
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49.1%] in those from the tacrolimus-treated patients, p=0.34 (Figure 5E, “in vivo” column). The 
proportions of TNFα+ plasmablasts within total B-cells were also similar in PBMCs from belatacept- 
and tacrolimus-treated patients: 1.2% [0.0 to 4.1%] and 1.7% [0.2 to 10.1%], respectively, p=0.34 
(Figure 5F, “in vivo” column). Belatacept did not affect the proportion of TNFα+ within plasmablasts 
nor the proportions of TNFα+ plasmablasts within total B-cells (Figure 5E-F, “additional in vitro” 
column). The proportions of TNFα+ plasmablasts could not be reliably determined in the presence 
of tacrolimus, because of the strong inhibition of plasmablast formation by tacrolimus in vitro. 
3.4 B-cell differentiation and plasmablast function in an isolated co-culture system
To eliminate the effects of other cell types and cytokines present in the PBMC-
based assay, we tested the effects of belatacept and tacrolimus in an isolated system of 
antigen-activated CXCR5+ Tfh and CD19+CD27+ memory B-cells (Supplementary Figure 3). 
The differentiation of memory B-cells into IgM producing plasmablasts was used as read out. 
Plasmablast formation of 13.2% [2.1-44.9%] was decreased by the addition of  belatacept to 
1.7% [1.3-4.2%], and by tacrolimus to 0.5% [0.1-0.9%], both p<0.05 (Supplementary Figure 3D). 
Tacrolimus more potently inhibited the plasmablast formation than belatacept, p<0.05. The same 
pattern was seen in the IgM production of 253.8 ng/mL [86.5-541.5 ng/mL] (Supplementary Figure 
3E). Belatacept decreased IgM production to 18.1 ng/mL [13.7-68.4 ng/mL], and tacrolimus to 
6.2 ng/mL [2.2-8.6 ng/mL] (both p<0.05; tacrolimus vs. belatacept p<0.05).
3.5 Immune regulatory phenotype (IL-10+ transitional B cell survival)
The presence of B-cells with a regulatory phenotype, i.e. IL10+ transitional B-cells, was 
assessed after donor antigen-stimulation in the presence or absence of belatacept or tacrolimus 
(Figure 6). 
In unstimulated, uncultured PBMCs the proportions of transitional B-cells were below 
3% in both treatment groups (Figure 5B, “in vivo drug” column). After donor antigen-stimulation, 
an increase in the proportion of transitional B-cells was observed in PBMCs from belatacept- 
and tacrolimus-treated patients, to 2.1% [0.0 to 8.2%], p<0.01, and 3.0% [0.0 to 24.7%], p<0.001, 
respectively (Figure 5B, “in vivo drug” column). The survival of these transitional B-cells was not 
different between the belatacept and tacrolimus groups. The in vitro addition of tacrolimus, 
however, diminished transitional B-cell survival (relative inhibition: -55.4% [-91.4 to +15.1%], 
p<0.001), while belatacept did not affect the survival of these potentially regulatory B-cells 
(relative inhibition: -27.2% [-100.0 to +247.4%], p=0.54), tacrolimus vs. belatacept, p<0.05.  
Both the transitional B-cells in the PBMCs obtained from belatacept-treated patients 
as those from tacrolimus-treated patients expressed IL-10 after donor antigen-stimulation: MFI 
617 [397 to 1577] and MFI 666 [297 to 1697], respectively, p=1.00 (Figure 6D, “in vivo” column). 
Belatacept in vitro did not decrease IL-10 production in transitional B-cells (Figure 6D, “additional 
in vitro” column). The MFI of IL-10 within transitional B-cells could not be reliably determined in the 
presence of tacrolimus, because of the decreased transitional B-cells survival in the presence of 
tacrolimus in vitro.
3.6 Summary of the effects of belatacept and tacrolimus on B-cells
 Donor antigen-driven CD86 upregulation was not fully inhibited by belatacept, 
especially on memory B-cells, even by supra-therapeutic doses of belatacept. In contrast to 
tacrolimus, belatacept could not inhibit donor antigen-driven plasmablast formation in a PBMC-
based assay, but only in an isolated Tfh-B-cell co-culture. Also in the latter, belatacept was less 
effective than tacrolimus. The survival of the potentially immune regulatory IL-10+ transitional 
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B-cells was, however, not affected by belatacept, while this was diminished by tacrolimus.
4. Redundancy of the immune system
4.1 The effect of belatacept and tacrolimus on redundant co-stimulatory pathways
To explain why belatacept did not inhibit plasmablast formation in our PBMC studies, 
and because patients’ cellular interactions are influenced by redundant and pleiotropic 
mechanisms of immune cells, surface receptors of other costimulatory pathways were measured 
(Supplementary Figure 4).
In PBMCs from 3 belatacept-treated and 3 tacrolimus-treated patients, the ICOS-
ICOSL, PD-1-PD-L1, and the CD40L-CD40 pathways were studied after donor antigen stimulation 
Expressions of all surface molecules, except for CD28 and ICOSL, were increased on Tfh and 
B-cells after donor antigen-stimulation (Supplementary Figures 4A and C). The upregulation of 
the costimulatory molecules on Tfh-cells was not fully suppressed by belatacept, and to a lesser 
extent than by tacrolimus (Supplementary Figure 4). 
5. Multivariable regression analyses
5.1 The effect of belatacept and tacrolimus in vitro on Tfh and B-cells
The effect of belatacept in vitro was compared to the effect of tacrolimus in vitro in 
multivariable regression analyses for proportions of CD86+ naïve and memory B-cells, plasmablast 
formation and transitional B-cell survival (adjusted for the variables as stated in Table 1). These 
cell subsets were chosen, because they significantly differed when belatacept was added 
compared to tacrolimus in vitro (Figures 4, 5 and 6). Multivariable analyses confirmed that 
belatacept and tacrolimus differed in inhibition of plasmablast formation: plasmablast formation 
was 4.5% (SE 1.3) higher in the presence of belatacept than in the presence of tacrolimus in 
vitro, p=0.001 (Table 1). In the multivariable analysis, transitional B-cell survival (defined as the 
proportion of transitional B-cells of total B-cells) was not significantly higher in the presence of 
belatacept compared to in vitro addition of tacrolimus (p=0.91). Finally, the free CD86 expression 
on CD27+ memory B-cells was 9.3% (SE 2.8) lower when the donor antigen-stimulated PBMCs 
were spiked with belatacept in vitro compared to tacrolimus in vitro, p=0.001, but no significant 
difference was found for free CD86-expression on the surface of naïve B-cells (p=0.12).
PBMCs were obtained 3 months after transplantation in non-rejectors, and during 
rejection before additional anti-rejection therapy was given in rejectors. Eleven of twenty 
belatacept-treated patients and two of twenty tacrolimus-treated patients developed a 
biopsy-proven acute rejection. Obtaining PBMCs during acute rejection did not alter the in vitro 
reaction to donor antigen or drug (Table 1).
The effects of belatacept and tacrolimus in vitro on the different Tfh and B-cell subsets 
are summarized in Table 2.
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Table 1: The effect of belatacept in vitro on free CD86 expression, plasmablast formation and transitional B-cell 
survival
Dependent variable Independent variables Beta SE p
CD86 express-
ing naïve B-cells 
(% CD86+ of 
CD19+CD27- B-cells)
 
Belatacept added in vitro (vs. tacroli-
mus added in vitro) -4.53 2.85 0.12
PBMCs obtained after transplantation 
(vs. before transplantation) 1.76 2.50 0.48
PBMCs obtained from rejector (vs. 
non-rejector) -0.09 3.02 0.98
Proportion of cell subset without in vitro 
drugs added  0.55 0.06 0.00
CD86 expressing 
memory B-cells 
(% CD86+ of 
CD19+CD27+ B-cells)
 
Belatacept added in vitro (vs. tacroli-
mus added in vitro) -9.34 2.84 0.02
PBMCs obtained after transplantation 
(vs. before transplantation) -1.15 2.49 0.65
PBMCs obtained from rejector (vs. 
non-rejector) 2.10 3.01 0.49
Proportion of cell subset without in vitro 
drugs added   0.61 0.07 0.00
Plasmablasts (% 
CD27+CD38++ of 
CD19+ B-cells)
 
Belatacept added in vitro (vs. tacroli-
mus added in vitro) 4.45 1.28 0.00
PBMCs obtained after transplantation 
(vs. before transplantation) -1.57 1.08 0.15
PBMCs obtained from rejector (vs. 
non-rejector) 2.34 1.32 0.08
Proportion of cell subset without in vitro 
drugs added  0.66 0.07 0.00
Transitional B-cells (% 
of CD19+ B-cells)
 
Belatacept added in vitro (vs. tacroli-
mus added in vitro)
-0.09 -0.01 0.91
PBMCs obtained after transplantation 
(vs. before transplantation)
-0.38 0.71 0.59
PBMCs obtained from rejector (vs. 
non-rejector)
0.40 0.86 0.65
Proportion of cell subset without in vitro 
drugs added 
0.24 0.07 0.00
A multivariable regression analysis was performed per cell subset with as dependent variable the value after 
donor antigen-stimulation plus in vitro drugs (belatacept or tacrolimus) and as independent variables addition 
of in vitro belatacept (vs. in vitro tacrolimus), the time point PBMCs were obtained (after vs. before transplan-
tation), PBMCs obtained during rejection (rejector vs. non-rejector), and the value after donor antigen-stimu-
lation without in vitro drugs added. Statistically significant p-values (<0.05) are underscored. 
Proportions of the different donor antigen-stimulated subsets without in vitro drugs added were most predic-
tive for the proportions in the presence of in vitro drugs. In 11 belatacept-treated patients and 2 tacrolim-
us-treated patients the PBMCs were obtained during acute rejection, before additional anti-rejection therapy 
was given. Obtaining PBMCs from patients who rejected or time point the PBMCs were obtained (before or 
after transplantation) were not predictive for the proportions of these cells.
PBMCs, peripheral blood mononuclear cells; Rejector vs. non-rejector, patients who rejected versus patients 
who did not reject within 12 months after transplantation (biopsy-proven); SE, standard error of beta
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Table 2: Effects of belatacept and tacrolimus in vitro on donor antigen-activated follicular T (Tfh) helper and 
B-cells (Table continues on next page)
Immunological 
reaction
Defined by Effect by 
belatacept in 
vitro
Effect by 
tacrolimus in 
vitro
Comparison belatacept vs 
tacrolimus*
Tfh cell generation CXCR5 expression 
↑ on CD4+ T-cells
Inhibition 
(minimal)
Inhibition 
(minimal)
bela = tac
Tfh cell activation PD-1 expression ↑ 
on CD4+CXCR5+ 
T-cells
Inhibition 
(partial)
Inhibition 
(partial)
bela = tac
Activated Tfh cell 
generation
CXCR5+PD-1+ 
double expression 
↑ on CD4+ T-cells
Inhibition 
(partial)
Inhibition 
(partial)
bela = tac
IL-21+ activated 
Tfh cell generation
The proportion 
of IL-21+ CX-
CR5+PD-1+ ↑ within 
CD4+ T-cells
Inhibition 
(partial)
Inhibition 
(partial)
bela = tac
IL-21 production 
by activated Tfh-
cells
Intracellular IL-21 
expression of CX-
CR5+PD-1+ CD4+ 
T-cells
None Inhibition 
(minimal)
bela = tac
B-cell activation CD86 expression ↑ 
on B-cells
Inhibition 
(partial)
Inhibition 
(partial)
bela is more efficient than 
tac**
Transitional B-cell 
survival
The proportion 
of CD24+CD38++ 
B-cells
None Inhibition
(partial)
bela is more benificial than 
tac***
Plasmablast for-
mation
Proportion of 
B-cells differ-
entiated into 
CD27+CD38++ 
B-cells
In PBMCs: 
None
In isolated 
system with 
Tfh and 
B-cells: Inhibi-
tion (almost 
completely)
In PBMCs: 
Inhibition 
(partial)
In isolated sys-
tem with Tfh 
and B-cells: 
Inhibition 
(completely)
bela is less efficient than 
tac****
bela is slightly less efficient 
than tac
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IgM production Total IgM in 
supernatant of 
co-cultures
In PBMCs: 
Inhibition 
(partial)
In isolated 
system with 
Tfh and 
B-cells: Inhibi-
tion (almost 
completely)
In PBMCs: 
Inhibition 
(partial)
In isolated sys-
tem with Tfh 
and B-cells: 
Inhibition 
(completely)
bela = tac
bela is slightly less efficient 
than tac
bela, belatacept; IgM, immunoglobulin M; PBMCs, peripheral blood mononuclear cells; tac, tacrolimus
* Comparison of the relative inhibition by belatacept in vitro and tacrolimus in vitro; ** These observations 
were confirmed in a multivariable regression analysis for memory B-cells, but not for naïve B-cells (Table 1); *** 
These observations were not confirmed in a multivariable regression analysis (Table 1); **** These observa-
tions were confirmed in a multivariable regression analysis (Table 1).
Discussion
 In this study, the effects of belatacept on Tfh-B-cell interaction were compared 
to those of tacrolimus for the first time in kidney transplant patients. No differences were 
observed in unstimulated uncultured PBMCs or donor antigen-stimulated PBMCs obtained 
from belatacept- or tacrolimus-treated patients, which may be explained by the predominant 
effects by mycophenolate mofetil and prednisone in both regimens. Therefore the isolated 
effects of in vitro belatacept and tacrolimus were compared. In vitro addition of both drugs only 
minimally inhibited Tfh-cell generation and partially decreased activation of Tfh-cells (defined 
by PD-1 upregulation). Activated Tfh-cells produced the highest levels of IL-21, and the total 
proportion of IL-21+ activated Tfh-cells in the presence of in vitro immunosuppression was also 
partially reduced. Still, IL-21 production and B-cell help by remaining Tfh-cells was sufficient in the 
presence of in vitro belatacept, because the donor antigen-driven formation of plasmablasts in 
our MLR-based PBMC assay was not inhibited by the co-stimulation blocker, in contrast to in vivo 
observations in animal studies.(14, 23) These newly-formed TNFα+ plasmablasts, that have been 
associated with aggressive reactivity in autoimmunity,(42) were suppressed in the presence of 
tacrolimus.
 A first explanation for these findings are the differences between our study and previous 
work.(14, 23, 24) Belatacept has always been compared to CsA and not with the more potent 
tacrolimus, and used in combination with other types of immunosuppressive agents, like T-cell 
depleting therapy or mTOR inhibition in the animal studies,(14, 23) or mycophenolate mofetil 
and prednisone in the BENEFIT trial.(24) The study presented here reports on the isolated effects 
of belatacept and tacrolimus on the functional interaction of patient-derived Tfh and B-cells. 
These differences might have led to an overestimation of the inhibition of Tfh-B-cell interaction 
by belatacept, not taking into account the effects of other immunosuppressive agents. 
 A second reason could be the significant residual expression of CD86 on donor antigen-
activated B-cells, even in the presence of supra-therapeutic concentrations of belatacept. 
This might be explained by 1) a lower affinity of belatacept for donor antigen-activated CD86 
molecules on B-cells; 2) a higher turnover of CD86 by B-cells; or 3) degradation of belatacept 
during the 7-day cultures. The latter is unlikely, since CD80 was efficiently blocked by belatacept. 
Until the study presented here, the efficacy of belatacept on occupying CD86 had only 
been studied on monocyte-derived dendritic cells, and not on B-cells.(41) As a result of the 
incomplete blockade of CD86 on B-cells, activation and consequently differentiation of B-cells 
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were not prevented by costimulation blockade. The production of IgM was, however, inhibited 
by belatacept (median ~50%), possibly because CD80 blockade or partial CD86 blockade also 
leads to impaired immunoglobulin responses.(43, 44) Nonetheless, belatacept was not more 
efficient than tacrolimus in preventing IgM production, and even slightly less efficient in an 
isolated system. The lower percentage of DSA-positive patients in the belatacept than in the CsA 
group in the BENEFIT trial (24) could be 1) a reflection of better compliance in the first group,(45, 
46) 2) the lower potency of CsA compared to tacrolimus,(25) and 3) higher concentrations of 
mycophenolate acid in the first group.(47, 48)
 A third answer can be found in redundant costimulatory pathways taking over during 
costimulation blockade of the CD28-CD80/86 pathway. Because belatacept affects only this 
pathway,(22) other costimulatory pathways, like CD40-CD40L and ICOS-ICOSL, may “bypass” 
blockade of CD28-CD80/86. In our small cohort study of n = 6 independent experiments, the 
upregulation of CD40L and ICOS on Tfh-cells were less reduced by belatacept than by tacrolimus, 
making these cells more capable of helping B-cells. Since tacrolimus has a direct effect on T and 
B-cells by inhibiting calcineurin downstream the surface receptors (27, 29, 49), its effect is not 
dependent on costimulation blockade. Further studies that test the combination of belatacept 
with CD40- or ICOS-blockade could confirm this hypothesis, but were beyond the scope of the 
study presented here.
 A final possibility is that belatacept less effectively inhibits dendritic cells (DCs) and 
their interaction with Tfh and B-cells than the interaction between Tfh and B-cells, especially in 
an in vitro setting in the absence of a germinal center.(50-52) Unlike in donor antigen-stimulated 
PBMCs, in an isolated system of pure CXCR5+ Tfh and memory B-cells, belatacept successfully 
inhibited plasmablast formation. A big difference between PBMCs and isolated Tfh and memory 
B-cells is the absence of patient DCs and their antigen-presenting function in the isolated 
system, i.e. the absence of the indirect and semi-direct pathways of antigen presentation.(53) 
The effect of belatacept on human dendritic cells is not yet studied and a lack hereof could 
explain the less efficient inhibition by belatacept on Tfh-B-cell interaction. Nevertheless, donor 
DCs, facilitating the direct pathway for antigen presentation, were still present in the isolated 
system. This suggests belatacept effectively inhibits the direct, but not the indirect or semi-direct 
pathways of antigen presentation. Absence of other cells, like natural killer cells, could also be 
an explanation for the successful inhibition by belatacept in the isolated system. We believe a 
PBMC-based assay is more similar to the milieu in patients than an isolated cell assay, because 
in the first system multiple cell types and redundant pathways are of importance. 
 It should be noted almost no IgG3 by ELISA and no anti-HLA IgG by Luminex were 
detected in the culture supernatants. Possibly because only materials of immunologically low 
risk patients were used. Since belatacept is an IgG1, it cannot be ruled out IgG1 antibodies 
were present in the co-cultures’ supernatants. Another limitation of this study is that anti-CD86 
monoclonal antibodies that are non-competitive to belatacept, and bind to another epitope 
than belatacept, are not commercially available.(41) The total CD86 expression, irrespective of 
saturated CD86 by belatacept in the co-cultures, could therefore not be determined.
A possible beneficial consequence of the incomplete inhibition of B-cells by costimulation 
blockade, is that belatacept favored the (potentially regulatory) IL-10+ transitional B-cell survival, 
while this was diminished by tacrolimus.(30-32) However, these findings were not confirmed by 
multivariable regression analyses. Therefore, the clinical relevance of these observations need 
to be validated in a larger population. Even more, since 1) most rejections occur within the 
first months after transplantation, when glucocorticoids are still used and negatively influence 
transitional B-cell survival,(30) and 2) the regulatory capacities of antigen-specific transitional 
B-cells have not yet been confirmed in functional studies in humans. Another favorable outcome 
of incomplete Tfh-B-cell inhibition by belatacept could be a lower infection risk and more potent 
vaccine responses in belatacept-treated patients than in tacrolimus-treated patients. So far 
no evidence for this emerged from previous studies, nor has it been confirmed in randomized-
controlled trials comparing belatacept and CNI-treated patients.(24, 54-56) 
In this functional study, belatacept was less potent than tacrolimus in inhibiting donor 
antigen-driven plasmablast formation. 
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Supplementary Figure 1. CD86 is not fully blocked by belatacept on alloantigen-activated B-cells, using 100x 
higher than therapeutic concentrations.
A typical example is shown for free CD80 and CD86 expression on memory B-cells after allo-antigen stimulation 
in the presence of two supra-therapeutic concentrations of belatacept and tacrolimus (A). The expression 
on naïve B-cells was gated in the same way. The relative inihibitions of CD80 and CD86 on naïve (CD27-) and 
memory (CD27+) CD19+ B-cells after allo-antigen stimulation is depicted for 6 independent mixed lymphocyte 
reactions using peripheral blood mononuclear cells of healthy controls (B). Allogeneic PBMCs were CD19-
depleted before adding them to the cultures. The expression of CD80 and CD86 without drugs is set to zero. 
N.B.: Lines in boxes represent medians, borders of boxes represent 25th and 75th percentiles, error bars present 
10th and 90th percentiles. Every box represents cultures of PBMCs obtained from n = 6 healthy controls. Using 
the Wilcoxon Signed Rank test, the median relative inhibitions by belatacept and tacrolimus were tested 
against a theoretical median of 0. Asterisks below boxes depict the p-values of these tests. The relative 
inhibitions  between the different concentrations were also compared using the Wilcoxon Signed Rank test. 
* = p<0.05 / ** = p<0.01 / *** = p<0.001 / **** = p<0.0001 / NS = not significant
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Supplementary Figure 2. IgG3 production after 7 days of donor-antigen stimulation of PBMCs
obtained after kidney transplantation. The calibration curve of the IgG3 ELISA started at 4.4 ng/mL (dotted 
line). IgG3 concentration was above this cut-off point in 8 cultures with donor-antigen stimulated PBMCs: 5x 
from tacrolimus-treated and 3x from belatacept-treated patients), and was inhibited in all these samples by 
tacrolimus or belatacept (right column). Because of the limited amount of IgG3+ supernatants no subgroup 
analysis per treatment arm was performed.
N.B.: * p<0.05
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Supplementary Figure 3. Belatacept inhibited plasmablast formation and IgM production in an allo-antigen 
activated co-culture of isolated follicular T helper (Tfh) cells and memory B-cells
A typical example of Tfh cells and memory B-cells is depicted before and after flow cytometric cell isolation 
(A). The purities are depicted of the isolated CD4+CXCR5+ T-cells and CD19+CD27+ memory B-cells in 6 
independent experiments, using materials of 3 healthy controls and 3 patients before transplantation (B). A 
typical example is shown for CD27+CD38++ plasmablasts after 7 days of alloantigen stimulation in a co-culture 
of isolated CD4+CXCR5+ T helper cells and CD19+CD27+ memory B-cells, in the presence or absence of 
belatacept 10 μg/mL or tacrolimus 10 ng/mL (C). Allogeneic PBMCs were CD3/19-depleted and irradiated (40 
Gy) before adding them to the cultures. The proportions of plasmablasts are shown for uncultured PBMCs, and 
alloantigen-stimulated isolated CD19+CD27+ memory B-cells and CD4+CXCR5+ T helper cells, in the presence 
or absence of belatacept 10 μg/mL or tacrolimus 10 ng/mL (D). For the experiments with belatacept and 
tacrolimus the same materials were used, namely of 3 healthy controls and 3 pre-transplant patients. The IgM 
concentration in the supernatants are shown for above mentioned co-cultures (E). 
N.B.: The black lines in the boxes represent the medians. The upper and lower borders of the boxes represent 
the 25th and 75th percentile. The error lines represent the 10th and 90th percentiles. bela=belatacept 10 μg/
mL, tac=tacrolimus 10 ng/mL 
* = p<0.05 / ** = p<0.01 / *** = p<0.001 / **** = p<0.0001
Chapter 3
68
SS
C
-A
FSC-A
PE
CD3
C
D
4
CD3
C
XC
R5
CD4
IC
O
S
PD
-1
C
D
40
L
C
D
28
CD4
uncultured PBMCs
after donor antigen
after donor antigen
+ belatacept
1.3%
15.4%
4.7%
2.3%
24.9%
12.3%
1.2%
16.3%
10.4%
99.9%
96.8%
98.5%
%
 IC
O
S 
%
 P
D
-1
%
 C
D
40
L
%
 C
D
28
donor
antigen
drugs
0
20
40
60
0
10
20
30
0
10
20
30
0
50
100
+
-
+
+
belatacept-group
tacrolimus-group
SS
C
-A
FSC-A
Pe
rC
P-
C
y5
CD19
C
D
27
CD19
4.9%
4.7%
8.8%
5.7%
20.2%
10.9%
12.5%
57.7%
28.7%
CD19
IC
O
S-
L
PD
-L
1
C
D
86
uncultured PBMCs
after donor antigen
after donor antigen
+ belatacept
MFI
2332
MFI
5722
MFI
7135N
or
m
al
ize
d
C
ou
nt
CD40
Baseline: MFI 2332
Donor antigen stimulation: MFI 7135
Donor antigen stimulation 
+ belatacept: MFI 5722
CD19+CD27- 
naïve B cells
%
 IC
O
S-
L 
M
FI
 C
D
40
%
 C
D
86
0
5
10
15
0
5
10
15
0
10
20
30
40
0
10
20
30
40
%
 P
D
-L
1 
0
2000
4000
6000
8000
0
2000
4000
6000
8000
0
20
40
60
80
100
0
20
40
60
80
100
CD19+CD27+ 
memory B cells
donor
antigen
drug
+
-
+
+
+
-
+
+
A.
C.
B.
D.
Supplementary Figure 4. Redundant co-stimulatory pathways in follicular T helper and B cells.
A typical example is shown for the expression of different co-stimulatory molecules on CD4+CXCR5+ T helper 
cells obtained from a belatacept-treated patient (A). PBMCs from tacrolimus-treated patients were gated 
the same way. The proportions of ICOS+, PD-1+, CD40L+ and CD28+ within CD4+CXCR5+ T helper cells are 
depicted for n=3 belatacept-treated patients (dots) and n=3 tacrolimus-treated patients (diamonds) in the 
presence or absence of belatacept 10 µg/mL or tacrolimus 10 ng/mL, respectively (B). A typical example 
is shown for the expression of different co-stimulatory molecules on memory (CD27+) B-cells obtained from 
a belatacept-treated patient 3 months after transplantation (C). Naïve (CD27-) B cells and B cells from 
tacrolimus-treated patients were gated the same way. The proportions of ICOS-L+, PD-L1+, and CD86+, and 
the Median Fluorescence Intensity (MFI) for CD40 within CD19+CD27- naïve and CD19+CD27+ memory B-cells 
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> Continuation of Supplementary Figure 3 legend
are depicted for n=3 belatacept-treated patients (dots) and n=3 tacrolimus-treated patients (diamonds)  in 
the presence or absence of belatacept 10 µg/mL or tacrolimus 10 ng/mL, respectively (D).
N.B.: All materials were obtained in stable, non-rejecting patients 3 months after transplantation. No statistical 
analyses were conducted.
Supplementary Table 1: Inclusion and exclusion criteria
Inclusion criteria:
•	 Recipient of a first or second renal allograft
•	 Recipient of a living donor (related or unrelated)
•	 Current or historical panel-reactive antibodies (PRA) < 
30%
•	 ≥1 HLA-DR mismatch
Exclusion criteria:
•	 Recipient <18 years of age at time of transplantation
•	 Recipient of a deceased donor
•	 Recipient of a third (or more) renal allograft 
•	 Recipient of a non-renal organ transplant (present, past 
or near-future)
•	 Recipient of an AB0-incompatible allograft
•	 Recipient with a historically positive cytotoxicity-
dependent cross-match
•	 Recipient with a history of lymphoma
•	 Recipient with a seronegative or unknown EBV status
•	 Recipient with HIV, hepatitis B or C, and/or untreated 
latent tuberculosis
•	 Recipient with a high risk for polyoma virus-associated 
nephropathy, which is mostly due to BK virus infection
•	 Recipient who already uses tacrolimus pre-
transplantation
•	 Pregnancy
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Supplementary Table 2: Monoclonal antibodies (Table continues on next page)
Experiment Markers Monoclonal 
antibodies
Firms Added 
(µL)*
MLRs using PBMCs for 
Tfh-B-cell interaction (n=40 
patients before and after 
transplantation)
CD3 Brilliant Violet 510
BioLegend, San Diego, 
CA 0.25
CD4 Brilliant Violet 421
BioLegend, San Diego, 
CA 2
CXCR5 Alexa Fluor 647 BD Pharmingen, San Diego, CA 0.25
PD-1 
(CD279) APC-Cy7
BioLegend, San Diego, 
CA 10
CD8 PerCP BD Biosciences, Franklin Lakes, NJ 5
IL-21 PE eBioscience, San Diego, CA 0.5
CD19 Brilliant Violet 510
BioLegend, San Diego, 
CA 5
CD24 APC eBioscience, San Diego, CA 5
CD27 PE-Cy7 eBioscience, San Diego, CA 1
CD38 Brilliant Violet 421
BioLegend, San Diego, 
CA 1
IgD APC-Cy7 BioLegend, San Diego, CA 5
CD86 PE Beckman Coulter, Brea, CA 10
IL-10 PE BD Biosciences, Franklin Lakes, NJ 0.5
TNFα PerCP-Cy5.5 BD Biosciences, Franklin Lakes, NJ 2
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MLRs using PBMCs for 
redundant costimulatory 
pathways (n=6 patients 
after transplantation)
CD3 Brilliant Violet 510
BioLegend, San Diego, 
CA 0.25
CD4 Brilliant Violet 421
BioLegend, San Diego, 
CA 2
CXCR5 Alexa Fluor 647 BD Pharmingen, San Diego, CA 0.25
PD-1 
(CD279) APC-Cy7
BioLegend, San Diego, 
CA 10
CD40-Li-
gand 
(CD154)
FITC BioLegend, San Diego, CA 5
ICOS 
(CD278) PE-Cy7
BioLegend, San Diego, 
CA 0.5
CD28 PerCP-Cy5.5 BD Biosciences, Franklin Lakes, NJ 10
CD19 Brilliant Violet 510
BioLegend, San Diego, 
CA 5
CD27 PE-Cy7 eBioscience, San Diego, CA 1
PD-Li-
gand 1 
(CD274)
Brilliant Violet 
421
BioLegend, San Diego, 
CA 2
CD40 FITC BioLegend, San Diego, CA 1
ICOS-Li-
gand 
(CD275)
APC BioLegend, San Diego, CA 1
CD86 PE Beckman Coulter, Brea, CA 10
MLRs in the presence of 
various concentrations of 
belatacept or tacrolimus 
(n=6 independent exper-
iments)
CD19 Brilliant Violet 510
BioLegend, San Diego, 
CA 5
CD27 PE-Cy7 eBioscience, San Diego, CA 1
CD80 APC BioLegend, San Diego, CA 5
CD86 PE Beckman Coulter, Brea, CA 10
Co-cultures of isolated Tfh 
and memory B-cells (n=6 
independent experiments)
CD4 PerCP BD Biosciences, Franklin Lakes, NJ 10
CXCR5 Alexa Fluor 647 BD Pharmingen, San Diego, CA 0.25
PD-1 
(CD279) APC-Cy7
BioLegend, San Diego, 
CA 10
CD19 Brilliant Violet 510
BioLegend, San Diego, 
CA 5
CD27 PE-Cy7 eBioscience, San Diego, CA 1
CD38 Brilliant Violet 421
BioLegend, San Diego, 
CA 1
CD86 PE Beckman Coulter, Brea, CA 10
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* The monoclonal antibodies were titrated to the optimal concentrations to discriminate between the positive 
and negative fraction for the tested marker. The depicted amounts of monoclonal antibodies were added 
to 100 µL cell suspension.
Supplementary Table 3 Characteristics of study subjects
Characteristics
Total 
randomized 
(n=40)
Randomized
pbelatacept 
(n=20)
tacrolimus 
(n=20)
Age at transplantation (years) 55 (21-76) 57 (25-76) 55 (21-76) 0.88
Gender (female) 10 (25%) 6 (30%) 4 (20%) 0.72
HLA A mismatch (mean ± SD) 1.2 (±0.6) 1.1 (±0.7) 1.4 (±0.5) 0.13
HLA B  mismatch (mean ±  SD) 1.4 (±0.5) 1.3 (±0.5) 1.5 (±0.5) 0.51
HLA DR  mismatch (mean ±  SD) 1.2 (±0.4) 1.1 (±0.4) 1.3 (±0.4) 0.70
HLA total  mismatch (mean ±  SD) 4.0 (±1.1) 3.5 (±1.1) 4.1 (±1.1) 0.07
current PRA 0% (0-17%) 0% (0-5%) 0% (0-17%) 0.30
highest PRA 4% (0-21%) 4% (0-6%) 4% (0-21%) 0.78
CMV seropositivity at transplantation 22 (55%) 10 (50%) 12 (60%) 0.75
Data represent medians (plus ranges) for continuous variables and numbers (plus percentages) for categorical 
variables, unless otherwise specified. Two-sided p values comparing the two treatment arms result from the 
Mann-Whitney U test for comparing continuous variables or the Fisher’s exact tests for comparing categorical 
variables. Two-sided p<0.05 was considered statistically significant. 
CMV, cytomegalovirus; HLA, human leukocyte antigen; PRA, panel reactive antibodies; SD, standard 
deviation.
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Abstract
Background 
The co-stimulatory inhibitor of the CD28-CD80/86-pathway, belatacept, allows 
calcineurin-inhibitor-free immunosuppression in kidney transplantation. However, aggressive 
T-cell mediated allogeneic responses have been observed in belatacept-treated patients, 
which could be explained by effector-memory T-cells that lack membrane expression of CD28, 
i.e. CD28-negative (CD28NULL) T-cells. CD28-positive (CD28POS) T-cells that down regulate their 
surface CD28 after allogeneic stimulation could also pose a threat against the renal graft. The 
aim of this study was to investigate this potential escape mechanism for CD28POS T-cells under 
belatacept treatment. 
Materials & Methods
 PBMCs, isolated T-cell memory subsets and isolated CD28POS T-cells were obtained 
from end-stage renal disease (ESRD) patients and co-cultured with allo-antigen in the presence 
of belatacept to mimic allogeneic reactions in kidney transplant patients under belatacept 
treatment. As a control, IgG was used in the absence of belatacept. 
Results
Despite high in vitro belatacept concentrations, a residual T-cell growth of ±30% was 
observed compared to the IgG control after allogeneic stimulation. Of the alloreactive T-cells, 
the majority expressed an effector-memory phenotype. This predominance for effector-memory 
T-cells within the proliferated cells was even larger when a higher dose of belatacept was added. 
Contrary to isolated naïve and central-memory T cells, isolated effector-memory T cells could 
not be inhibited by belatacept in differentiation or allogeneic IFNγ production. The proportion of 
CD28-positive T cells was lower within the proliferated T cell population, but was still substantial. A 
fair number of the isolated initially CD28POS T-cells differentiated into CD28NULL T-cells, which made 
them not targetable by belatacept. These induced CD28NULL T-cells were not anergic as they 
produced high amounts of IFNγ upon allogeneic stimulation. The majority of the proliferated 
isolated originally CD28POS T-cells, however, still expressed CD28 and also expressed IFNγ.
Conclusion
 This study provides evidence that, apart from CD28NULL T-cells, also CD28POS, mostly 
effector-memory T-cells can mediate allogeneic responses despite belatacept treatment.
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Introduction
The co-stimulatory inhibitor of the CD28-CD80/86-pathway, belatacept, is a promising 
alternative for calcineurin-inhibitors in kidney transplantation.(1-3) This co-stimulatory inhibitor 
does not directly down-regulate or block CD28 on T-cells, but induces T-cell anergy by depriving 
T-cells from the necessary co-stimulatory signal from CD80/86 on antigen-presenting cells.(4) 
Aggressive T cell-mediated allogeneic responses have been observed in belatacept-treated 
patients.(1) This phenomenon can be explained by the actions of memory T-cells that are less 
or not susceptible to co-stimulatory blockade of the CD28-CD80/86 pathway.(5, 6) In vitro 
studies demonstrated that, despite the presence of belatacept, effector-memory T-cells which 
lack membrane expression of CD28, i.e.CD28-negative (CD28NULL) T-cells, produce high levels 
of effector cytokines upon allogeneic stimulation.(6-8) CD28POS T-cells can down regulate their 
surface CD28 when the transcriptional initiator element of CD28 is disrupted,(9) which occurs 
after repeated antigen-stimulation (e.g. as the result of physiological aging, chronic viral 
infection, malignancy, auto-immunity, and transplantation).(10) So, in belatacept-treated 
patients, in addition to pre-existing CD28NULL T-cells, CD28POS T-cells that down regulate their surface 
CD28 after allogeneic stimulation could also pose a threat to the renal graft. In solid organ 
transplantation, seemingly opposing functions of CD28NULL T-cells have been reported. These 
cells can have immunoregulatory functions(11, 12), show features of immunoquiescence(10), 
as well as mediate allogeneic or anti-viral immune responses.(5-7, 13, 14) One study reported 
CD4POSCD28NULL T-cells could play an important role in glucocorticoid-resistant rejection occurring 
during belatacept treatment.(8) No studies on peripheral blood mononuclear cells (PBMCs) 
derived from end-stage renal disease (ESRD) patients have been conducted to determine the 
ability of their CD28POS T-cells to down regulate surface CD28 in the presence of belatacept, 
making them resistant to blockade of the CD28-CD80/86-pathway.
The aim of this study was to investigate a potential escape mechanism for CD28POS 
T-cells under belatacept treatment, i.e. the down regulation of surface CD28 by these cells 
after allogeneic stimulation. PBMCs, isolated T-cell memory subsets and isolated CD28POS T-cells 
were obtained from ESRD patients (one day before kidney transplantation) and co-cultured 
with donor antigen in the presence or absence of belatacept to mimic allogeneic reactions in 
kidney transplant patients under belatacept treatment, and therefore explain the aggressive T 
cell-mediated responses in these patients.(1)
Materials and methods
Study population and materials
Defrosted PBMCs from patients sampled one day before kidney transplantation were 
analyzed. This study was approved by the Medical Ethical Committee of the Erasmus MC University 
Medical Center in Rotterdam, the Netherlands (MEC-2007-228, MEC-2010-022). All patients gave 
written consent to collect their biomaterial as part of the ongoing transplant biobank programs. 
None of the transplant donors were from a vulnerable population and all donors or next of 
kin provided written informed consent that was freely given. Samples were randomly selected 
when enough patient and donor material were available, and when patient and donor were 
not identical for HLA class II. The patient characteristics are depicted in Supplementary Table 
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1. Materials of 61 patients were used for the PBMC study (n=33), for the isolated T-cell memory 
subset study (n=4) and for the isolated CD28POS T-cell study (n=24).
Flow cytometric isolation of recipients’ PBMCs
By use of an AriaII FACS sorterTM (Becton Dickinson, BD, Franklin Lakes, NJ), pure CD28POS 
cells (purity 98% [95-100%]) were isolated. PBMCs were stained with CD3 Brilliant Violet 510 
(BioLegend, San Diego, CA), CD4 Pacific Blue (BD, Franklin Lakes, NJ), CD8 APC-Cy7 (BD Pharm, 
San Diego, CA), CD28 APC (BD), and the viability dye 7-AAD PerCP (BD). Pure memory subsets 
(≥95% pure) were isolated using CD3 Brilliant Violet 510 (BioLegend), CD45RO PE-Cy7 (BD) and 
CCR7 PE (BD): naïve (TN cells: CCR7+CD45RO-), central-memory (TCM cells: CCR7+, CD45RO+), 
effector-memory (TEM cells: CCR7-, CD45RO+), and end-stage terminally-differentiated EMRA 
(TEMRA cells: CCR7-CD45RO-) T-cells.
Mixed lymphocyte reactions (MLRs)
The IC50 for belatacept was determined in 6 independent MLR assays with PBMCs 
of healthy volunteers (Figure 1). PBMCs were washed in serum-free medium and suspended 
in PKH67 FITC or PKH26 PE 1:50 in 1 mL Diluent C per 10 million cells (Membrane Dye Kit by 
Sigma-Aldrich, St. Louis, MO). After incubation of 4 minutes at room temperature, fetal bovine 
serum (FBS) was added to stop the incorporation of the PKH dye. Subsequently, PBMCs were 
washed twice in RPMI + 10% heat-inactivated FBS. Finally 5x104 PKH-26 PE or PKH-67 FITC labeled 
(MFI>10,000) responders’ PBMCs were incubated for 1 hour with 15 different concentrations of 
belatacept (Bristol-Myers Squib, NYC, NY, kindly provided by the manufacturer) ranging from 0-5 
mg/mL before the stimulator cells were added for 7 days. A lower concentration (100 ng/mL) 
and a higher concentration (500 ng/mL) for belatacept were used in further experiments.
5x104 PKH-26 PE or PKH-67 FITC labeled (MFI>10,000) patients’ PBMCs, FACS-isolated 
T-cell memory subsets or FACS-isolated CD28POS cells were incubated for 1 hour in 100 ng/mL or 
500 ng/mL belatacept (Bristol-Myers Squibb, New York City, NY) or 100 or 500 ng/mL IgG (human 
IgG, Sigma-Aldrich, St. Louis, MO) as control. Hereafter 5x104 CD3-depleted and irradiated 
(total dose of 40 Gy) stimulator PBMCs were added to the culture. Subsequently, the cells were 
incubated for 1 week at 37°C and analyzed by flow cytometry (BD FACSDiva 8.0.1, BD, Franklin 
Lakes, NJ).
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Figure 1. Despite the dose-dependent inhibition by belatacept of T-cell proliferation, residual T-cell proliferation 
is present despite high doses of belatacept
Experiments were performed with PBMCs derived from healthy volunteers (n=6). A representative sample 
is shown (A). The IC50 was calculated using a logarithmic transformation of belatacept concentrations (log 
[inhibitor]- versus- response curve) (B). The relative inhibition by belatacept in MLRs with patients’ PBMCs is 
given for CD4POS and CD8POS T-cells. The human IgG control has been set at the zero-line (C).
N.B.: In (C) black lines represent the medians. The upper and lower borders of the boxes represent the 25th and 
75th percentiles. The error lines represent the10th and 90th percentiles. Values above 1.5 quartile distances 
of the box are considered outliers and are represented by a dot. Twenty independent experiments were 
conducted using the lower dose of belatacept (100 ng/ml) and 13 using the higher dose of belatacept (500 
ng/mL).
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001
Flow cytometry
PBMCs were characterized (n=33) before and at day 7 of the MLR. Memory subsets 
were defined by CCR7 and CD45RA surface expression: naïve (TN cells: CCR7+CD45RA+), central-
memory (TCM cells: CCR7+, CD45RA-), effector-memory (TEM cells: CCR7-, CD45RA-), and end-
stage terminally-differentiated EMRA (TEMRA cells: CCR7-CD45RA+) T-cells. At day 7 the cells were 
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plugged with brefeldin A (Golgiplug, BD Pharm; 1 µg/mL) for 4 hours. Thereafter, the allogeneic 
intracellular IFNγ-production was measured. Also the intracellular IFNγ production capacity was 
assessed, by re-stimulating part of the cells at day 7 with phorbolmyrisate acetate (PMA) 0.05 
µg/mL and ionomycin 1 µg/mL (Sigma-Aldrich, St Louis, MO). FACS- isolated memory subsets of 
recipient cells (n=4 independent experiments) were stained before and after MLR using CD3 
Brilliant Violet 510 (BioLegend), CD4 APC (BD), CD8 APC-Cy7 (BioLegend), CCR7 PE (BD) and 
CD45RO PE-Cy7 (BD). Intracellular staining was done using IFNγ Brilliant Violet 421 (BioLegend). 
The proportion of PKH67-FITC negative cells was assessed as measurement for proliferation. 
FACS-sorted CD28POS cells (n=24 independent experiments) were stained for CD28-expression 
and IFNγ-production after 7 days of antigen stimulation. Monoclonal antibodies used for surface 
marker staining and intracellular cytokine staining for PBMCs and isolated CD28POS cells were 
CD3 Brilliant Violet 510 (BioLegend, San Diego, CA), CD4 PerCP (B DBiosciences, Frankin Lakes, 
NJ), CD4 APC-Cy7 (BioLegend), CD8 APC (BD), CD8 APC-Cy7 (BD Pharmingen, San Diego, CA), 
CCR7 PE (BD Pharmingen), CD45RA brilliant violet 421 (BioLegend), CD28 APC (BD), CD28 PerCP-
Cy5 (BD) and IFNγ BV421 (BioLegend) or IFNγ APC (BD Pharmingen). The proportion of PKH-26 PE 
or PKH-67 FITC-negative cells was also assessed as measurement for proliferation. 
Calculating the relative inhibition by belatacept
 The relative inhibition by belatacept was expressed as the proliferation of T-cells in the 
presence of belatacept compared to the proliferation in the presence of IgG control, which was 
set to 100%:
Statistical analyses
 The differences between measurements before and after 7 days of MLR, and between 
IgG control and belatacept, were analyzed using the Wilcoxon signed-rank test. The differences 
between belatacept 100 ng/mL and belatacept 500 ng/mL were analyzed using the Mann-
Whitney-U test.
 Graph pad prism 5.01 (GraphPad Software, San Diego, CA) was used for statistical 
analyses. P-values with a 2-sided α of 0.05 were considered statistically significant. When not 
otherwise specified, medians [range] are presented.
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Figure 2. Predominance of effector-memory T-cells after allogeneic stimulation was enhanced by belatacept
A representative sample of 33 measurements is depicted for the gating strategy of the memory subsets 
within the proliferated, alloreactive CD8POS T-cells after 7 days of allo-antigen stimulation, in the presence and 
abcense of belatacept, as well as the memory subsets before allo-antigen stimulation (A). Memory subsets 
were gated the same way for CD4POS T-cells.  The percentages of naïve, central memory, effector-memory and 
terminally-differentiated EMRA T-cells are given before allogeneic stimulation within CD4POS and CD8POS T cells, 
and after allogeneic stimulation in the presence of human IgG control, 100 ng/mL or 500 ng/mL belatacept 
for proliferated CD4POS T-cells and for CD8POS T-cells (B).
N.B.: Black lines represent the medians. The upper and lower borders of the boxes represent the 25th and 75th 
percentiles. The error lines represent the10th and 90th percentiles. Values above 1.5 quartile distances of the 
box are considered outliers and are represented by a dot. Twenty independent experiments were conducted 
using the lower dose of belatacept (100 ng/ml) and 13 using the higher dose of belatacept (500 ng/mL).
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001, TN=naïve T-cells, TCM=central-memory T-cells, TEM=effector-
memory T-cells, TEMRA=terminally differentiated EMRA T-cells
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Results
Despite the dose-dependent inhibition by belatacept of T-cell proliferation, residual T-cell 
proliferation was still present when high doses of belatacept were added
Belatacept inhibited T-cell proliferation in a dose-dependent manner (Figure 1).The IC50 
of belatacept for T-cell proliferation was 215 ng/mL [CI95% 123-376 ng/mL) in MLRs of healthy 
volunteers’ PBMCs. Remarkably, even at very high concentrations, belatacept could not inhibit 
T-cell proliferation more than ±70%, resulting in a residual proliferation of ±30%.
A concentration lower and a concentration higher than the IC50 of belatacept 
were used in further experiments (100 ng/mL and 500 ng/mL), to ensure the inhibitory effects of 
belatacept were dose-dependent.
In MLRs of PBMCs of ESRD patients stimulated with allo-antigen, both CD4POS and CD8POS 
T-cells were significantly inhibited in proliferation by the lower and higher dose of belatacept, in 
a dose-dependent manner (Figure 1C).
Predominance of effector-memory T-cells after allogeneic stimulation was enhanced by 
belatacept
The T-cells that proliferated upon allogeneic stimulation were analyzed in the presence 
and absence of belatacept to gain more insight into the alloreactive T-cells that were less 
susceptible to belatacept (Figure 2A). A predominance of effector-memory T-cells was seen 
within the proliferated CD4POS and CD8POS T-cells after allo-antigen stimulation in the presence 
of the higher dose of belatacept (500 ng/mL). 89% [41-94%] of the alloreactive CD4POS T cells 
expressed an effector-memory phenotype in the presence of 500 ng/mL belatacept vs. 64% 
[15-95%] for the IgG control, p<0.01. Similar observations were made for CD8POS T cells: 82% [52-
92%] in the presence of 500 ng/mL belatacept vs. 66% [8-93%] for the IgG control, p<0.01. In 
parallel with the proportional increase of effector-memory T cells amongst alloreactive T cells, 
the proportion of naïve and central-memory T cells decreased. The predominance for effector-
memory T cells was not enhanced when the lower dose of belatacept was used.   
Phenotyping and function of alloreactive effector-memory T-cells
Since the allo-reactive proliferated T-cells mostly consisted of effector-memory T-cells, 
these cells were further analyzed for CD28-expression and allogeneic IFNγ-production (Figure 
3). The proliferated effector-memory T-cells were compared to the total effector-memory 
T-cell population (both proliferated and non-proliferated cells). Within the proliferated effector-
memory CD4POS T-cell population, the percentage of CD28POS T-cells (85% [41-98%]) was lower 
than in the total CD4POS effector-memory population (93% [76-98%]), p=0.01, but still substantial 
(Figure 3B). No selection of CD28NULL T-cells occurred in the presence of belatacept, since similar 
proportions of CD28POS cells within the proliferated CD4POS effector-memory T-cells were observed 
in the presence of the IgG control, belatacept 100 ng/mL or 500 ng/mL. In the proliferated CD8POS 
effector-memory T-cell population 45% [1-85%] of the cells were CD28POS compared to 63% [30-
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Figure 3. A large proportion of alloreactive T cells is CD28POS, and allogeneic IFNγ production is not inhibited 
by belatacept
A representative sample of 33 experiments is depicted for the gating strategy of CD4POSand CD8POS 
effector-memory T-cells and their CD28 expression and the intracellular IFNγ production (A). The percentage 
of CD28POSeffector-memory T-cells, (B) and the percentage of IFNγ producing cells (C) was assessed in 
the total and in the proliferated effector-memory CD4POS and CD8POS populations upon 7-day allogeneic 
stimulation by means of MLR. The percentages are given in the presence of human IgG control, 100 ng/mL or 
500 ng/mL belatacept. 
N.B.: Black lines represent the medians. The upper and lower borders of the boxes represent the 25th and 75th 
percentiles. The error lines represent the10th and 90th percentiles. Values above 1.5 quartile distances of the 
box are considered outliers and represented are by a dot. Twenty samples were used for the lower dose of 
belatacept (100 ng/ml) and 13 samples for the higher dose of belatacept (500 ng/mL). 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001
100%] in the total CD8POS effector-memory T-cell population, p=0.01 (Figure 3B). Despite adding 
the lower or higher dose of belatacept, similar proportions of CD28POS cells were observed 
among the proliferated CD8POS effector-memory T cells as in the IgG control (Figure 3B).
9% [2-96%] of the proliferated CD4POS effector-memory T-cells and 5% [0-36%] of the 
proliferated CD8POS effector-memory T-cells produced IFNγ upon allogeneic stimulation. The 
allogeneic production of this important cytokine by CD4POS and CD8POS effector-memory T-cells 
was not significantly inhibited by the lower or higher dose of belatacept. The allogeneic IFNγ 
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production by proliferated CD4POS effector-memory T-cells (9% [2-96%]) was significantly higher 
than the production by the total CD4POS effector-memory T-cell population (3% [1-75%]), p=0.03 
(Figure 3C). This difference was not observed between the proliferated and total CD8POS effector-
memory T-cells. A fair proportion of CD4POS and CD8POS T cells had the capacity to produce IFNγ 
after re-stimulation with PMA/ionomycin (Supplementary Figure 1). 
Isolated effector-memory T cells were not inhibited in differentiation or IFNγ production by 
belatacept
For detailed information regarding the experiments using isolated memory subsets, 
see Supplementary Table 2. Sufficient cell numbers were not available for all test conditions. 
The differentiation of isolated effector-memory T-cells into central-memory or end-stage 
differentiated effector-memory T-cells was not inhibited by belatacept 500 ng/mL (Figure 4A 
and Supplementary Table 3). The differentiation of isolated naïve or central-memory T-cells 
into other subsets was successfully suppressed by belatacept (Supplemenary Figure 2A 
and Supplementary Table 3). Each subset, except for TEMRA cells, was successfully inhibited in 
proliferation by 500 ng/mL belatacept (Figure 4B, Supplemenary Figure 2B and Supplementary 
Table 4). The proliferation within the newly formed memory subsets, however, was high and 
not inhibited by belatacept, especially in the newly formed effector-memory and TEMRA cells 
(Figure 4B and Supplementary Table 4). Intracellular IFNγ concentrations were highest in the 
newly formed memory subsets differentiated from isolated naïve, effector-memory and TEMRA 
cells (Supplementary Table 5). Belatacept 500 ng/mL could not prevent the IFNγ production by 
these induced subsets (Supplementary Table 5). IFNγ production by isolated effector-memory 
T-cells was also not blocked by belatacept (Figure 4C and Supplementary Table 5). Belatacept 
could, however, inhibit IFNγ production by the isolated naïve and central-memory T-cells 
(Supplemenary Figure 2C), as well as in the newly formed subsets differentiated from central-
memory T-cells (Supplementary Table 5). 
The indirect target of belatacept, CD28, can be down-regulated by T-cells upon allogeneic 
stimulation, resulting in IFNγ-producing CD28NULL T-cells
 To study the dynamics of CD28-expression on T-cells, pure CD28POS and CD28NULL cell 
populations were studied after allogeneic stimulation (Figure 5). A fair proportion of the isolated 
CD28NULL T-cells up-regulated CD28, but more importantly, also a proportion of the CD28POS 
T-cells down-regulated CD28. (Figure 5A-B) Therefore, CD28-expression was also studied within 
proliferated isolated CD28POS T-cells, in the presence or absence of belatacept (Figure 5C). The 
inhibitory effect on isolated CD28POS T-cell proliferation is depicted in Supplementary Figure 3. 
After allogeneic stimulation, in the presence of belatacept 100 ng/mL, 6% [1-49%] of the CD4POS 
T-cells did not express CD28 anymore and 5% [1-53%]of the CD8POS population. These percentages 
were similar to the percentages of CD28NULL T-cells in the absence of belatacept (Figure 5D). 
Similar proportions of CD28NULL T-cells were found for cultures with the higher concentration of 
belatacept.
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Figure 4. Isolated effector-memory T cells are not inhibited in differentiation or IFNγ production by belatacept
FACS-sorted effector-memory T-cells (CD3+CCR7-CD45RO+) were stimulated for 7 days with allo-antigen 
(purities≥99%). One of in total four independent experiments is shown in this figure. The surface expression 
of CCR7 and CD45RO was assessed on CD4POS and CD8POS T cells after 7 days of MLR to determine the 
differentiation of effector-memory T cells into other memory subsets; an example of CD4POS isolated effector-
memory T cells is shown in (A). The proliferation by the isolated effector-memory T cells, and by the cells 
differentiated into central-memory and end-stage terminally-differentiated effector-memory T-cells in 
particular, is depicted (B), as well as the allogeneic IFNγ production by these cells (C). bela=belatacept 500 
ng/mL, TN=naïve T-cells, TCM=central-memory T-cells, TEM=effector-memory T-cells, TEMRA=terminally differentiated 
EMRA T-cells
  The allogeneic IFNγ production was compared between T-cells that remained 
CD28POS and T-cells that had down-regulated their CD28 surface molecules (Figure 5C for typical 
examples). In the presence of 100 ng/mL belatacept, the proportion of CD4POSCD28NULL T-cells 
that produced IFNγ (39% [4-93%]) was comparable to cells that remained CD28POS (15% [2-68%]), 
p=0.08. (Figure 5E) The same was seen when 500 ng/mL belatacept was added. Within the 
CD8POS T-cells, in the presence of 100 ng/mL belatacept, slightly more CD28POS T-cells produced 
IFNγ than the cells that turned CD28NULL: 7%[0-96% ] vs. 4% [0-66%], respectively, p=0.003. This 
difference was not observed when 500 ng/mL belatacept was added to the cultures. Similar 
percentages of IFN-γ production were found for the IgG control samples, i.e. in the absence of 
belatacept. (Figure 5E) 
Discussion
Here, the ability of ESRD patients’ CD28POS T-cells to down-regulate surface CD28 upon 
allogeneic stimulation was studied after belatacept was added ex vivo. Kidney transplantation 
was mimicked to explain the severe T-cell-mediated immune responses that have been 
observed in belatacept-treated patients.(1) Although the overall allogeneic proliferation by 
T-cells was inhibited by belatacept, this inhibition never reached 100% (Figure 1). Moreover, a 
part of the antigen-reactive T-cells down-regulated surface CD28 molecules without becoming 
anergic (i.e. their capacity to produce intracellular IFNy production upon allogeneic stimulation 
remained intact; Figure 5E). Even in the presence of belatacept, the co-stimulatory inhibitor 
of the CD80/86-CD28 pathway, these originally CD28POS T-cells were not susceptible to co-
stimulatory blockade and are therefore a selection of the most dangerous immune cells for the 
allograft.(6, 7) In addition, amongst the antigen-reactive proliferated T-cells, a large proportion 
remained CD28POS and also produced intracellular IFNγ. Explanations for the severe alloreactivity 
in belatacept-treated patients include the possibility that belatacept inhibits negative regulators 
of the immune system(15, 16); ineffectively permeate lymph nodes and kidney tissue(17); or 
the alloreactivity is the result of heterologous immunity, like EBV positive memory T cells may 
cross-react with donor HLA expressed on the transplanted kidney.(18) Based on our research 
presented here, we postulate three additional mechanisms for the severe alloreactivity in 
belatacept-treated patients(1): (i) proliferation is not inhibited in all T-cells; (ii) naïve and central-
memory T-cells differentiate into effector-memory T-cells, which are less susceptible to 
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Figure 5. The indirect target of belatacept, CD28, can be down regulated by T-cells upon allogeneic stimulation, 
resulting in IFNγ-producing CD28NULL T-cells
FACS-sorted CD28POS T-cells (A) and FACS-sorted CD28NULL T-cells (B) from n=16 kidney-transplant candidates 
were stimulated for 7 days with allo-antigen (purities ≥95%). CD28-expression was assessed after 7 days of 
MLR and compared to the CD28-expression of the pure starting populations. Gating strategies to determine 
proliferated CD4POS and CD8POS T-cells are depicted, as well as a typical example for proliferation with and 
without belatacept. The gating strategy for CD28 expression within proliferated CD4POS and CD8POS T-cells, 
including allogeneic IFNγ production, is depicted in a typical example (C). IFNγ expression is depicted in 
this typical example in the presence of 100 ng/mL belatacept. The proportion of CD4POS and CD8POS T-cells 
which lost their CD28-molecules are shown for the study population (D). The percentage of IFNγ producing 
cells within T-cells that remained CD28POS and within T-cells that differentiated into CD28NULL are shown, in the 
presence and absence of belatacept (E).  
N.B.: Black lines represent the medians. The upper and lower border of the boxes represent the 10th and 90th 
percentile. The error lines represent the10th and 90th percentiles. Values above 1.5 quartile distances of the 
box are considered outliers and are represented by a dot. Levels of significance in (B) were given for the 
difference between proliferation in the presence of belatacept and the IgG control. *=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001, TN=naïve T-cells, TCM=central-memory T-cells, TEM=effector-memory T-cells, 
TEMRA=terminally differentiated EMRA T-cells
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immunosuppressive drugs(19, 20); and (iii) T-cells can down-regulate their cell surface CD28 
molecule and consequently become independent of co-stimulatory signals from CD80/86.
The log [inhibitor]- versus - response curve of belatacept (Figure 1B) demonstrated that 
a plateau phase is reached for its inhibitory capacity. Even when high doses of belatacept 
(>1 mg/mL) were added in vitro, the maximum inhibition was ±70%. In the BENEFIT study, 
serum belatacept concentrations were not higher than 10 µg/mL(1, 21), suggesting that T-cell 
proliferation may also be incompletely blocked in vivo. The IC50 of belatacept found in our in 
vitro experiments (0.22 µg/mL, 95% CI 0.12-0.38 µg/mL) was similar to the serum belatacept 
concentrations of stable patients 2-5 years after kidney transplantation that received belatacept 
every 8 weeks (0.13 - 0.21 µg/mL).(2) Because the volume of distribution of belatacept is low(22), 
the concentration in lymph nodes or graft tissue is presumably even lower, which could result in 
even more proliferation of allo-reactive T-cells.
It is known that CD28NULL T-cells are not susceptible to belatacept and can produce 
high amounts of effector cytokines.(5-7) When adding belatacept to patients’ PBMCs ex vivo, 
a smaller proportion of CD28POS T-cells, thus a larger proportion of CD28NULL T-cells was observed 
within the cells proliferated upon allogeneic stimulation (Figs.3B and 5D). This can be explained 
by a selection of CD28NULL T-cells, because these cells are not susceptible to belatacept. Another 
explanation is that not all CD28POS T-cells are inhibited by belatacept and that their CD28 co-
stimulatory molecule is down-regulated, since CD28NULL T-cells were present in cultures of isolated 
CD28POS T-cells after one week of MLR. (Figure 5A and 5D) When adding the higher dose of 
belatacept to MLRs with patients’ PBMCs (Figure 3), the predominance of CD28NULL T-cells was not 
observed, possibly because belatacept at this concentration sufficiently inhibited the activation 
of CD28POS T-cells and subsequently prevented the differentiation into CD28NULL T-cells. Another 
possibility could be that equal numbers of CD28NULL T-cells upregulated CD28 as the number 
of CD28POS T-cells that down-regulated CD28, and therefore the net-result was no increase of 
CD28NULL T-cells. Nevertheless, apart from CD28NULL T-cells, a large proportion of allo-reactive, 
proliferated T cells was CD28POS, which means that despite their surface CD28 molecules these 
cells were not susceptible for belatacept.
To accurately establish the dynamics of CD28-expression by alloreactive T-cells of ESRD 
patients in the presence of belatacept, the proportion of CD28NULL T-cells was measured after 
one week of allogeneic stimulated pure CD28POS T-cells. (Figure 5) Indeed, even in the presence 
of belatacept, a proportion of T-cells lost their CD28 surface molecules upon allogeneic 
stimulation, making them not susceptible to inhibition of the CD28-pathway. These CD28NULL T-cells 
did not become anergic, since they remained capable of producing intracellular IFNγ upon 
allogeneic stimulation. For CD4POS and CD8POS T-cells, both CD28POS or newly-formed CD28NULL 
T-cells produced comparable large amounts of allogeneic IFNγ (Figure 5E). The differentiation of 
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Supplementary Figure 1. CD4POS and CD8POS T-cells from end-stage renal disease patients have a high IFNγ 
production capacity
The intracellular IFNγ production is depicted for both CD4POS and CD8POS T-cells after 7 days of allo-antigen 
stimulation with and without 4 hours PMA/ionomycin re-stimulation. bela=belatacept 100 ng/mL
CD28POS T-cells into IFNγ–producing CD28NULL T-cells reflects the absence of belatacept-induced 
anergy of these T-cells (Figure 5), possibly because of alternative routes for co-stimulation.(23)
In the present study, using PBMCs of kidney transplant candidates, the alloreactive 
cells mostly had effector-memory T-cell features, especially after allogeneic stimulation in the 
presence of belatacept (Figure 2). However, the absolute numbers of such responding cells were 
lower because belatacept inhibits T-cell proliferation (Figure 1). The predominance of effector-
memory T cells is in line with previous findings from studies using animals(5) or PBMCs from healthy 
volunteers. (6, 7) These effector memory T-cells are less susceptible to the currently prescribed 
immunosuppressive drugs, like tacrolimus(19), and are especially less subject to co-stimulation 
blockade.(23) The predominance of effector-memory T-cells could be the result of less affected 
proliferation of the pre-existing effector-memory T-cells. Isolated effector-memory T cells could, 
however, be inhibited in proliferation by belatacept (Figure 4B and Supplementary Table 4), 
but not in differentiation into central-memory and TEMRA T cells or in IFNγ production (Figure 4B, 
Supplementary Tables 3 and 5). The selection of effector-memory T-cells was evident when the 
higher dose of belatacept was added, since naïve and central-memory T-cells are then more 
sufficiently inhibited (Figs. 1 and 2). In addition, the predominance of effector-memory T-cells 
could also 
Chapter 4
90
A. Isolated naïve T-cells (CD4+)
7 days allo-antigen stimulation
7 days allo-antigen stimulation
+ belatacept
Isolated central-memory T-cells (CD4+)
56.1%
TN
4.7%
TCM
37.3%
TEM
1.9%
TEMRA
1.0%
TEMRA
78.4%
TN
6.6%
TCM
14.0%
TEM
7 days allo-antigen stimulation
7 days allo-antigen stimulation
+ belatacept
Isolated TEMRA-cells (CD4+)
7 days allo-antigen stimulation
7 days allo-antigen stimulation
+ belatacept
0.5%
TN
43.2%
TCM
56.8%
TEM
0.0%
TEMRA
0.0%
TEMRA
0.8%
TN
67.3%
TCM
32.7%
TEM
66.9%
TEMRA
66.5%
TEMRA
32.0%
TEM
29.4%
TEM
1.2%
TN
2.5%
TCM
1.3%
TCM
0.2%
TN
B.
Isolated naïve T-cells (CD4+)
Isolated central-memory T-cells (CD4+)
7 days allo-antigen stimulation 7 days allo-antigen stimulation
+ belatacept
Isolated TEMRA-cells (CD4+)
27.5% 7.0%
74.4% 47.5%
34.6% 36.4%
C. Isolated naïve T-cells (CD4+) Isolated central-memory T-cells (CD4+) Isolated TEMRA-cells (CD4+)
Proliferated Proliferated
Proliferated Proliferated
Proliferated Proliferated
7-days allo-antigen 7-days allo-antigen 7-days allo-antigen7-days allo-antigen 
+ bela
7-days allo-antigen 
+ bela
7-days allo-antigen 
+ bela
37.7% 16.4% 16.6% 11.0% 17.4% 20.1%
CD45RO
C
C
R7
CD4
IF
N
γ
Supplementary Figure 2. Belatacept inhibits differentiation, proliferation and allogeneic IFNγ production by 
naïve and central-memory T-cells
For detailed information about these experiments refer to Supplementary Tables B-E. The differentiation of 
isolated T-cell memory subsets (naïve, central-memory and end-stage terminally-differentiated effector-
memory T-cells) into other memory subsets is depicted in the presence and absence of 500 ng/mL belatacept 
(A). All starting population were ≥97% pure. The proliferation of these isolated memory subsets was assessed 
in the presence and absence of 500 ng/mL belatacept (B), as well as the allogeneic IFNγ production (C).
bela=belatacept 500 ng/mL, TN=naïve T-cells, TCM=central-memory T-cells, TEM=effector-memory T-cells, 
TEMRA=terminally differentiated EMRA T-cells
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Supplementary Figure 3. The proliferation of isolated CD28POS T-cells is inhibited by belatacept
The relative inhibition of kidney-transplant candidates’ CD28POS-isolated CD4POS and CD8POS T-cells in the 
presence of 100 (n=16) or 500 ng/mL (n=8) belatacept is shown (B). The human IgG control has been set at 
the zero-line.
be the result of differentiation of naïve and central-memory T-cells into the effector-memory 
phenotype upon allogeneic stimulation (Supplementary Figure 2.).(24)
 A limitation of our study is the low availability of patient materials, which makes it difficult 
to test multiple conditions, e.g. the distinction between allorecognition via the direct or indirect 
pathway. Also, the difference between patients and healthy controls would be an interesting 
question, but does not address to our initial study purpose.
In conclusion, CD28-positive, mostly effector-memory T-cells can become resistant to 
belatacept by down-regulating their surface CD28 molecules, indicating differentiation into 
highly allo-reactive CD28NULL T-cells. This study provides evidence that not only CD28NULL T-cells but 
also CD28POS T-cells can mediate anti-donor responses despite belatacept treatment.
Supplementary Table 1: Patient characteristics
PBMC 
study (n 
= 33)
Isolated T-cell 
memory subsets 
study (n=4)
Isolated CD28POS cells study (n = 24)
Age in years (median + range) 49 (20-75) 70 (53-74) 55 (19-71)
Gender (female) 33% 0% 25%
HLA mismatches with allo-anti-
gen (mean ± SD) 4.0 (±1.3) 3.8 (±1.5) 4.1 (±1.4)
CMV seropositive 70% 50% 71%
Renal replacement therapy 67% 0% 55%
•	 Time on renal 
replacement therapy in 
months (median + range)
21 (2-71) - 6 (1-73)
CD28POS, CD28-positive; HLA, human leukocyte antigen; MLR, mixed lymphocyte reaction; PBMCs, peripheral 
blood mononuclear cells; SD, standard deviation
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Supplementary Table 2: Detailed information about the experiments using isolated T-cell memory subsets.
No. 1 2 3 4
PBMCs # 39 * 10^6 51 *10^6 62 * 10^6 72 * 10^6
Isolated TN
# 0,07 * 10^6 2,8 * 10^6 1,4 * 10^6 0,3 * 10^6
No bela - + + +
bela - + + +
ics - + + -
Isolated TCM
# 0,14 * 10^6 1,8 *10^6 0,7 * 10^6 0,12 * 10^6
No bela + + + +
bela + + + -
ics - + + -
Isolated TEM
# 2,7 * 10^6 1,5 * 10^6 2,7 * 10^6 0,8 * 10^6
No bela + + + +
bela + + + +
ics + + + +
Isolated TEMRA
# 0,12 * 10^6 0,3 * 10^6 1,6 * 10^6 0,05 * 10^6
No bela + + + -
bela - - + -
ics - - + -
#, number of cells; +, experiment performed; -, experiment not performed due to too low or no cell numbers; No 
bela, no belatacept added to culture; bela, belatacept 500 ng/mL added to culture; ics, intracellular staining 
for IFNγ; No., Number of experiment performed (total n=4 independent experiments); PBMCs, peripheral blood 
mononuclear cells (number of cells before FACS isolation); TCM, central-memory T cells; TEM, effector-memory T 
cells; TEMRA, end-stage terminally-differentiated effector-memory T cells; TN, naïve T cells
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Supplementary Table 3: Differentiation by isolated T-cell memory subsets upon allo-antigen stimulation (Table 
continues on next page)
No. Starting subset
Purity 
starting 
subset
Bela CD4+ T cells after 7 days allo-antigen stimulation
CD8+ T cells after 7 days 
allo-antigen stimulation
% within 
CD3+ 
cells
ng/mL TN (%)
TCM 
(%) TEM (%)
TEMRA 
(%)
TN 
(%)
TCM 
(%)
TEM 
(%)
TEMRA 
(%)
1
TN
99,3 0 - - - - - - - -
500 - - - - - - - -
2
99,9 0 56,1 4,7 37,3 1,9 75,6 2,7 20,9 1,2
500 78,4 6,6 14,0 1,0 93,7 2,3 3,9 0,2
3
99,6 0 95,7 1,1 2,6 0,7 97,1 0,8 1,8 0,4
500 95,8 1 2,5 0,8 98,8 0,6 0,4 0,2
4
99,9 0 98,9 0,7 0,5 0 97,8 1 1,2 0,2
500 99,3 0,6 0,1 0,3 99,2 0,8 0,1 0
1
TCM
98,4 0 0,0 43,2 56,8 0 0,3 75,7 24,4 0
500 0,0 67,3 32,7 0 0,4 95,5 4,2 0
2
95,2 0 0,3 56,5 43,4 0,1 1,5 83,9 14,7 0,2
500 0,3 91 4 0,1 2,3 95,5 2,3 0,2
3
97,9 0 0,9 91,4 7,8 0,2 4,3 94,3 1,7 0,3
500 0,8 97,7 1,4 0,2 4,3 92,3 2,9 0,7
4
98,7 0 1,9 98,1 0,1 0 4 93,8 2,3 0
500 - - - - - - - -
1
TEM
99,5 0 0 10,6 86,7 3,3 0 1,6 97 1,8
500 0 16,3 81,3 3,5 0 2,9 96,4 1,1
2
99,8 0 0,2 56,5 43,4 0,1 1,5 83,9 14,7 0,2
500 0,1 96 4 0,1 0,8 98,8 0,6 0
3
99,4 0 0 5,8 94,2 0,3 0 1,3 98,1 0,7
500 0 5,5 94,5 0,2 0 1,5 98,2 0,6
4
100 0 0 19,9 78,6 1,5 0,1 4,5 91,9 4
500 0 21,7 77,2 1,1 0,1 5,8 91,5 3,4
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1
TEMRA
99,9 0 2,1 0,5 26,1 71,5 2 0,3 4,6 93,3
500 - - - - - - - -
2
99,8 0 0,7 0,1 6,8 92,4 2,6 0,2 8,6 89
500 - - - - - - - -
3
99,8 0 1,2 2,5 29,4 66,9 3,5 1,9 2 93
500 0,2 1,3 32 66,5 3,6 2,4 2,4 91,9
4
97,4 0 - - - - - - - -
500 - - - - - - - -
The percentage of every memory subsets is depicted within the total CD4POS and CD8POS T cell population after 
7 days allo-stimulation.
-, experiment not conducted; bela, belatacept; No., Number of experiment performed (total n=4 
independent experiments); TCM, central-memory T cells; TEM, effector-memory T cells; TEMRA, end-stage 
terminally-differentiated effector-memory T cells; TN, naïve T cells
Supplementary Table 4: Proliferation by isolated T-cell memory subsets upon allo-antigen stimulation (Table 
continues on next page)
No.
Start-
ing 
subset
Bela CD4+ T cells after 7 days allo-antigen stimulation
CD8+ T cells after 7 days allo-antigen 
stimulation
ng/
mL
Total 
(%)
TN    
(%)
TCM 
(%)
TEM 
(%)
TEMRA 
(%)
Total 
(%)
TN    
(%)
TCM 
(%)
TEM 
(%)
TEM-
RA 
(%)
1
TN
0 - - - - - - - - - -
500 - - - - - - - - - -
2
0 27,5 1,1 38,4 99,8 94,8 21 0,9 41,2 99,6 85,3
500 7 0,2 29,3 98,8 85,7 2,8 0 16,3 99,4 38
3
0 3,5 0,1 32,3 99 78,2 2 0 13,8 98,5 39,8
500 3,6 0,1 35,3 99,2 91,8 0,5 0 7,6 88,2 33,7
4
0 0,9 0 37,9 91,2 28 1,2 0 24,1 91,7 0
500 0,2 0 8 84,6 66,7 0 0 0 0 0
1
TCM
0 74,4 1,4 46,2 99,9 N.A. 31,2 0 9,5 99,7 N.A.
500 47,5 1,2 27 99,5 N.A. 6,1 0 2 96,4 N.A.
2
0 43,3 0,8 10,1 99,8 100 14,6 0 4,4 99,5 N.A.
500 9,7 0,8 2,2 99,5 99,2 1,6 1,9 0,6 98,6 N.A.
3
0 8,3 0,8 2,3 97,9 95 0,9 0 0,2 75 0
500 1,8 0,9 0,3 94,8 98,5 2,5 0 0,8 84,2 N.A.
4
0 0,4 0 0,3 54,8 N.A. 3,9 0 0,6 100 N.A.
500 - - - - - - - - - -
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1
TEM
0 35,9 0 1,8 37,7 81,7 3,4 0 0,4 3,2 12,4
500 27,3 0 1,4 28,6 84,4 0,9 N.A. 0 0,7 18,8
2
0 10,4 7,2 3,7 98,2 N.A. 3,3 0 0,9 98 100
500 7,4 13,4 3,8 98,3 N.A. 0,4 0 0,2 74 33,3
3
0 2,6 20 0,1 2,6 41,1 0,3 0 0 0,3 11,5
500 1,9 0 0,1 1,8 50,5 0,7 N.A. 0,6 0,7 17,1
4
0 4,1 0 2,6 4,1 32,2 0,3 N.A. 1,2 0,3 1,3
500 3,1 N.A. 1,4 3,3 25,6 0,3 0 0 0,2 4,7
1
TEMRA
0 22,2 0 87 3,6 3 0 N.A. 55,9 0,2
500 - - - - - - - - - -
2
0 22,4 0 N.A. 94,2 1,5 7,9 0 N.A. 87,5 0,5
500 - - - - - - - - - -
3
0 34,6 0 0 79,1 10,1 0,4 0 0 23,4 0,2
500 36,4 0 0 79,6 10,8 0,6 0 0 31,4 0,2
4
0 - - - - - - - - - -
500 - - - - - - - - - -
The percentage of proliferation is given within the total CD4POS and CD8POS T cell population, and within the 
CD4POS and CD8POS memory subsets after 7 days allo-stimulation.
-, experiment not conducted; bela,  belatacept; No., Number of experiment performed (total n, 4 indepen-
dent experiments); N.A., not applicable (not enough cells to assess this measurement); TCM, central-memory T 
cells; TEM, effector-memory T cells; TEMRA, end-stage terminally-differentiated effector-memory T cells; TN, naïve 
T cells
Supplementary Table 5: Intracellular IFNγ expression by isolated T-cell memory subsets upon allo-antigen 
stimulation (Table continues on next page)
No. Starting subset Bela
CD4+ T cells after 7 days allo-antigen 
stimulation
CD8+ T cells after 7 days allo-antigen 
stimulation
ng/
mL
Total 
(%)
TN    
(%)
TCM 
(%)
TEM 
(%)
TEMRA 
(%)
Total 
(%)
TN    
(%)
TCM 
(%)
TEM 
(%)
TEMRA 
(%)
1
TN
0 - - - - - - - - - -
500 - - - - - - - - - -
2
0 37,7 15,8 83,3 24,8 14,7 27,1 16,7 94,1 43 8,8
500 16,4 16,7 94,5 32,3 8,3 12,7 22,9 93,9 51,8 22,3
3
0 2,7 2,9 74,3 5,4 9,7 3,4 3,9 84,8 13,7 18,1
500 2,5 2,7 63,8 5,1 6,3 2,7 4,1 64,4 49 12
4
0 - - - - - - - - - -
500 - - - - - - - - - -
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1
TCM
0 - - - - - - - - - -
500 - - - - - - - - - -
2
0 16,6 N.A. 12,1 12,3 12,3 13,8 11,6 10,3 36,9 16,7
500 11 N.A. 8,5 14 4,2 8,3 11,1 7,7 21,1 25
3
0 8,2 N.A. 7,2 6,4 1,7 5,2 3,2 7 0 0
500 4,1 N.A. 4,1 1,5 0,7 2,6 2,4 2,7 5,3 0
4
0 - - - - - - - - - -
500 - - - - - - - - - -
1
TEM
0 16,7 N.A. 84,7 10 10,7 4,9 N.A. 76,2 2 6,6
500 18,3 N.A. 86,8 10,4 10,4 5,9 N.A. 79,9 2,2 8,7
2
0 9,6 N.A. 8 5,3 8,3 5,6 N.A. 5,9 25,3 0
500 10 N.A. 8,8 2,3 5,5 4,1 N.A. 6 4 0
3
0 3,3 N.A. 57,2 2,2 2,9 2 N.A. 60,3 1,2 0
500 3,7 N.A. 58,3 2,7 3,5 3,1 N.A. 59,9 2,1 1,4
4
0 20,9 N.A. 82,3 3,8 1,7 2,3 N.A. 53,6 1 1,3
500 24,3 N.A. 85,5 4,3 1,5 2,8 N.A. 59 1,1 1,6
1
TEMRA
0 - - - - - - - - - -
500 - - - - - - - - - -
2
0 - - - - - - - - - -
500 - - - - - - - - - -
3
0 17,4 N.A. N.A. 26,5 16,2 4,6 N.A. N.A. 21,9 0,9
500 20,1 N.A. N.A. 28,4 19,3 5,9 N.A. N.A. 20,6 1,3
4
0 - - - - - - - - - -
500 - - - - - - - - - -
The percentage of IFNγ production is given within the total CD4POS and CD8POS T cell population, and within the 
CD4POS and CD8POS memory subsets after 7 days allo-stimulation.
-, experiment not conducted; bela,  belatacept; No., Number of experiment performed (total n, 4 indepen-
dent experiments); N.A., not applicable (not enough cells to assess this measurement); TCM, central-memory T 
cells; TEM, effector-memory T cells; TEMRA, end-stage terminally-differentiated effector-memory T cells; TN, naïve 
T cells
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Abstract
Background
Belatacept, an inhibitor of the CD28-CD80/86 co-stimulatory pathway, allows for calcineurin-
inhibitor free immunosuppressive therapy in kidney transplantation but is associated with a higher 
acute rejection risk than ciclosporin. Thus far, no biomarker for belatacept-resistant rejection 
has been validated. In this randomized controlled trial, acute rejection-rate was compared 
between belatacept- and tacrolimus-treated patients and various immunological biomarkers 
for acute rejection were investigated.
Methods
Forty kidney-transplant recipients were 1:1 randomized to belatacept or tacrolimus combined with 
basiliximab, mycophenolate mofetil and prednisolone. The 1-year incidence of biopsy-proven 
acute rejection was monitored. Potential biomarkers, namely CD8+CD28-, CD4+CD57+PD1- 
and CD8+CD28++ EMRA T-cells were measured pre- and post-transplantation and correlated to 
rejection. Pharmacodynamic monitoring of belatacept was performed by measuring free CD86 
on monocytes. 
Results
The rejection incidence was higher in belatacept-treated than tacrolimus-treated patients: 55% 
vs. 10%; p = 0.006. All three graft losses, due to rejection, occurred in the belatacept group. 
Although 4 of 5 belatacept-treated patients with >35 cells CD8+CD28++ EMRA T-cells/µL 
rejected, median pre-transplant values of the biomarkers did not differ between belatacept-
treated rejectors and non-rejectors. In univariable Cox regressions, the studied cell subsets were 
not associated with rejection-risk. CD86 molecules on circulating monocytes in belatacept-
treated patients were saturated at all time points. 
Conclusions
Belatacept-based immunosuppressive therapy resulted in higher and more severe acute 
rejection compared to tacrolimus-based therapy. This hypothesis-generating study did not 
identify cellular biomarkers predictive of rejection. In addition, the CD28-CD80/86 co-stimulatory 
pathway appeared to be sufficiently blocked by belatacept and also did not predict rejection.
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Introduction
 Belatacept, an inhibitor of the CD28-CD80/86 co-stimulatory pathway, has the 
potential to improve long-term outcomes of kidney transplantation.(1-5) Seven year follow-
up of the BENEFIT study demonstrated a higher patient and graft survival, as well as better 
graft function in patients who were treated with belatacept as compared to ciclosporin.(1) 
Nonetheless, the higher incidence and severity grade of acute rejection (AR) that have been 
observed among belatacept-treated patients remain a concern.(6-9) Up until now, belatacept 
has not been compared head-to-head with tacrolimus in randomized controlled trials (RCTs) in 
kidney transplantation without the use of lymphocyte-depleting therapy.(10-12) Observations 
made in uncontrolled studies suggest that the performance of belatacept in terms of preventing 
acute rejection as compared with tacrolimus may be inferior.(13, 14)
Identification of patients pre-transplantation who will develop AR during belatacept 
treatment would greatly help to personalize immunosuppressive therapy and maximize the 
potential of the drug. Experimental studies in rhesus macaques and ex vivo studies using human 
lymphocytes have demonstrated that antigen-experienced, cytotoxic CD28-CD8+ T-cells are not 
dependent on co-stimulatory signaling via CD80/86 and are therefore less susceptible to the 
immunosuppressive effects of belatacept.(15-17) Recently, Espinosa and colleagues suggested 
that patients with a high frequency of cytotoxic CD57+PD1-CD4+ T-cells were at increased risk 
of AR during belatacept treatment.(18) A preliminary study in non-human primates suggested 
another biomarker for AR under belatacept, namely CD28++ end-stage differentiated (EMRA) 
CD8+ T-cells that rapidly downregulate CD28 after kidney transplantation.(19) Biomarkers 
such as these may help in risk stratification and a more rational use of belatacept, but require 
prospective validation. 
Alternatively, therapeutic drug monitoring (TDM) of belatacept therapy may 
improve outcomes. Because serum belatacept concentrations tend to vary little between 
individual patients, pharmacokinetic TDM is currently not recommended.(5, 20) However, 
pharmacodynamic TDM of belatacept is feasible. Ex vivo flow cytometric measurement of CD86 
occupancy on monocytes by belatacept reflects effector T-cell function,(21) demonstrating 
the potential of TDM to improve outcomes of belatacept therapy. However, no data from 
prospective clinical trials is available to provide guidance in this respect. 
Here, the results of a RCT are reported in which forty patients were randomized to 
receive either belatacept- or tacrolimus-based immunosuppressive therapy after de novo 
kidney transplantation. The primary aims of this RCT were to compare the AR rate between 
belatacept and tacrolimus-treated patients and to identify biomarkers that were predictive of 
AR. 
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Materials and Methods
Refer to Supplemental Digital Content (SDC), Materials and Methods for additional 
and detailed information.
Study design
This was an investigator-initiated, prospective, randomized controlled, parallel group, 
open-label, single-center, clinical trial. Adult patients (≥18 years) who were scheduled to receive 
a single-organ, blood group AB0-compatible kidney from a living donor at the Erasmus MC, 
Rotterdam, the Netherlands, were eligible for participation. Historical and current cross-match-
dependent cytotoxicity tests were negative. Table 1 lists the inclusion and exclusion criteria in 
detail. The study was approved by the institutional review board of the Erasmus MC (Medical 
Ethical Review Board number 2012-421) and was registered in the Dutch national trial registry 
(http://www.trialregister.nl/trialreg/index.asp; number NTR4242, registered October 2013). 
Written informed consent was obtained from all patients before inclusion and randomization. 
The study was carried out in compliance with the Good Clinical Practice guidelines (http://apps.
who.int/prequal/info_general/documents/gcp/gcp1.pdf) and the Declaration of Istanbul.(22) 
Randomization procedure and intervention
Enrolled patients were randomly assigned on a 1:1 basis by one of the coordinating 
investigators (G.N.G. or D.A.H.) to either receive tacrolimus (Prograf®; Astellas Pharma, Leiden, 
the Netherlands) or belatacept (Nulojix®; Bristol Myers-Squibb, New York City, NY). Randomization 
was performed by use of 40 sealed, opaque, sequentially numbered envelopes containing 
treatment allocation. The random allocation sequence was generated by an independent 
biostatistician by use of a random number generator. Before the start of the study, it was 
determined that 20 patients would be allocated to each treatment arm. Data were collected 
and monitored by the coordinating investigators in a hospital-based electronic study database.
Tacrolimus was dosed based on bodyweight (a dose of 0.2 mg/kg/day in two equally 
divided doses, rounded off to the nearest 0.5 mg) according to the package insert (https://www.
astellas.us/docs/prograf.pdf). Thereafter, the tacrolimus dose was adjusted based on whole-
blood predose concentrations. The tacrolimus target predose concentrations were as follows: 
10-15 ng/mL (weeks 1 and 2), 8-12 ng/mL (weeks 3 and 4) and 5-10 ng/mL from week 5 onwards. 
Belatacept was dosed according to the Less-Intensive (LI) regimen as described previously.(6, 7) 
Belatacept was administered intravenously in a dose of 10 mg/kg on the day of transplantation 
(day 0) and on days 4, 15, 30, 60 and 90 after transplantation. Thereafter, the dose was reduced 
to 5 mg/kg and given as monthly infusions up until month 12 after transplantation (end of study). 
Additional treatment is discussed in the SDC.
Safety
Refer to SDC, Material and Methods for data collection on (serious) adverse events.
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Table 1: Inclusion and exclusion criteria
Inclusion criteria:
•	 Recipient of a first or second renal allograft
•	 Recipient of a living donor (related or unrelated)
•	 Current or historical panel-reactive antibodies (PRA) < 30%
•	 ≥1 HLA-DR mismatch
Exclusion criteria:
•	 Recipient <18 years of age at time of transplantation
•	 Recipient of a deceased donor
•	 Recipient of a third (or more) renal allograft 
•	 Recipient of a non-renal organ transplant (present, past or near-
future)
•	 Recipient of an AB0-incompatible allograft
•	 Recipient with a historically positive cytotoxicity-dependent cross-
match
•	 Recipient with a history of lymphoma
•	 Recipient with a seronegative or unknown EBV status
•	 Recipient with HIV, hepatitis B or C, and/or untreated latent 
tuberculosis
•	 Recipient with a high risk for polyoma virus-associated nephropathy, 
which is mostly due to BK virus infection
•	 Recipient who already uses tacrolimus pre-transplantation
•	 Pregnancy
Primary end points
 The overall aim of this trial was to determine the effect of belatacept and tacrolimus-
based immunosuppressive regimens on alloreactivity after kidney transplantation. The primary 
end point of the study presented here was the incidence of biopsy-proven acute rejection (BPAR) 
within the first year after transplantation. BPAR-rates were compared between belatacept- 
and tacrolimus-treated patients. We postulated that the incidence of BPAR would be higher 
among belatacept-treated patients(7) and that BPAR-biomarkers could be identified. All kidney 
transplant biopsies were obtained for cause and no protocol biopsies were obtained. Refer to 
SDC, Materials and Methods for BPAR scoring system. 
Pre-transplant circulating frequencies of CD8+CD28-, CD4+CD57+PD1- and end-stage 
terminally differentiated memory (EMRA) CD8+CD28++ T-cells, as well as their intracellular 
expression of a Granzyme B (GrB: an important cytotoxic protease during acute rejection) 
were measured as immunological primary end points.(19, 23, 24) These cell subsets were also 
measured post-transplantation, during acute rejection before additional anti-rejection therapy 
was given, or 3 months after transplantation in non-rejecting belatacept-treated patients. Free 
CD86 expression on circulating CD14+ monocytes was determined pre-transplantation as a 
predictor for rejection; and before every dose of belatacept administered after transplantation 
as a pharmacodynamic drug monitoring tool. A for belatacept competitive monoclonal 
Chapter 5
104
antibody was used (clone HA5.2B7, Beckman Coulter, Brea, CA). In patients who rejected, the 
free CD*6 expression was also assessed before additional anti-rejection therapy was given. Refer 
to SDC, Material and Methods for detailed information about our laboratory studies, including 
detection methods for DSA. 
No formal statistical power calculation for the present study was performed, because 1) 
when the study was designed, it was unclear what the difference would be between belatacept 
and tacrolimus-treated patients in terms of BPAR, as only data from the BENEFIT and BENEFIT-EXT, 
in which the comparator was ciclosporin, were available at the time;(6, 7) 2) there were no 
published data available regarding the studied biomarkers and their association with BPAR that 
could serve for such a power calculation; and 3) because of financial constraints, we chose to 
conduct the present randomized controlled clinical trial with a limited number of patients in both 
arms.(25) In our view, the present trial should therefore be regarded as a hypothesis-generating, 
pilot study. It may serve as the basis for a larger study by providing the data needed to perform 
a statistical power calculation. 
Statistical analyses
Additional information is depicted in SDC, Materials and Methods. Percentages and 
counts are given for categorical variables, and medians plus ranges for continuous variables, 
unless otherwise specified. Continuous variables were compared between the belatacept and 
the tacrolimus group or between belatacept-treated rejectors and non-rejectors using the 
Mann-Whitney U test, and categorical variables using the Fisher’s exact test. Patient and death-
censored graft survival, as well as death-censored BPAR-free survival were compared between 
the belatacept and tacrolimus group using the log-rank test. All included patients were analyzed 
according to the intention-to-treat principle. 
To determine if high numbers of cytotoxic CD4+CD57+PD-1+, CD8+CD28-, or CD8+CD28++ 
EMRA T-cells, as well as CD86 molecules/monocyte were risk factors for BPAR, univariable Cox 
regression analyses were performed with death-censored BPAR-free survival as the dependent 
variable. Independent variables included the aforementioned cell types after log transformation 
(to ensure approximately normal distribution of these variables), treatment arm, age, gender, 
ethnicity, HLA mismatches, HLA-DR mismatches, highest PRA, and cytomegalovirus (CMV) 
serostatus. Independent variables with a p<0.10 in the univariable analyses were intended to be 
included in a multivariable Cox regression analysis to predict BPAR. 
Repeated measurements of CD86 occupancy on monocytes over time were compared 
between the study groups using a linear mixed model. To ensure a normal distribution of the 
model residuals, the dependent variable in the model was log transformed. Predictors were 
the values of CD86 molecules/monocyte pre-transplantation, time point after transplantation 
(coded as categorical variable), treatment arm (belatacept or tacrolimus) and an interaction 
effect of time point and treatment arm to account for different trends over time between groups. 
The dependent variable was the value of CD86 molecules/monocyte after transplantation at a 
given time point. A random intercept was included in the linear mixed model to account for the 
within-subject correlations.
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All tests were two-tailed and statistical significance was defined as a p-value <0.05. 
Bonferroni’s correction for multiple testing was applied when necessary.(26) Statistical analyses 
were performed using IBM SPSS version 21 (SPSS Inc., Chicago, IL).
88 Eligible patients
280 Screened patients
40 Randomized patients
20 Belatacept group
(intention-to-treat population)
20 Tacrolimus group
(intention-to-treat population)
17 Completed 12-month
follow-up
19 Completed 12-month
follow-up
No informed consent (n = 48)
Not included (n = 192) 
Deceased donor kidney transplantation (n = 97)
AB0-incompatible kidney transplantation (n = 18)
Third kidney transplantation or more (n = 6)
Historically positive CDC (n = 1)
Current or historical PRA>30% (n = 10)
No HLA-DR mismatch (n = 23)
Use of CNI at the time of transplantation (n = 12)
Participation in other clinical trial (n = 6)
Non-renal transplantation (n = 3)
Re-transplanted during trial (n = 1)
EBV seronegative (n = 9)
HIV seropositive (n = 1)
Chronic hepatitis C infection (n = 1)
MGUS/indolent lymphoma (n = 2)
Logistic problems (n = 2)
Graft loss (n = 3) Death (n = 1)
Figure 1: Trial flowchart. 
All patients who were included in the study were randomized, underwent transplantation and received at 
least one dose of belatacept or tacrolimus.
CDC, cytotoxicity dependent cross-match; CNI, calcineurin inhibitor; EBV, Epstein Barr Virus; HIV, human 
immunodeficiency virus; HLA, human leukocyte antigen; MGUS, monoclonal gammopathy of unknown 
significance; PRA, panel reactive antibodies
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Table 2: Baseline characteristics at time of transplantation
Belatacept group
(n = 20)
Tacrolimus group
(n = 20)
p
Age (years) 57 (25-76) 55 (21-76) 0.88
Male / female 14 (70%) / 6 (30%) 16 (80%) / 4 (20%) 0.72
Ethnicity 1.00
•	 Caucasian 17 (85%) 16 (80%)
•	 African 2 (10%) 2 (10%)
•	 Asian 1 (5%) 2 (10%)
Body weight (kg) 79.0 (56.6-111.4) 93.6 (51.4-120.0) 0.06
HLA A mismatch (mean ± SD) 1.1 (± 0.7) 1.4 (± 0.5) 0.13
HLA B mismatch (mean ± SD) 1.3 (± 0.5) 1.5 (± 0.5) 0.51
HLA DR mismatch (mean ± SD) 1.1 (± 0.4) 1.3 (± 0.4) 0.70
Current PRA (%) 0 (0-5) 0 (0-17) 0.30
Peak PRA (%) 4 (0-6) 4 (0-21) 0.78
CMV status 0.80
•	 Donor + / Recipient - 3 (15%) 2 (10%)
•	 Donor + / Recipient + 4 (20%) 7 (35%)
•	 Donor - / Recipient - 7 (35%) 6 (30%)
•	 Donor - / Recipient + 6 (30%) 5 (25%)
Donor age (years) 59 (24-71) 51 (22-80) 0.18
Related / unrelated donor 6 (30%) / 14 (70%) 5 (25%) / 15 (75%) 1.00
Cause of end-stage renal disease 0.09
•	 Diabetes mellitus 3 (15%) 7 (35%)
•	 Hypertension 2 (10%) 5 (25%)
•	 IgA nephropathy 1 (5%) 3 (15%)
•	 Polycystic kidney disease 3 (15%) 3 (15%)
•	 Obstructive nephropathy 3 (15%) 1 (5%)
•	 Unknown 5 (25%) 0 (0%)
•	 Other 3 (15%) 1 (5%)
Renal replacement therapy 0.91
•	 None (pre-emptive) 10 (50%) 12 (60%)
•	 Hemodialysis 7 (35%) 6 (30%)
•	 Peritoneal dialysis 3 (15%) 2 (10%)
Time on dialysis (days) 425 (123-2782) 605 (465-1519) 0.41
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Number of kidney transplantation 1.00
•	 First 19 (95%) 20 (100%) 1.00
•	 Second 1 (5%) -
Continuous variables are presented as medians (plus ranges) and categorical variables as numbers (plus 
percentages), unless otherwise specified
BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; HLA, human leukocyte antigen; PRA, panel 
reactive antibodies (current = PRA at time of transplantation, peak = historically highest measured PRA); SD, 
standard deviation.
Results
Patients
Between October 1st, 2013 (first patient, first visit) and February 26th, 2015 (last patient, 
first visit) 280 patients were screened, of whom 88 were eligible for participation (Figure 1). 
Forty-eight patients did not wish to participate. Major reasons were fear of acute rejection 
and inconvenience of the monthly belatacept infusions. Forty patients were randomized and 
included in the intention-to-treat analysis. The baseline characteristics of these patients are 
described in Table 2. Seventeen (85%) patients in the belatacept and 19 (95%) in the tacrolimus 
group completed the 1-year follow-up period (last patient, last visit occurred on February 19th, 
2016). 
Patient and graft survival
Patient survival was 95% in the tacrolimus group and 100% in the belatacept group (p = 
0.32). One patient, randomized to the tacrolimus group, died 294 days after transplantation as a 
result of traumatic head injury. Three graft losses, all in the belatacept group, occurred on days 
12, 59 and 161 after transplantation, resulting in a 1-year death-censored graft-survival of 85% in 
the belatacept group vs. 100% in the tacrolimus group (p = 0.08). All three graft losses were the 
result of glucocorticoid-resistant acute rejection (Banff type IIB in two cases and type III in the 
third patient(23)).
Biopsy-proven acute rejection
In total, 29 for cause biopsies were performed in the belatacept group and 10 in the 
tacrolimus group in 14 and 6 patients, respectively, p = 0.015. The incidence of BPAR was higher 
among the belatacept-treated patients than in the tacrolimus-treated patients: n = 11 (55%) 
vs. n = 2 (10%), respectively; p = 0.006 (Table 3). The death-censored BPAR-free survival was 
significantly lower in the belatacept-treated patients than in the tacrolimus-treated patients, 
(p = 0.002; Figure 2). Median time to rejection of patients who experienced AR was 56 (3–120) 
days in the belatacept group and 81 (10–152) days in the tacrolimus group. BPAR was of a more 
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severe histological grade in the belatacept than in the tacrolimus group (p = 0.003; Table 3). 
A detailed overview of the clinical course of the individual patients is depicted 
in Figure 3. In the belatacept group, n = 10 patients (50%) were treated for BPAR with pulse 
methylprednisolone therapy. Six patients (30%) received additional treatment with alemtuzumab, 
which is the preferred T-cell depleting antibody in our center.(27) In retrospect, and after 
revision by the second pathologist, one more patient in the belatacept group (case no. 13) 
was diagnosed as suffering from rejection but he was not treated with additional anti-rejection 
therapy. This patient had a so-called isolated v-lesion and despite not treating him, his graft 
function has remained excellent to the present day. After exclusion of this particular case, the 
BPAR rate was still significantly higher in the belatacept group than in the tacrolimus group. Nine 
patients (45%), all suffering from BPAR, were converted from belatacept to tacrolimus. 
In the tacrolimus group, n = 2 patients were treated for BPAR: in one case with 
methylprednisolone pulse therapy only, in the other, additional treatment with alemtuzumab was 
given. Five patients (2 in the belatacept and 3 in the tacrolimus arm) received methylprednisolone 
for suspected rejection (For details see Figure 3 legend). 
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Figure 2: Biopsy-proven acute rejection (BPAR)-free survival. 
The time to first BPAR is depicted for the belatacept (dotted line) and the tacrolimus (solid line) group. In the 
tacrolimus group one patient died 294 days after transplantation due to traumatic head injury. 
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Figure 3: Clinical outcomes. 
Each line represents the post-transplant course of the 20 individual belatacept- and 20 individual 
tacrolimus-treated patients (separated by the bold dotted line). Time of BPAR ( ), anti-rejection therapy 
(methylprednisolone intravenously [ ] or alemtuzumab subcutaneously [ ]), switch to tacrolimus ( ), 
development of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) ( ), graft loss ( ) and 
death ( ) are shown.In the belatacept group, n = 1 (5%) patient (no. 15) received methylprednisolone for 
presumed rejection pending the results of a kidney biopsy. Biopsy revealed an alternative diagnosis namely 
ascending urinary tract infection. In one other case, methylprednisolone was administered for suspected 
rejection (no. 14). A biopsy was not performed because of a coagulation disorder. In the tacrolimus group, n = 
3 (15%) patients received methylprednisolone for presumed rejection pending biopsy results. In all three cases 
an alternative diagnosis was made: acute tubular necrosis in two patients (no. 12 and 14) and an ascending 
urinary tract infection in one case (no. 16). One belatacept-treated patient (no. 13) was not treated for 
rejection, because the diagnosis of vascular rejection (isolated v-lesion) was only made in retrospect after 
revision of the biopsy.
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Safety
 In total, 205 AEs occurred in the belatacept group (mean 10.3 per patient) and 238 
in the tacrolimus group (mean 11.9 per patient); p = 0.41 (SDC, Table 1). Of these, 22 and 35, 
respectively, were judged to be serious (means per patient 1.1 and 1.8, respectively; p = 0.15), 
excluding BPAR, graft loss, and death. 
 eGFR, excluding graft losses, was not different between belatacept-treated and 
tacrolimus-treated patients 12 months after transplantation (SDC, Table 2): 54 (28–89) and 50 
(33–84) mL/min per 1.73m2, respectively; p = 0.57. Median protein/creatinine ratio was 13.2 (5.7–
343.8) mg/mmol in the belatacept group and 9.0 (5.3–43.5) mg/mmol in the tacrolimus group; p 
= 0.44. Additional routine measurements are depicted in SDC, Table 2. 
 For the on-therapy analysis on month 12; graft function before, during and after BPAR 
in the belatacept group; the incidence of DSA and non-DSA; and pharmacokinetic drug 
monitoring, refer to SDC, Results and SDC, Tables 3-5. 
Table 3: Incidence of rejection according to the treatment group
Belatacept 
group
(n = 20)
Tacrolimus 
group
(n = 20)
p
Borderline 0 (0%) 0 (0%) -
Type 1 1.00
•	 1A 0 (0%) 0 (0%)
•	 1B 1 (5%) 1 (5%)
Type 2 0.003
•	 2A 2 (10%) 1 (5%)
•	 2B  6 (30%) 0 (0%)
Type 3 1 (5%) 0 (0%) 1.00
Mixed 1 (5%) 0 (0%) 1.00
Total BPAR 11 (55%) 2 (10%) 0.006
The incidence of the first rejection episodes is given. The highest Banff score is depicted if sequential biopsies 
were performed. 
BPAR, Biopsy-proven acute rejection 
Immunological primary end-points (biomarkers)
Three potential biomarkers for (belatacept-resistant) rejection were measured pre-
transplantation, namely CD8+CD28- T-cells, CD4+CD57+ PD1- T-cells, and CD8+CD28++ EMRA 
T-cells. There were no significant differences in the numbers or percentages of these cells at 
baseline between the tacrolimus and belatacept groups (Table 4). The limited number of 
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patients experiencing BPAR in the tacrolimus group (n = 2) precluded a meaningful statistical 
comparison between rejectors and non-rejectors in this group. Gating strategies, pre-transplant 
numbers and percentages of the above-mentioned cell subsets are depicted for future rejectors 
and non-rejectors in the belatacept group (SDC, Table 6; Figure 4), and no statistically significant 
differences were observed. Intracellular Granzyme B (GrB) expression was measured in the 
cell subsets (Figure 4A). Next, we analyzed whether high numbers or proportions of these cell 
types increased BPAR risk within the first 12 after transplantation by conducting univariable Cox 
regression analyses (Table 5):
Table 4: Absolute numbers and percentages of T cell subsets pre-transplantation
Belatacept 
group
(n = 20)
Tacrolimus group
(n = 20)
p
CD8+ CD28- T-cells/uL 95 (13 – 696) 135 (26 – 371) 0.72
CD28- % of CD8+ T-cells 26.5 (6.4 – 82.8) 35.8 (7.4 – 75.3) 0.95
CD4+ CD57+ PD1- T-cells/uL 6 (1 – 126) 9 (2 – 73) 0.18
CD57+ PD1- % of CD4+ T-cells 0.8 (0.2 – 38.2) 1.3 (0.2 – 8.1) 0.95
CD8+ CD28++ EMRA T-cells/uL 5 (1 – 74) 11 (0 – 118) 0.84
CD28++ % of CD8+ EMRA T-cells 10.8 (1.8 – 49.3) 9.0 (2.1 – 35.8) 0.82
Data represent medians (plus ranges).
1) CD8+CD28- T-cells
CD8+CD28- T-cells are mostly effector-memory cytotoxic T-cells that produce large amounts 
of pro-inflammatory cytokines,(15-17) and are not susceptible to co-stimulation blockade by 
belatacept. Almost 70% (31–89%) of CD8+CD28- T-cells produced GrB. Higher numbers and 
proportions of pre-transplant CD8+CD28- T-cells (irrespective of their intra-cellular GrB expression) 
did not significantly increase BPAR risk in the first 12 months after transplantation (Hazard Ratio 
[HR] 1.06; 95%-CI 0.61 to1.83 and HR 1.05; 95%-CI 0.50 to 2.20, respectively; Table 5). 
2) CD4+CD57+PD1- T-cells 
Next, pre-transplant CD4+CD57+PD1- T-cells were compared between rejecting and non-
rejecting belatacept-treated patients. These cells were recently described as being cytolytic, 
CD28-, and to be associated with belatacept-resistant rejection.(18) The proportion of pre-
transplant CD4+CD57+PD1- T-cells was low (<2% of the CD4+ T-cell population in most patients). 
Approximately 24% (1–74%) of these cells were GrB positive. Neither the absolute number nor the 
proportion of these cell predicted BPAR (HR 0.89; 95%-CI 0.58 to 1.27, and HR 0.90; 95%-CI 0.59 to 
1.38, respectively; Table 5). 
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3) CD8+CD28++ EMRA T-cells
Finally, CD8+CD28++ EMRA T-cells were analyzed as high numbers of these cells predicted 
belatacept-resistant rejection in primates.(19) It was postulated that these cells rapidly down-
regulate their surface CD28 expression after transplantation, making them resistant to co-
stimulatory blockade.(19) Circa 3% (0–3%) of these cells expressed intracellular GrB. The absolute 
numbers or proportions of pre-transplant CD28++ cells within the CD8+ EMRA T-cell population did 
not increase BPAR risk (HR 0.86; 95%-CI 0.58 to 1.27, and HR 1.23; 95%-CI 0.64 to 2.33, respectively; 
Table 5) Interestingly, from the 5 patients with >35 CD8+CD28++ EMRA T-cells/µL, 4 were rejectors 
and only 1 was a non-rejector (Figure 4B). In the tacrolimus group the n=2 rejectors had <10 
CD8+CD28++ EMRA T-cells/µL pre-transplantation. 
Table 5: Univariable Cox regression analyses for the risk of biopsy-proven acute rejection
Independent variables
 
Hazard 
Ratio
95%-CI
p
Lower Upper
Age (years) 1.002 0.964 1.042 0.91
Gender (female vs male) 1.540 0.474 5.015 0.47
Ethnicity (Non-Caucasian vs Caucasian) 0.090 0.002 5.431 0.25
Highest PRA (%) 0.853 0.668 1.088 0.20
HLA total mismatches (4 or more vs less than 4) 1.568 0.512 4.800 0.43
HLA DR mismatches (2 vs 1) 0.623 0.138 2.810 0.54
CMV seropositivity (positive vs negative) 0.453 0.148 1.389 0.17
Treatment group (belatacept vs tacrolimus) 7.206 1.592 32.614 0.01
CD8+ CD28- T-cells/uL pre-transplantation 1.061 0.614 1.832 0.83
CD28- % of CD8+ T-cells pre-transplantation 1.048 0.500 2.196 0.90
CD4+ CD57+ PD1- T-cells/uL pre-transplantation 0.886 0.577 1.360 0.58
CD57+ PD1- % of CD4+ T-cells pre-transplantation 0.904 0.592 1.382 0.64
CD8+ CD28++ EMRA T-cells/uL pre-transplantation 0.858 0.581 1.268 0.44
CD28++ % of CD8+ EMRA T-cells pre-transplantation 1.226 0.644 2.331 0.54
CD86 molecules/monocyte 0.327 0.049 2.192 0.25
CI, confidence interval; CMV, cytomegalovirus; HLA, human leukocyte antigen; PRA, panel reactive antibod-
ies
N.B.: To ensure normal distribution, numbers and proportions of the biomarkers and CD86 molecules/mono-
cyte were log transformed before including them in the univariable Cox regression analyses. This means that 
the hazard ratio represents the relative increase in risk for each log unit increase of the independent variable 
rather than one unit increase of this variable. 
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Figure 4: CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T-cells pre-transplantation. 
CD4+ and CD8+ T-cells were gated from 7-AAD negative CD3+ lymphocytes (based on forward and 
sideward scatter) and EMRA T-cells were gated as CCR7- and CD45RO- T-cells. Typical examples are given 
for non-rejectors and rejectors in the belatacept group for CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ 
EMRA T-cells and their intracellular Granzyme B expressions (A). The absolute numbers and percentages of 
CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T-cells are presented for non-rejectors and rejectors 
(B).
The above-mentioned cell surface biomarkers were also measured in belatacept-
treated patients during acute rejection and before additional anti-rejection therapy was given, 
and were compared with the month 3 samples from patients who remained rejection-free (SDC, 
Figure 1). No statistically significant differences were observed between rejecting and non-
rejecting belatacept-treated patients.
The only significant risk factor for rejection in this study population was the use of a 
belatacept-based immunosuppressive regimen (HR 7.2; 95%-CI 1.6 to 32.6; p = 0.01) compared 
to tacrolimus-based therapy (Table 5). Since no other variable significantly influenced acute 
rejection risk and the sample size was small, no multivariable Cox regression analysis was 
conducted.
Pharmacodynamic monitoring of belatacept
 The pharmacodynamic effect of belatacept was monitored by measuring free CD86 
molecules on circulating monocytes. CD86 was saturated by belatacept at all time points, in 
both rejectors as non-rejectors. Moreover, pre-transplantation CD86 molecules/monocyte were 
not predictive for BPAR (HR 0.33, 95%-CI 0.1-2.2). For details about CD86-expression on monocytes 
in belatacept- and tacrolimus-treated patients, refer to SDC, Results and SDC, Figure 2. 
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Discussion
In this RCT, a belatacept-based and a tacrolimus-based immunosuppressive regimen 
without lymphocyte-depleting induction therapy were compared head-to-head for the first time 
in de novo kidney transplantation. The results of this trial demonstrate that belatacept is not as 
potent as tacrolimus in preventing rejection. 
In comparison to the 1-year results of the BENEFIT-trial where ciclosporin was used as 
comparator,(7) we found a more pronounced difference in both BPAR incidence and severity. 
Ninety-one percent of BPAR in the belatacept group was classified as type II (or higher),(28) 
while in the BENEFIT-trial this was 69%. The use of lymphocyte-depleting therapy to treat rejection 
was comparable: circa 50% of BPAR in the BENEFIT-trial vs. 55% in this study. The incidence of graft 
loss caused by BPAR was higher in this study than in the BENEFIT-trial: 3 of 11 vs. 2 of 39 rejecting 
patients, respectively. 
This larger difference in rate and severity of BPAR is not explained by dissimilarities 
between study groups. In the present study 1) there were no transplantations with deceased 
donors; 2) there were no patients with a PRA >30%; and 3) the proportion of Caucasians was 
larger. All 3 characteristics are associated with a lower BPAR risk.(29-35) In contrast, the proportion 
of pre-emptive transplantations was high in our study (55% of included patients), which may have 
led to the inclusion of patients with a more potent immune system.(36-38) Another explanation 
for the higher BPAR-rate could be that in this study TDM for MPA was performed, whereas this 
was not the case in the BENEFIT-trial. It is therefore, theoretically possible that belatacept-treated 
patients in BENEFIT were exposed to higher MPA concentrations.(1) However, we feel that this 
is an unlikely explanation as ciclosporin lowers exposure to MPA, whereas tacrolimus does not 
have such an effect.(39) 
Our findings are in line with the higher BPAR rates observed in large retrospective 
studies and a small cohort study comparing belatacept to tacrolimus.(13, 14, 18) Wen et al. 
conducted a retrospective cohort study using registry data of a time period of 3 years, and 
compared 1-year clinical outcomes between belatacept- and tacrolimus-treated adult kidney 
transplant recipients.(39) Although the incidence of BPAR was not as high as in the present trial, 
Wen et al. also observed significantly higher BPAR rates among belatacept-treated patients as 
compared with tacrolimus-treated patients who would have been eligible for participation in 
the BENEFIT-study: 15% of patients treated with belatacept and lymphocyte depleting antibody 
therapy, versus 23% of patients treated with belatacept without lymphocyte depleting antibody 
therapy, versus 6% of tacrolimus-treated patients. Nonetheless, it is important to stress that the 
higher incidence of BPAR in the present study should be interpreted with caution, because the 
study here included limited numbers of patients, had limited statistical power and may therefore 
be a chance finding.  
In this study, no suitable pre-transplant biomarker was found to predict belatacept-
resistant BPAR.(15, 16, 18, 19) The first potential biomarker, pre-transplant CD8+CD28- T-cell 
number, seemed a logical choice as these highly cytotoxic cells lack surface CD28 and are 
therefore not susceptible to belatacept.(15-17) Possible explanations for the observation that 
these cells were not associated with BPAR may be that 1) even though these cells are highly 
cytotoxic, they lack proliferative capacity,(40) and 2) the CD28-CD80/86 pathway is not the 
sole mediator of belatacept-resistant rejection. Targeting other co-stimulatory pathways, like 
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CD40-40L, simultaneously with belatacept, might be more efficient to prevent BPAR.(41, 42) 
Preliminary data from Cortes-Cerisuelo et al. suggest that not the lack of CD28 on these cells 
before transplantation, but the potential to down-regulate CD28 after donor antigen stimulation 
is associated with BPAR in belatacept-treated patients.(43) 
 The second biomarker, pre-transplant CD4+CD57+PD1- T-cell number, was associated 
to belatacept-resistant rejection in an observational cohort study.(18) These findings were not 
confirmed here. Apart from differences in study design, the dissimilarities in study populations 
may explain this discrepancy. 23-26 Our study population 1) was mostly Caucasian; 2) received 
mostly pre-emptive transplants; and 3) was shorter on dialysis. These factors have, however, 
not been associated with CD57 expression, and the proportions of CD4+CD57+PD1- T-cells were 
similar pre-transplantation. Age and CMV status, which influence these proportions(40, 44-48), 
were also comparable (data not shown). 
 The final biomarker, CD8+CD28++ EMRA T-cell number, showed potential to predict 
BPAR under belatacept, even though the group medians did not differ between rejectors and 
non-rejectors. One of the 9 non-rejectors and 4 of the 11 rejectors had high numbers of these 
cells pre-transplantation (>35 cells/µL). In-depth analysis of the antigen-specificity of these 
CD8+CD28++ EMRA T-cells in larger studies seems warranted.(49)
 Pharmacodynamic drug monitoring in the form of measuring free, non-belatacept 
bound CD86 molecules on circulating monocytes was not useful to predict BPAR under 
belatacept therapy, since free molecules were not higher in rejectors pre-transplantation, and 
followed the same dynamics in rejectors as in non-rejectors. 
 Limitations of this study are the small sample size and the resulting increased chance 
of type II errors. The increased rejection risk among belatacept-treated patients therefore needs 
to be confirmed in larger RCTs. Ideally, such trials will also include biomarker studies and analyze 
pre-transplant donor-specific immunity. Also, research on regulatory T-cells would be of interest 
since blockade of CD80/86 leads to anergic T-cells,(50) which consequently may fail to activate 
regulatory T-cells via CD28. Studies on antigen-specific biomarkers, such as the IFNγ Elispot assay, 
would also be useful to study in larger, prospective trials.(51, 52) 
 In conclusion, this small RCT showed that belatacept-based immunosuppressive 
therapy results in a significantly higher rejection-rate and severity compared with standard, 
tacrolimus-based therapy. There were no differences in pre-transplant cellular biomarkers 
between rejectors and non-rejectors. Belatacept adequately blocked the CD28-CD80/86 co-
stimulatory pathway in all patients, making insufficient saturation an unlikely explanation for this 
higher rejection risk. These results should be regarded as hypothesis-generating and need to be 
further validated in independent cohorts.  
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Supplemental Digital Content (SDC)
Supplemental Materials and Methods
Additional (immunosuppressive) treatment – detailed information
The additional immunosuppressive therapy was identical in both groups and consisted 
of basiliximab (Simulect®; Novartis Pharma B.V., Arnhem, the Netherlands) in a dose of 20 mg administered 
intravenously on day 0 (immediately before kidney transplant reperfusion) and day 4 after transplantation. Patients 
also received a starting dose of 1000 mg mycophenolate mofetil (MMF; CellCept®; Roche Pharmaceuticals, 
Woerden, the Netherlands) twice daily aiming for plasma mycophenolic acid (MPA) predose concentrations 
between 1.5 and 3.0 mg/L. In addition, all patients received prednisolone in a dose of 50 mg 
twice daily intravenously on days 0–3, followed by 20 mg orally once daily (on days 4–14), after 
which the dose was tapered to 5 mg at month 3 after transplantation. Patients continued to 
receive 5 mg of prednisolone for the rest of the first post-transplant year.
All patients received trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis 
Jirovecii pneumonia for at least 3 months. Patients receiving a kidney from a cytomegalovirus 
(CMV)-positive donor and patients who were seropositive for CMV received prophylaxis with 
valganciclovir for a duration of 6 months.
Additional anti-rejection therapy consisted of 3 doses of 1000 mg methylprednisolone 
intravenously for 3 consecutive days. In case of glucocorticoid-resistant rejection, lymphocyte-
depleting therapy with 1 dose of 30 mg of alemtuzumab was administered subcutaneously.(1) 
Primary end points – BPAR scoring methods
BPAR was scored as part of routine clinical care by a renal pathologist (M.C.C.) 
according to the Banff ’15 classification using 2 µm paraffin sections stained for HE, PAS, Jones 
and also immunohistochemistry for C4d on 4 µm sections. After the completion of the study, 
all biopsies were reviewed again in a blinded fashion by two pathologists (M.C.C. and J.v.d.T.) 
according to the Banff ’15 classification.(2) In case of discrepancy, biopsies were reviewed and 
consensus was reached. 
Safety
Data on clinical outcomes and (serious) adverse events [(S)AEs] were collected 
for safety and included patient- and graft survival, estimated GFR (eGFR), proteinuria, and 
development of donor-specific anti-HLA antibodies (DSA). DSA were retrospectively measured 
in patient sera one day before transplantation, and 1, 6 and 12 months after transplantation. 
In addition, we monitored delayed graft function, malignancies, (opportunistic) infections, 
post-transplant diabetes mellitus (PTDM), neurologic events, and acute tacrolimus-induced 
nephrotoxicity. PTDM was defined as the need for glucose-lowering medical therapy that 
persisted after month 3 post-transplantation in a patient not needing such treatment pre-
transplantation. Acute tacrolimus nephrotoxicity was defined as any ≥15% increase of serum 
creatinine with a return to baseline after tacrolimus dose reduction and after exclusion of other 
causes of renal transplant function deterioration.
Routine laboratory investigations included blood glucose, glycated hemoglobin 
(HbA1c), thrombocytes, leucocytes, hemoglobin (Hb), mean corpuscular volume (MCV), low-
density lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides.Blood pressure and 
body weight were measured at every visit to the outpatient clinic. 
Laboratory Studies – detailed information 
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Blood samples were collected on days 0 (pre-transplant), 4, 30, 90, and months 6 and 
12. Serum was collected on days 0, 15, 30, and months 6 and 12. Blood and sera were also 
collected during clinically suspected rejection, before additional anti-rejection therapy was 
given. In addition, blood and urine samples were collected on a routine basis as part of routine 
clinical care. Proportions of CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T-cells were 
determined pre-transplantion (1 day before transplantation) and post-transplant (3 months after 
transplantation or during rejection)  on thawed isolated peripheral blood mononuclear cells. 
Absolute numbers of cells in blood
 The Becton & Dickinson (BD Biosciences, San José, CA) multi-test 6-color®, CD14 FITC 
(Serotec, Kidlington, United Kingdom) and TruCount Tubes® were used to measure absolute 
numbers of CD3+ T-cells, CD4+ T-helper cells, CD8+ cytotoxic T-cells, and CD14+ monocytes. 
Absolute numbers were measured in 50 µL blood in the presence of 0.5 mL BD Pharm Lyse. All 
proportions of subsets measured in PBMCs (see below) were calculated back to these absolute 
numbers. 
 
Flow cytometry of cytotoxic T-cells in peripheral blood mononuclear cells (PBMCs)
 Using the Ficoll density method, PBMCs were isolated and stored at -190°C before 
further characterization. T-cells were identified by CD3 (AF700, BD), CD4 (V450, BD) and CD8a 
(APC-eF780, eBioscience). The immuno-regulatory receptor PD-1 (PE, BioLegend), the cytotoxic 
marker CD57 (FITC, BD), and the co-stimulatory molecule CD28 (APC, BD) were determined 
on CD4+ and CD8+ T-cells. EMRA CD8+ T-cells were defined by CD8+ CCR7-CD45 RO-, using 
CCR7 (PE, BD) and CD45RO (PE-Cy7, BD). Intracellular expression of GrB (PE-CF594, BD) was also 
assessed.  
Saturation of CD86 on monocytes and B-cells in blood
The surface expression of free CD86 on CD14+ monocytes was assessed using the Lyse-
Wash method according to the manufacturer’s instruction. Cells were surface-stained in 100 µL 
blood and erythrocytes were subsequently lysed in 2 mL BD FACS Lysing solution®, and washed 
away before measurement. Monoclonal antibodies used were the leukocyte marker CD45 
PerCP (BD); CD19 PE-Cy7 (BioLegend); CD14 FITC (Serotec); and the for belatacept competitive 
binder of the co-stimulatory molecules of the CD28-pathway, CD86 PE (clone HA5.2B7 Beckman 
Coulter, Brea, CA).(3) Numbers of CD86 molecules per monocyte were calculated by using 
QuantiBrite beads according to manufacturer’s manual (BD). 
Detection of serum DSA
 Using the Luminex single antigen bead assay (Thermo Fisher Scientific, Waltham, MA) as 
previously described,(4)  the development of DSA was determined by measuring the presence 
of DSA against HLA class I and II before and at different set time points after transplantation in 
serum. The MFI cut-off for positivity was 1000.
Panel reactive antibodies
Sera were tested for HLA-antibody specificities by standard National Institutes of Health 
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(NIH) complement-dependent microlymphocytotoxicity test (LCT) using a panel of 54 donors 
yielding a measurement of the PRA (Panel Reactive Antibody). If samples tested positive using 
a Human Linker for Activation of T cell ELISA (LAT) or a Complement-Dependent Cytotoxicity 
Crossmatch(CDC), HLA antibodies were specified with Luminex single antigen test (LABScreen 
SA, One Lambda Inc., Canoga Park, CA, USA).
 
Statistical analyses – additional information
Patient, graft and biopsy-proven acute rejection (BPAR)-free survival were defined as 
1) time from transplantation to mortality, 2) time from transplantation to transplant nephrectomy, 
re-initiation of dialysis or (pre-emptive) re-transplantation, and 3) time from transplantation to 
the diagnosis of BPAR, respectively, or as the end of the 12-month follow-up period, whichever 
came earlier. 
In addition to intention-to-treat analyses, on-therapy analyses were conducted 
and included evaluable patients who were still on their assigned regimen 12 months after 
transplantation. 
Categorical variables (+ reference groups) in the univariable Cox regression analyses 
included treatment arm (belatacept vs. tacrolimus), gender (female vs. male), ethnicity (non-
Caucasian vs. Caucasian), HLA mismatches (4 or more vs. less than 4), HLA-DR mismatches (2 vs. 
1), highest PRA, and CMV serostatus (positive vs. negative).
Supplemental Results
On-therapy analysis
The on-therapy analysis at month 12 revealed that eGFR and protein/creatinine ratios 
were similar between non-rejecting tacrolimus and belatacept-treated patients: median eGFR 
57 (45-89) and 58 (37-84) mL/min per 1.73m2, respectively (SDC, Table 3). Graft-loss censored 
median eGFR in belatacept-treated patients that suffered from rejection (n = 7) was 36 (28-76) 
mL/min per 1.73m2 at month 12, which was lower than in the non-rejecting belatacept group, 
p = 0.001. 
Graft function in time in belatacept-treated rejectors
 The graft function before, during and after BPAR (after additional anti-rejection therapy) 
is displayed in SDC, Table 4, for the belatacept-group. Before and after BPAR the highest eGFR 
is depicted for each patient. It should be noted 6 patients had a decrease in eGFR after BPAR 
was diagnosed (including 3 graft losses), 2 patients had a similar eGFR after treatment for BPAR, 
and 3 patients had an improved eGFR.
Donor-specific and non-donor-specific anti-HLA antibodies (DSA and non-DSA) 
None of the patients had DSA pre-transplantation. During the first post-transplant year, 
2 patients developed DSA, both in the belatacept group (Figure 3 and SDC, Table 5). One month 
after transplantation, patient no. 2 in the belatacept group developed DSA against HLA-DQ2 
(Median Fluorescence Intensity [MFI] 3787; most likely C1q-negative(5), but these disappeared 
hereafter without additional therapy and no AR occurred. Patient no. 20 in the belatacept group 
developed DSA during her fourth rejection episode (right before losing her graft), which were 
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also detectable in the cross match-dependent cytotoxicity test, against HLA-A1 (MFI 18000), B8 
(MFI 22700), DR3 (MFI 11000), DR52 (MFI 5500) and DQ2 (MFI 16500) (SDC, Table 5). At this time 
she had already been switched to a tacrolimus-based regimen and had been treated with 
methylprednisolone and alemtuzumab (Figure 3). 
Two and three patients, in the belatacept and tacrolimus group, respectively, had 
non-donor specific anti-HLA antibodies (non-DSA) pre-transplantation. In both the belatacept 
and the tacrolimus group two patients developed non-DSA after transplantation (SDC, Table 5). 
Pharmacokinetic drug monitoring 
SDC, Table 2 depicts belatacept doses, tacrolimus doses and pre-dose concentrations 
(C0), MMF doses and mycophenolic acid (MPA) C0, and prednisolone doses. MPA C0 were not 
different between the belatacept and tacrolimus groups after 12 months: 2.30 (0.99–3.54) and 
1.83 (0.57–3.67) mg/mL, respectively; p = 0.25. Also prednisolone doses were similar between the 
belatacept and tacrolimus group in month 12; p = 0.59. 
Pharmacodynamic drug monitoring
The number of belatacept-free CD86 molecules on monocytes was calculated by 
measuring the MFI of bound anti-CD86-PE antibodies. These antibodies bind to CD86 molecules 
to the same epitope but with lower affinity than belatacept, which allows for measurement of 
free CD86 molecules.(3) A typical example is depicted for the MFIs of CD86-PE on monocytes 
for a patient treated with belatacept and a patient treated with tacrolimus (SDC, Figure 2A). As 
evidenced by a linear mixed model, belatacept significantly decreased free CD86 molecules 
on monocytes at different time points after transplantation compared to tacrolimus (SDC, 
Figure 2B). Free CD86 molecules/monocyte were 5.9-fold (95%-CI 5.4 to 7.7-fold) higher on day 
4 and 5.3-fold (95%-CI 4.0 to 7.0-fold) higher 1 month after transplantation in tacrolimus-treated 
patients compared to belatacept-treated patients, p <0.0001. Hereafter the difference in free 
CD86 molecules/monocyte between the belatacept- and tacrolimus-treated patients reduced, 
because almost half of the belatacept-treated patients had been converted to tacrolimus-
based therapy. In these patients (n = 8), free CD86 expression returned to baseline 3–5 months 
after conversion (SDC, Figure 2C). Pre-transplant values for (future) rejectors and non-rejectors in 
the belatacept group were significantly different: 753 (428 – 928) free CD86 molecules/monocyte 
versus 882 (528 – 1528) cells/monocyte, respectively, p = 0.04 (SDC, Figure 2D). However, the 
pre-transplant values showed a great overlap between rejectors and non-rejectors, and the 
numbers of pre-transplant CD86 molecules on monocytes were not associated with acute 
rejection risk (Table 5). No significant differences between (future) rejectors and non-rejectors 
were observed in post-transplant dynamics of free CD86 molecules/monocyte (SDC, Figure 2E).
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Supplemental Tables
SDC, Table 1 Adverse events, intention-to-treat analysis* (Table continues on next pages)
Belatacept group
(n = 20)
Tacrolimus group
(n = 20)
p
Blood or lymphatic system 0.75 (0.97) 1.00 (0.92) 0.22
•	 Leucopenia 7 7
•	 Anemia 6 10
•	 Thrombocytopenia 1 1
•	 Other 1 2
Bleeding and thrombotic events 0.30 (0.57) 0.40 (0.60) 0.52
•	 Major bleeding 0 2
•	 Minor bleeding 4 2
•	 Thrombosis 2 4
Cancer 0 0 -
Cardiovascular 0.95 (0.83) 1.20 (0.83) 0.33
•	 Acute coronary syndrome / 
myocardial ischemia 1 1
•	 Cardiac decompensation / 
volume overload 2 3
•	 Hypertension 12 17
•	 Other 4 3
Gastrointestinal 0.65 (0.67) 0.60 (1.00) 0.40
•	 Diarrhea 2 4
•	 Other 11 8
Infection 2.25 (1.86) 1.90 (1.83) 0.46
•	 Opportunistic infection 0.45 (0.69) 1.90 (1.83) 0.57
	 BKV 2 1
	 CMV 1 2
	 EBV 1 0
	 HSV 0 1
	 VZV 0 0
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	 Fungal 5 2
•	 Other infection 1.80 (1.70) 1.60 (1.64) 0.61
	 Urinary tract infection 20 14
	 Upper respiratory tract 
infection 8 4
	 Pneumonia 2 0
	 Gastrointestinal 
infection 1 2
	 Other 5 12
Locomotor system disorder 0.25 (0.55) 0.20 (0.52) 0.70
Metabolism or nutrition 1.75 (1.16) 2.00 (1.56) 0.84
•	 Post-transplant diabetes mellitus 1 7
•	 Hypo- / hyperglycemic 
dysregulation 4 9
•	 Calcium disorder (hypo- / 
hypercalcemia) 6 3
•	 Potassium disorder (hypo- / 
hyperkalemia) 6 9
•	 Hypophosphatemia 6 6
•	 Dyslipidemia 8 4
•	 Liver enzyme abnormality 3 1
•	 Other 1 1
Nervous system 0.50 (1.00) 0.65 (0.88) 0.36
•	 CVA/TIA 1 0
•	 Tremor 2 8
•	 Headache 1 1
•	 Other 6 4
Skin-related disorders 0.15 (0.37) 0.30 (0.47) 0.26
Surgical or procedural complication 0.10 (0.31) 0.20 (0.52)
•	 Acute tubular necrosis 1 2
•	 Delayed graft function 1 1
•	 Renal infarction 0 1
•	 Other 0 0
Tacrolimus-induced nephrotoxicity 0.05 (0.22) 0.40 (0.60) -
Urological complication 0.55 (0.76) 0.60 (0.88) 0.96
•	 Hydronephrosis 1 4
•	 Urinary leakage 2 1
•	 Other 8 7
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Wound-related problem 0.15 (0.37) 0.25 (0.44) 0.44
•	 Wound infection 2 3
•	 Other 1 2
Other 1.80 (1.44) 2.20 (2.04) 0.63
Total 10.25 (4.18) 11.90 (5.43) 0.41
(<Table on previous pages)
* Mean number of adverse events (+ standard deviation) per patient are depicted for both treatment groups 
for the different categories of adverse events. Numbers of adverse events per subcategory are depicted per 
treatment group.
BKV, BK virus; CMV, cytomegalovirus; CVA, cerebrovascular accident; EBV, Epstein-Barr virus; HSV, herpes 
simplex virus; N/A, not applicable; VZV, varicella zoster virus; TIA, transient ischemic attack.
SDC, Table 2: Clinical outcomes, intention-to-treat analysis* (Table continues on next page)
 Belatacept group (n = 20) Tacrolimus group (n = 20)
 n M3 n M6 n M12 n M3 n M6 n M12 p†
Blood pressure
•	 Systolic / diastolic 18
137 (98 
- 167) / 
83 (40 - 
94)
17
138 
(93 - 
181) / 
80 (50 
- 109)
17
147 
(106 - 
165) / 
81 (50 
- 85)
20
144 
(108 – 
178) / 
85 (59 
– 98)
20
138 
(96 – 
184) / 
84 (55 
– 95)
19
145 
(110 – 
170) / 
85 (45 
– 97)
0.64 
/ 
0.42
Kidney function
•	 Creatinine 
(µmol/L) 18
127 (73 
– 276) 17
114 
(74 – 
219)
17
128 
(71 – 
207)
20
122 
(64 – 
242)
20
126 
(61 – 
179)
19 126 (79 – 179) 0.80
•	 eGFR (mL/min) 18 52 (18 – 72) 17
62 (26 
– 88) 17
54 (28 
– 89) 20
50 (23 
– 80) 20
53 (33 
– 85) 19
50 (33 – 
84) 0.57
•	 Protein/Creatinine 
ratio 18
19.3 
(5.2 – 
443.2)
17
18.2 
(5.8 – 
87.7)
17
13.2 
(5.7 – 
343.8)
20
15.3 
(7.3 – 
115.0)
20
12.1 
(4.2 – 
209.6)
19 9.0 (5.3 – 43.5) 0.44
Glucose metabolism
•	 Glucose (mmol/L) 18 5.6 (4.7 – 9.4) 17
5.5 
(2.9 – 
13.7)
17
5.6 
(2.9 – 
13.7)
20
6.2 
(3.7 – 
10.7)
20
6.6 
(4.7 – 
13.5)
19 6.1 (4.3 – 26.7) 0.06
•	 HbA1c (mmol/
mol) 6
36 (29 – 
74) 3
37 (33 
– 50) 5
41 (33 
– 49) 6
48 (37 
– 67) 5
42 (30 
– 73) 10
46 (33 – 
75) 0.31
Lipids
•	 Cholesterol total 
(mmol/L) 18
4.6 (2.9 
– 7.5) 16
4.7 
(3.0 – 
6.9)
16
4.7 
(3.4 – 
7.2)
20
4.5 
(2.9 – 
6.5)
20
4.5 
(3.2 – 
5.9)
19 4.7 (3.1 – 6.9) 0.55
•	 Triglycerides 
(mmol/L) 18
2.1 (1.1 
– 4.1) 16
1.9 
(1.1 – 
4.0)
16
2.2 
(1.2 – 
3.2)
20
2.0 
(0.8 – 
5.3)
20
1.8 
(0.7 – 
4.2)
19 1.6 (0.9 – 5.9) 0.13
•	 HDL-cholesterol 
(mmol/L) 18
1.1 (0.7 
– 3.0) 16
1.2 
(0.9 – 
3.1)
16
1.2 
(0.8 – 
3.5)
20
1.3 
(0.8 – 
2.7)
20
1.2 
(0.6 – 
2.8)
19 1.4 (0.8 – 3.4) 0.66
•	 LDL-cholesterol 
(mmol/L) 18
3.0 (1.2 
– 5.3) 16
2.8 
(1.0 – 
4.9)
16
2.8 
(1.3 – 
5.3)
20
2.4 
(1.2 – 
4.4)
20
2.6 
(1.2 – 
4.3)
19 2.7 (1.2 – 4.3) 0.30
Hematology
•	 Hemoglobin 
(mmol/L) 18
7.2 (5.0 
– 9.5) 17
7.6 
(6.3 – 
9.6)
17
8.2 
(7.0 – 
9.9)
20
7.5 
(6.5 – 
9.4)
20
7.7 
(6.2 – 
10.5)
19 8.4 (6.5 – 10.5) 0.85
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•	 MCV (fL) 18 96 (89 – 100) 17
93 (88 
– 98) 17
92 (83 
– 97) 20
94 
(69 – 
106)
20
90 
(68 – 
102)
19 88 (72 – 108) 0.20
•	 Thrombocytes 
(×10^9/L) 17
222 
(162 – 
401)
17
232 
(119 – 
477)
17
214 
(138 – 
394)
20
231 
(148 – 
495)
20
235 
(131 – 
457)
19
245 
(163 – 
380)
0.21
•	 Leucocytes 
(×10^9/L) 18
6.3 (1.0 
– 15.5) 17
6.9 
(1.9 – 
11.1)
17
6.4 
(2.2 – 
17.4)
20
5.9 
(1.3 – 
11.8)
20
7.4 
(1.7 – 
14.2)
19 8.4 (4.0 – 12.0) 0.12
Pharmacokinetics
•	 Belatacept dose 
(mg) 16
800 
(575 – 
938)
11
400 
(300 – 
45)
10
381 
(300 – 
450)
- N/A - N/A - N/A N/A
•	 Tacrolimus dose 
(mg) 22
10.0 
(10.0 – 
10.0)
6
5.5 
(3.5 – 
10.0)
7
5.0 
(3.0 – 
8.0)
20
4.0 
(2.0 – 
8.0)
20
4.0 
(2.0 – 
6.0)
19 4.0 (2.5 – 7.0) 0.19
•	 Tacrolimus 
concentration 
(ug/L)
22 2.2 (1.5 – 5.5) 6
5.8 
(4.2 – 
8.3)
7
7.2 
(4.5 – 
8.6)
20
7.0 
(4.1 – 
10.7)
20
6.3 
(2.6 – 
9.9)
19 6.8 (4.4 – 13.3) 0.53
•	 Mycophenolate 
mofetil dose (mg) 18
1000 
(500 – 
2000)
17
1000 
(500 – 
2000)
17
1000 
(500 – 
2000)
20
1000 
(500 – 
2000)
19
1000 
(0 – 
2000)
18 1000 (0 – 2000) 0.47
•	 Mycophenolate 
acid 
concentration 
(mg/mL)
17
3.04 
(0.52-
10.00)
16
2.45 
(0.98 – 
5.21)
17
2.30 
(0.99 – 
3.54)
20
2.53 
(1.03 
– 
10.00)
19
1.69 
(0.96 
– 
4.24)
18
1.83 
(0.57 – 
3.67)
0.25
•	 Prednisone dose 
(mg) 18
5.0 (5.0 
– 10.0) 17
5.0 
(5.0 – 
10.0)
17
5.0 
(5.0 – 
10.0)
20
5.0 
(5.0 – 
10.0)
20
5.0 
(5.0 – 
10.0)
19 5.0 (2.5 – 10.0) 0.59
* Censored for graft loss and death; † Comparison between patients from the belatacept group and the 
tacrolimus group 12 months after transplantation
Target tacrolimus C0 of 5 – 10 ng/mL were achieved in 75%, 85% and 95% of patients in the tacrolimus group 3, 
6 and 12 months after transplantation, respectively. Target MPA C0 of 1.5 – 3.0 mg/mL were achieved in 45%, 
40% and 40% of patients in the tacrolimus group respectively 3, 6 and 12 months after transplantation, and in 
30%, 40% and 60% of patients in the belatacept group respectively 3, 6 and 12 months after transplantation. 
Data present medians (plus ranges). 
BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high density lipoproteins; LDL, low 
density lipoproteins; M3, 3 months after transplantation; M6, 6 months after transplantation, M12, 12 months 
after transplantation; MCV, mean corpuscular volume 
SDC, Table 3: Graft function 12 months after transplantation
Belatacept 
non-rejectors 
(n=9)
Belatacept 
rejectors, 
censored for 
graft loss (n=8)
Belatacept 
rejectors, 
including graft 
loss (n=11)
Tacrolimus 
(n=19)
Tacrolimus 
non-
rejectors 
(n=17)
Creatinine 
(µmol/L)
106
(71-143)
163
(93-207)
-
126
(79-179)
119
(79-178)
eGFR (mL/
min)
57
(45-89)
36
(28-76)
34
(0-76)
50
(33-84)
58
(37-84)
Protein/
Creatinine 
ratio
11.4
(7.9-25.0)
12.2
(5.7-343.8)
-
9.0 
(5.3-43.5)
9.0
(5.3-43.5)
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Data are medians (plus ranges). Graft function was compared between 1) the belatacept-treatedrejectors 
and belatacept-treated non-rejectors and 2) the tacrolimus-treated and belatacept-treated non-rejectors, 
using the Mann-Whitney U test. Creatinine concentrationat month 12 was significantly higher and eGFR at 
month 12 was consequently significantly lower in belatacept-treated rejectors than in belatacept-treated 
non-rejectors, both p=0.001. These parameters did not differ between non-rejecting belatacept-treated and 
tacrolimus-treated patients at month 12.
In the group of “Belatacept rejectors, including graft loss” the 3 patients that lost their grafts were set to an 
eGFR of zero on month 12. Creatinine and Protein/Creatinine ratio were not calculated for this group, since 
these could not be determined for the 3 patients after graft loss. 
eGFR, estimated glomerular filtration rate
SDC, Table 4: Response to anti-rejection therapy in belatacept-treated rejectors
 Creatinine eGFR
No. 
(Patient) Best before BPAR Best after
Best 
before BPAR Best after
3 84 132 93 59 35 52
5 89 698 N/A 56 5 0
6 155 211 136 39 27 45
7 148 188 164 45 34 40
13 89 107 93 80 65 76
14 109 148 110 72 50 71
15 227 279 145 25 19 41
16 106 210 152 62 28 41
17 305 807 N/A 14 5 0
19 325 367 161 18 16 41
20 162 175 N/A 33 30 0
Patient numbers are the same depicted as in Figure 3. For detailed clinical course per patient, please refer to 
this figure. Creatinine and estimated glomerular filtration rates (eGFR) are given for the 10 belatacept-treated 
rejectors before, during and after rejection (when applicable, before second rejection episodes). Both before 
and after rejection the highest measuredeGFRs are depicted. Patients no. 6, 16 and 19 were switched to tac-
rolimus (almost) immediately after rejection occurred. Patients no. 5 lost her graft immediately after rejection, 
and patients no. 17 and 20 were switched to tacrolimus, but still lost their grafts thereafter (eGFRs after rejec-
tion were set to zero). Patients no.7, 14 and 15 were switched to tacrolimus after a second episode of acute 
rejection. Patient no. 13 was diagnosed with BPAR after revision of the biopsy, and was therefore not treated 
with additional anti-rejection therapy. This patient had an isolated v-lesion which may explain the excellent 
outcome despite no treatment. Finally, patient no. 3 was switched after his third rejection episode.    
N/A, not applicable
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SDC, Table 5: Anti-HLA antibodies in serum
Belatacept group
(n = 20)
Tacrolimus group
(n = 20)
p
Donor-
specific
Pre-existent - - -
De novo
2 (10%)
[Patients no. 2 and 20]
- 0.49
Non donor-
specific
Pre-existent
2 (10%)
[Patients no. 2 and 12]
3 (15%)
[Patients no. 3, 11 and 12]
1.00
De novo
2 (10%)
[Patients no. 7 and 20]
2 (10%)
[Patients no. 6 and 20]
1.00
Patient numbers are the same as in Figure 3. None of the patients had donor-specific anti-human leukocyte 
antigen (HLA) antibodies (DSA) pre-transplantation. During the first post-transplant year, 2 patients developed 
DSA, both in the belatacept group. Patient no. 2 in the belatacept group developed DSA against HLA-DQ2 
(MFI 3787) one month after transplantation, but these disappeared hereafter without additional therapy and 
no acute rejection occurred. Patient no. 20 in the belatacept group had DSA, which were also detectable in 
the cross match-dependent cytotoxicity test, against HLA-A1 (MFI 18,000), -B8 (MFI 22700), -DR3 (MFI 11000), 
-DR52 (MFI 5500) and -DQ2 (MFI 16500) during her fourth rejection episode right before losing her graft. At 
this time she was already switched to a tacrolimus-based regimen and had been treated with multiple 
methylprednisolone and alemtuzumab gifts (Figure 3). 
Two and three patients, in the belatacept and tacrolimus group, respectively, had non donor-specific anti-
HLA antibodies (non-DSA) pre-transplantation. Patient no. 2 in the belatacept group had non-DSA against DR1 
that remained present after transplantation, without clinical consequences. Patient no. 12 in the belatacept 
group had non-DSA against HLA-Dp11 which disappeared after transplantation. No rejection occurred. 
Patients no. 3, 11 and 12 in the tacrolimus group had non-DSA pre-transplantation against HLA-B76, -DP1, 
and -DP; -DR4; and -B15; respectively. Only patient no. 3 suffered from an acute rejection Banff type 2B. No 
serum was available from this patient at the time of rejection, but in sera from month 1 to 12 no non-DSA were 
detected. Also in the other 3 patients pre-existent anti-HLA antibodies disappeared after transplantation. 
Two patients in the belatacept group (no. 7 and no. 20) developed non-DSA. Patient no. 7 in the belatacept 
group developed non-DSA against HLA-DQ3 (measured on day 30) before he was diagnosed with an acute 
Banff type 2B rejection 44 days after transplantation. These non-DSA were also positive during rejection. After 
treatment with methylprednisolone they were no longer detectable and remained so throughout follow-up. 
Patient no. 7 in the belatacept group developed non-DSA against HLA-A24, -A68, and -DQ3 simultaneously 
with DSA. Two patients in the tacrolimus group (no. 6 and no. 20) developed non-DSA, without clinical 
consequences in the first year after transplantation against HLA-DP14 and HLA-A24, respectively. 
SDC, Table 6: Baseline characteristics of (future) rejectors and non-rejectors in the belatacept group (Table 
continues on next page) 
Belatacept (n = 20)
p rejectors
(n = 11)
non-rejectors
(n = 9)
Age at transplantation (years) 47 (25-76) 60 (40-74) 0.41
Male / female 7 (64%) / 4 (36%) 7 (78%) / 2 (22%) 0.49
Ethnicity 0.07
•	 Caucasian 11 (100%) 6 (67%)
•	 African - 2 (22%)
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•	 Asian - 1 (11%)
•	 Hispanic 83.3 (63.5 - 111.4) 76.0 (56.6 - 98.6) 0.26
Body weight (kg) 1.0 (± 0.6) 1.1 (± 0.8) 0.84
HLA A mismatch (mean ± SD) 1.4 (± 0.5) 1.2 (± 0.4) 0.63
HLA B mismatch (mean ± SD) 1.2 (± 0.4) 1.0 (± 0.5) 1.00
HLA DR mismatch (mean ± SD) 0 (0 - 4) 0 (0 - 5) 0.55
Current PRA (%) 4 (0 - 6) 4 (0 - 5) 0.37
Peak PRA (%) 0.37
CMV status at transplantation 1 (9%) 2 (22%)
•	 Donor + / Recipient - 2 (18%) 2 (22%)
•	 Donor + / Recipient + 6 (55%) 1 (11%)
•	 Donor - / Recipient - 2 (18%) 4 (44%)
•	 Donor - / Recipient + 60 (43 - 69) 53 (24 – 71) 0.33
Donor age at transplantation (years) 4 (36%) / 7 (64%) 2 (22%) / 7 (78%) 0.64
Related / unrelated donor 0.90
Cause of end-stage renal disease 1 (9%) 2 (22%)
•	 Diabetes mellitus - 2 (22%)
•	 Hypertension - 1 (11%)
•	 IgA nephropathy 2 (18%) 1 (11%)
•	 Polycystic kidney disease 2 (18%) 1 (11%)
•	 Obstructive nephropathy 3 (27%) 2 (22%)
•	 Unknown 3 (27%) 0 (0%)
•	 Other 0.37
Renal replacement therapy 7 (64%) 3 (33%)
•	 None (pre-emptive) 3 (27%) 4 (44%)
•	 Hemodialysis 1 (9%) 2 (22%)
•	 Peritoneal dialysis 560 (147-2633) 425 (123-2782) 1.00
Time on dialysis therapy (days) 1.00
Number of kidney transplantation 10 (91%) 9 (100%)
•	 First 1 (9%) -
•	 Second 47 (25-76) 60 (40-74) 0.41
Continuous variables are presented as medians (plus ranges) and categorical variables as numbers (plus 
percentages), unless otherwise specified
BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; HLA, human leukocyte antigen; PRA, panel 
reactive antibodies; SD, standard deviation.
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SDC, Figure 1. CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T-cells during rejection or 3 months after 
transplantation.
CD4+ and CD8+ T-cells were gated from 7-AAD negative CD3+ lymphocytes (based on forward and sideward 
scatter) and EMRA T-cells were gated as CCR7- and CD45RO- T-cells (See Figure 4). The absolute numbers and 
percentages of CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T-cells are presented for non-rejectors 
3 months after transplantation and for rejectors during acute rejection before additional anti-rejection therapy 
was given.
N.B.: From 1 rejector no materials were obtained during rejection, because biopsy-proven acute rejection was 
diagnosed in retrospect after revision by a second pathologist.
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SDC, Figure 2. Pharmacodynamic drug monitoring of belatacept.
The median fluorescence intensity (MFI) of CD86 was assessed on circulating monocytes in belatacept and 
tacrolimus-treated patients using a competitive monoclonal antibody (clone HA5.2B7, solid line) with an 
IgG control (dotted line) (A). Free CD86 molecules per monocyte were calculated from MFIs (medians + 
interquartile ranges) and compared between the belatacept (triangles) and tacrolimus (squares) group on 
different time points in an intention-to-treat analysis using a linear mixed model (B). Free CD86 molecules/
monocyte in tacrolimus-treated patients compared to belatacept-treated patients were 5.9-fold (95% CI 4.5 
to 7.7-fold) higher on day 4; 5.3-fold (95% CI 4.0 to 7.0-fold) higher on month 1; 3.7-fold (95% CI 2.8 to 4.8-fold) 
higher on month 3; 2.6-fold (95% CI 2.0 to 3.4-fold) higher on month 6; and 2.1-fold (95% CI 1.6 to 2.8-fold) on 
month 12. Free CD86 molecules/monocytes were measured in n = 8 patients which were converted to a 
tacrolimus-based therapy after acute belatacept-resistant rejection (C). Numbers of free CD86 molecules/
monocytes pre-transplantation were compared between non-rejectors
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(n = 9) and rejectors (n = 11) in the belatacept group (D), as well as CD86 molecules/monocyte on day 4 and 
month 3 or during rejection after transplantation (E). AR, acute rejection; D-1, one day pre-transplantation; D4, 
four days after transplantation; M1, one month after transplantation; M3, three months after transplantation; 
M6, six months after transplantation; M12, twelve months after transplantation; MMF, mycophenolate mofetil 
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001
N.B.: In (D) black lines represent the medians; the upper and lower border of the boxes represent the 25th and 
75th percentiles; the error lines represent 10th and 90th percentiles.
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Abstract
Background
Belatacept has been associated with an increased acute rejection rate after kidney 
transplantation. This case report sheds light on the possible immunological mechanisms 
underlying this phenomenon by analyzing the immunological mechanisms in patient serum, 
peripheral blood mononuclear cells, rejected kidney tissue, and graft infiltrating cells.
Methods
A 61-year old female treated with belatacept, who received her first kidney transplant 
from her husband was admitted with an acute, vascular rejection 56 days post-transplantation 
which necessitated a transplantectomy. Histology and immunohistochemistry were performed 
on biopsy and explant tissue. CD86-expression on peripheral monocytes was assessed. Using 
Ficoll density methods, peripheral blood and graft infiltrating lymphocytes were isolated and 
phenotyped.
Results
 The explant showed a vascular rejection (Banff ACR grade III) and a perivascular 
infiltrate mostly consisting of T-cells. No evidence for antibody-mediated rejection was found. In 
contrast to the peripheral blood monocytes, CD86 was still expressed by part of the mononuclear 
cells in the explant. Isolated graft cells were mostly CCR7-CD45RO+ effector-memory CD4+ 
and CD8+ T-cells (60-70%). CD28-positive as CD28-negative T-cells were present in the explant, 
showing a great IFNγ production capacity and expressing granzyme B. 
Conclusions
We postulate that this glucocorticoid-resistant cellular rejection occurring under 
belatacept was predominantly mediated by cytotoxic memory T-cells, which are less susceptible 
to co-stimulatory blockade by belatacept, or resulted from incomplete CD80/86 blockade at 
the tissue level.
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Introduction
Belatacept is the first Food and Drug Administration-approved inhibitor of the CD28-
CD80/86 co-stimulatory pathway used for the prevention of kidney allograft rejection.(1) 
Belatacept treatment results in a significantly better renal function compared with cyclosporin-
based therapy (2, 3), but acute rejection occurs more frequently in belatacept-treated patients, 
and these rejections are also more severe according to Banff criteria.(4) However, 1-year graft 
survival was comparable between belatacept- and cyclosporin-treated patients despite the 
increased rejection risk.(4) The higher acute rejection incidence may be explained by differences 
in the susceptibility of immune cells to the inhibiting effects of belatacept. Cytotoxic T-memory 
lymphocytes do not express CD28 and are not dependent on this molecule for their activation.
(5, 6) However, little data exists on the immunological processes in peripheral blood and at the 
tissue level, during rejection under belatacept-based treatment.(7, 8) 
 Here, a case is described of early, glucocorticoid-resistant, acute cellular rejection in 
a belatacept-treated patient, which led to acute kidney allograft loss. Lymphocytes and sera 
isolated from blood and lymphocytes from the explanted allograft were studied to gain more 
insight into the immunological mechanisms responsible for this severe rejection.
Case presentation
 A 61-year-old female with end-stage renal disease caused by recurrent urinary tract 
infections, received her first, blood group-compatible, preemptive, living-unrelated donor (her 
husband), kidney transplant on December 17, 2013. The transplant was 1-2-2 mismatched 
(for HLA A2, B18, B60, DR4 and DR8, respectively). The pretransplant complement-dependent 
cytotoxicity (CDC) cross-match was negative. Current and historical panel reactive antibodies 
(PRA) were 4%. She had 2 children with her husband, and never received blood transfusions. She 
was treated with belatacept according to the Less-Intensive regimen (3) as part of a clinical trial 
(NTR4242, Dutch Trial Register, www.trialregister.nl), and with basiliximab, mycophenolate mofetil 
(MMF) and prednisolone. 
 The initial post-operative course was uneventful, and she was discharged with a 
serum creatinine of 97 µmol/mL. Fifty-six days after transplantation, she was admitted with fever, 
malaise, headache and cough. Apart from mild hypertension (153/87 mmHg), tachycardia (118 
bpm), and graft tenderness, the physical examination was unremarkable. 
 Laboratory examination revealed renal insufficiency with a rise of her serum creatinine 
from 100 µmol/L (measured on post-operative day 53) to 698 µmol/L at the time of presentation 
(post-operative day 56). C-reactive protein and the leucocyte count were elevated (277 
mg/L and 15.4 x 109 cells/L). Lactate dehydrogenase was 691 IU/mL. The urinary sample 
contained leucocytes (4+), albumin (2+), and erythrocytes (1+), but was negative for nitrite. The 
mycophenolic acid plasma concentration 3 days before admission was 2.16 mg/L. Abdominal 
ultrasound showed a normal-sized and perfused kidney allograft without hydronephrosis. 
Because of presumed urinary or upper respiratory tract infection, she was treated with 
broad-spectrum antibiotics. A renal biopsy was obtained, after which she received intravenous 
methylprednisolone 1 gram daily for three consecutive days, which is the first line therapy for 
acute rejection at our center. This did not result in an improvement of her renal function. 
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Figure 1. Histology of the renal graft under belatacept treatment. 
(A) Severe endarteritis with subtotal occlusion of the artery is depicted (Jones 20x). (B) Diffuse cortical necrosis 
and hemorrhage and glomerular congestion is shown (Jones 20x). (C) Endothelialitis, fibrinoid necrosis and 
transmural infiltration are depicted (HE, 20x).  
N.B.: A and B, The histology is shown for the renal graft biopsy prior to transplantectomy. C, The histology is 
shown for the explant.
C-reactive protein, leucocyte count, and LDH rose to a maximum of 306 mg/L, 42 x 109/L, and 
954 IU/mL, respectively. Additional testing revealed an Epstein-Barr virus (EBV) reactivation with 
low-grade viremia (280 copies/mL) prior to the start of pulse-glucocorticoid therapy. Renal 
scintigraphy demonstrated absent perfusion of the allograft. Therefore, no T-cell depleting 
therapy was given and a transplantectomy was immediately performed on post-operative day 
59. 
Investigation of the kidney biopsy and explant
The renal allograft biopsy demonstrated an acute vascular rejection (Banff ACR 
grade II, i1 t1 v2 g3 ptc3 C4d0 ti3) with large vessel thrombosis and diffuse cortical necrosis 
(Figure 1A and 1B). Three days later, the explant showed a severe vascular rejection (Banff 
ACR grade III, i1 t1 v3 g3 ptc3 C4d0 ti3) with endothelialitis, fibrinoid necrosis and transmural 
infiltration (Figure 1C). Histopathology and additional immunohistochemistry showed no signs of 
antibody-mediated rejection. (Supplementary Figure 1) No subendothelial deposits nor CD138+ 
plasma cells were present in the biopsy and explant. Light microscopy also did not show large 
amounts of granulocytes or macrophages expressing Fc-receptors (not shown). The presence of 
glomerulitis and peritubular capillaritis could fit the vascular antibody-mediated rejection (AMR/
V+) pattern, as well as the vascular T-cell mediated rejection (TCMR/V+) pattern as described by 
Lefaucheur et al.(9) because these 2 overlap. The high grade of interstitial inflammation pleads 
against AMR. Moreover, transplant glomerulopathy was absent. Furthermore C4d, IgM and IgG 
were negative. (Supplementary Figure 1) 
Donor-specific anti-HLA antibodies (DSA)
 The pretransplant and posttransplant sera were screened for the presence of HLA 
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Figure legend on next page 
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Figure 2. Immunohistochemistry of the kidney biopsy.
Immunohistochemistry demonstrated severe endothelialitis and tubulitis. Left panel indicates infiltrate in the 
vascular wall (arrow) with endothelitis. Right panel indicates tubulointerstitial infiltration. CD3+ T cells were 
located perivascular and endovascular, as were CD4+ and CD8+ cells. CD68+ macrophages were diffusely 
present in the explant. A small amount of CD20+ B cells were also located perivascular. 
Figure 3. CD86 was still expressed on part of the CD4+ mononuclear cells in the kidney biopsy. 
Surface staining for CD86 was assessed (arrows) including CD68, CD4 and CD8 stainings on sequential slides. 
The renal biopsy during rejection in the belatacept-treated patient showed small amounts of CD86+ cells (15-
20 CD86-positive cells per 100 mononuclear cells). Original magnification 20x. The location and morphology of 
these CD86+ cells suggests mostly CD4+ monocytes expressed CD86.
antibodies by CDC, and these sera were negative. Additional screening using the Luminex assay 
by single-antigen-LABScreen beads (OneLambda, Canoga Park, CA, USA) was performed, 
which revealed DSA against only HLA-DR4 at the time of rejection (median fluorescence intenstity 
[MFI] 600). In retrospect, DSA against HLA-DR4 could also be detected before transplantation 
(MFI 722). However, the MFI cut-off for clinically relevant DSA in our facility (Leiden University 
Medical Center, which also harbors The Eurotransplant Reference Laboratory) is 1000 or greater 
and hence, these signals were considered negative. In addition, these DSA were negative in 
the C1q-binding antibody assay (C1qScreen, One Lambda). No de novo DSA were formed 
after transplantation as analyzed by CDC and Luminex. During the work-up for a second 
transplantation, after all immunosuppression was withdrawn and her transplant had been 
CD86 biopsy (20x) CD68 biopsy (20x)
CD4 biopsy (20x) CD8 biopsy (20x)
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removed, the titer of the DSA against HLA-DR4 increased with an MFI of 2600 (144 days after 
transplantectomy), but remained C1q-negative. No DSA against HLA-A, -B, -Cw, -DP or -DQ 
were found before transplantation or during rejection.
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2M after Rejection (M4)
2M after Rejection (M4)
CD28 isotype control
CD28 isotype control
Figure 4. The CD28NULL CD4+ and CD28NULL CD8+ T-cells decreased in the blood during rejection. 
(A) The gating strategy for CD4+ and CD8+ is depicted. First cells were gated by size and granularity in the 
forward and sideward scatter. CD4+ and CD8+ were gated from CD3+ cells. (B-C) In both T-cell subsets CD28-
positive and CD28-negative cell percentages were determined before transplantation, during rejection and 
2 months after rejection (after removal of the graft).
D-1 = 1 day before transplantation, M2 = 2 months after transplantation, M4= 4 months after transplantation.
Immunohistochemistry of the kidney biopsy and explant
 A severe endothelialitis was observed in the renal cortex (Figure 2). CD3+ T-lymphocytes 
were present perivascular and endovascular, and composed both CD4+ and CD8+ cells. The 
CD4+ expression could also be explained by the numerous CD68+ infiltrating macrophages. 
Also, a small amount of perivascular CD20+ B-lymphocytes was observed. No CD138+ plasma 
cells nor IgM or IgG were detectable (Supplementary Figure 1). The immunohistochemistry of the 
explant showed a comparable picture (Supplementary figure 2).
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Figure 5. The CD86 molecules on CD14+ monocytes were completely blocked by belatacept after 
transplantation, including the moment of rejection. 
The Median Fluorescence Intensity (MFI) is given for CD86-PE (dark grey) and the negative isotype control 
(IgG2B, light grey). D-1 = 1 day before transplantation, D4 = 4 days after transplantation, D30 = 30 days after 
transplantation, M2 = 2 months after transplantation, M4= 4 months after transplantation.
 The expression of CD86 in the biopsy and explant was measured to assess whether this 
co-stimulatory molecule was fully blocked by belatacept (Figure 3 and Supplementary Figure 
3). In both specimens, small numbers of CD86+ cells were found in the infiltrate. These cells were 
mononuclear and were CD86+ in both cytoplasm and on the surface, and were most likely 
CD4+ monocytes based on their morphology. For comparison, a type II vascular T-cell mediated 
rejection biopsy under tacrolimus was stained for CD86 and CD68 (Supplementary Figure 3C). 
A high CD86 expression was observed. The location and morphology of these CD86+ cells 
suggested these cells were mostly CD68+ monocytes and macrophages. 
Fluorescence in situ hybridization of the perivascular infiltrate confirmed that >95% of 
the infiltrating cells was from recipient origin (double X-chromosome positive, Supplementary 
figure 4). No EBV encoded small RNAs (EBERs) were present in the transplant (not shown). 
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Figure 6. The rejected renal graft contained CD28NULL T-cells, granzyme B producing CD8+ T-cells and both 
CD4+ and CD8+ T-cells with great IFNγ-production capacity. 
(A) The gating strategy for CD4+ and CD8+ is depicted. First,  graft-infiltrating lymphocytes were gated by 
size and granularity in the forward and sideward scatter. CD4+ and CD8+ were gated from viable (i.e. 7-AAD 
negative) CD3+ cells. In both T-cell subsets CD28-positive and CD28-negative were determined. In addition, 
the memory phenotype was determined, with the use of CCR7 and CD45RO, in the total CD4+ and CD8+ 
T-cell population (B) as well as in CD28POS and CD28NULL T-cells (C). The intracellular granzyme B expression 
was determined in CD4+ and CD8+ T-cells in CD28NULL and CD28POS T-cells (D) and in CD45RO+ and 
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CD45RO- T-cells (E). The intracellular IFNγ-production capacity was determined in CD4+ and CD8+ T-cells upon 
4 hours of stimulation with PMA/ionomycin (F). The intracellular IFNγ-production is also specified for CD28POS 
and CD28NULL CD8+ T-cells (G).   
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Figure 7. A small proportion of the graft infiltrating cells were B cells. The gating strategy for CD19+ cells is 
depicted. First cells were gated by size and granules content in the forward and sideward scatter. Memory 
phenotype was determined within viable (i.e. 7-AAD negative) CD19+ cells, using IgD and CD27. The 
percentage of CD27+CD38HIGH plasmablasts was also determined (within viable CD19+ B-cells).
Immunophenotyping of peripheral blood lymphocytes
CD28 expression on T-cells was assessed before transplantation, during rejection and 
2 months after transplantectomy when immunosuppressive drugs had been stopped. (Figure 
4) Seventy-five percent of the CD8+ T-cells (280 cells/µL), and 1% of the CD4+ T-cells (12 cells/
µL), did not express CD28 before transplantation. Interestingly, during rejection, a decrease in 
CD4+CD28-negative (CD28NULL) (from 1% to 0.1%) and CD8+CD28NULL (from 75% to 54%) was 
observed (0.6 cells/µL and 57 cells/µL, for CD4 and CD8, respectively). After rejection, the 
proportions of these cells almost returned to baseline levels (CD4+CD28NULL: 0.3% [3 cells/µL] and 
CD8CD28NULL 72% [161 cells/µL]). 
To assess whether belatacept blocked the co-stimulatory pathway in blood, the 
expression of CD86-molecules on monocytes and B-cells was measured using a whole-blood 
assay (Figure 5). Before transplantation, CD86 was measured on all monocytes, but it was fully 
blocked after the first dose (day 4) and before the 4th belatacept dose (day 30), and during 
rejection. Two months after discontinuation of belatacept, CD86 expression approached 
pretransplantation levels. CD86 was not expressed on peripheral B-cells before nor after 
transplantation (not shown). 
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Supplementary figure 1. No signs of humoral reactivity during rejection under belatacept. 
No CD138+ plasma cells, C4d, IgM or IgG could be detected in the kidney biopsy.
The phenotype of CD4+FoxP3+ T-cells was compared to the phenotype of a stable 
belatacept-treated patient at month 3 after transplantation and to the phenotype of a 
tacrolimus-treated patient during an acute rejection episode 9 days after transplantation. 
(Supplementary Figure 5) No differences were found in intracellular FoxP3 and surface CTLA-4 
expression between these two patients and the case described here. Also the expression of 
intracellular Helios was similar between the 3 patients.
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CD68 5x
*
Supplementary figure 2. Immunohistochemistry of the explant. 
CD3+ T cells were located perivascular (arterisk [*]), as were CD4+ and CD8+ cells. CD68+ macrophages were 
diffusely present in the explant. A small amount of CD20+ B cells were also located perivascular.
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CD86 explant (20x)
Rejection during belatacept treatment Rejection during belatacept treatmentA. B.
C. Rejection during tacrolimus treatment
CD86 biopsy (20x)
CD86 biopsy (20x) CD68 biopsy (20x)
Rejection during tacrolimus treatment 
(sequential slide)
Supplementary Figure 3. CD86 was expressed in the kidney biopsy (before anti-rejection therapy) and in the 
explant (after anti-rejection therapy), but this expression was lower than in a rejection under tacrolimus. 
A similar expression of CD86 (15-20 CD86+ cells per 100 mononuclear cells) was shown in the biopsy (A) and 
in the explant (B). As a control a type 2B (C4d0) rejection under a tacrolimus-based regimen is shown (C) 
with CD68 staining in a sequential staining (70-80 CD86+ cells per 100 mononuclear cells). The location and 
morphology of these CD86+ cells suggests mostly CD68+ monocytes and macrophages expressed CD86.
Isolated graft lymphocytes
The CD4:CD8 ratio of the isolated graft lymphocytes was ~1:1 (43% CD4+ and 36% 
CD8+, Figure 6A). The proportion of CD28NULL within CD4+ T cells was 5% (compared to 0.1% in 
peripheral blood) and the proportion of CD28NULL within CD8+ T cells was 51% (compared to 
54% in peripheral blood; Figure 6A). The majority of the isolated CD4+ and CD8+ T-lymphocytes 
were effector memory T-cells (59% and 66%) and terminally-differentiated EMRA cells (30% and 
19%; Figure 6B). The majority of both CD28-positive (CD28POS) as CD28NULL T-cells was CD45RO+ 
(Figure 6C). Intracellular granzyme B was present in CD8+ T-lymphocytes, but not in CD4+ 
T-lymphocytes (Figure 6D-E). Of the CD8+CD28POS T-lymphocytes, 47% expressed granzyme B, 
and of the CD8+CD28NULL T-lymphocytes, 50% was positive for granzyme B (Figure 6D). About 60% 
of CD45RO+ memory CD8+ T-cells and 17% of the CD45RO- CD8+ T-cells expressed granzyme 
B (Figure 6E). The IFNγ-production capacity was high in CD4+ and CD8+ T-cells: 39% and 67%, 
respectively (Figure 6F). Both CD28POS and CD28NULL CD8+ T-cells had a high IFNγ-production 
capacity (66% and 64%, respectively; Figure 6G).
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63x 100x
100x
perivascular infiltrate
Positive control
Positive control
Supplementary figure 4. Fluorescence In Situ Hybridization (FISH) of the perivascular infiltrate. 
Probes: X-chromosomes (green) and control chromosomes 15 (red). Every cell which contains a double X 
signal is from female origin and therefore from the recipient. Female chromosomes and female lymphocyte 
on the right served as a positive control.
A small proportion of the isolated lymphocytes consisted of B-cells (8.3%), which were 
mostly naïve CD27-IgD+ (79.6%) and switched memory CD27+IgD- (10.7%) B-cells. (Figure 7) 
About 3.6% of the B-cells were CD27+CD38HIGH plasmablasts. 
Discussion
 This is the first immunological characterization, both in peripheral blood and in allograft 
tissue, of a severe, glucocorticoid-resistant, acute T-cell-mediated, kidney transplant rejection 
occurring under belatacept-based immunosuppression. We believe there was little evidence to 
support an antibody-mediated mechanism of this rejection. Although this possibility cannot be 
ruled out, histological examination was compatible with a T-cell mediated rejection.(9) The DSA 
were negative before transplantation and during rejection, and non-complement binding. 
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Supplementary Figure 5. Similar phenotype of FoxP3+ CD4+ T-cells in acute rejection under belatacept 
treatment, acute rejection under tacrolimus treatment and a stable/non-rejecting belatacept-treated patient. 
Lymphocytes were gated by size and granularity in the forward and sideward scatter. CD3+CD4+ T-cells 
expressing intracellular FoxP3 were considered as regulatory T cells (Tregs).
Although serum DSA could have been negative due to deposition in the renal graft (10), the 
absence of C4d, IgM and IgG from the tissue pleads against this (Supplementary Figure 1). 
The occurrence of this rejection during belatacept-based immunosuppression therapy 
may have several explanations: (i) The co-stimulatory CD28-CD80/86 pathway was not sufficiently 
inhibited at the tissue level (i.e. in lymph nodes and/or the kidney); (ii) memory T-cells, which are 
independent of the CD28/CD80-86 pathway for their activation, mediated the rejection; (iii) the 
rejection was initiated through other co-stimulatory pathways; and (iv) belatacept inhibited the 
negative regulators of alloreactive T-cells, i.e. Tregs.
With regard to the first explanation, the CD86-occupancy on CD14+ monocytes was 
measured prospectively in whole blood. Monocyte CD86-occupancy correlates with the inhibition 
by belatacept of in vitro effector T-cell function and with serum belatacept concentrations.(8) 
In the present case, CD86 on peripheral blood monocytes was completely blocked both before 
and during rejection. However, in the kidney allograft, CD86 expression was not completely 
blocked as evidenced by the presence of CD86+ mononuclear cells. This difference between 
allograft tissue and peripheral blood might be explained by the small volume of distribution 
of belatacept, which implicates lower tissue than plasma concentrations.(11) The high CD86-
expression in a rejection-biopsy of a tacrolimus-treated patient (Supplementary Figure 3) 
indicated that this anti-CD86 monoclonal antibody was also competitive with belatacept, as 
was the monoclonal antibody used in the whole blood flowcytometric assay (Figure 5). (12)
 Regarding the second possibility, the large number of CD28NULL T-cells in peripheral 
blood before transplantation is a reflection of the presence of memory T-lymphocytes. As a 
consequence of her 2 pregnancies, part of these effector-memory T-cells may have been 
directed against HLA antigens of her husband.(13) The decrease of these blood CD28NULL 
T-lymphocytes during rejection and the presence of CD28NULL T-lymphocytes within isolated 
lymphocytes from the rejected graft suggest these cells may have migrated from the periphery 
into the allograft. Alternatively, the decrease of these cells was the result of immunosuppression. 
However, CD28NULL effector-memory T-cells are less susceptible to immunosuppressants (14, 15), 
so this is a less likely explanation. In fact, the documented low susceptibility of memory T-cells to 
the effects of glucocorticoids is in line with the clinical course of this case.(16, 17) 
 A significant proportion of the effector T-cell memory population probably was 
directed against antigens other than HLA. Memory against EBV could be an explanation since 
the patient had a sub-clinical EBV reactivation at the time of rejection.(18) EBV-specific memory 
T-cells can be cross-reactive to HLA-B*44:02 (19) but the donor did not express this HLA-antigen. 
The mild EBV reactivation therefore probably did not cause this rejection. Nevertheless, EBV-
specific memory T-cells could have a yet unknown cross-reactivity with other HLA molecules. (20) 
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 Third, this rejection could be explained by memory T-cells which were activated through 
other co-stimulatory pathways, like OX40-OX40L and ICOS-ICOSL.(21) This remains speculative as 
these pathways have been studied mostly in animals. Finally, impaired immunoregulation may 
have played a role as CD28 is also an important mediator of Treg homeostasis.(22, 23) Blockade 
of CD80/86 leads to anergic T-cells (24), which consequently may fail to activate Tregs via CD28. 
This could explain the lower expression of FOXP3 on mRNA level in renal tissue in belatacept-
treated patients compared to the levels in cyclosporin-treated patients.(7) In contrast, in another 
study, FOXP3+ protein concentrations in T-cells were higher in belatacept-treated patients during 
rejection than in cyclosporin-treated patients.(8) In our patient the Treg phenotype was similar 
to a non-rejecting belatacept-treated patient and a tacrolimus-treated patient undergoing 
rejection (Supplementary Figure 5). The effect of belatacept on Treg function requires more 
research. The comparable expression of FoxP3, CTLA4, and Helios do not point to impaired Treg 
function by belatacept. Finally, CD80/86 signaling might also be important for suppression of 
Th17 cells via CD28 and CTLA4.(25) 
 In conclusion, this case sheds light on the immunologic mechanisms possibly 
underlying the higher rejection risk associated with belatacept-based immunosuppression. 
This glucocorticoid-resistant cellular rejection occurring under belatacept was predominantly 
mediated by cytotoxic memory T-cells, which are less susceptible to co-stimulatory blockade by 
belatacept, and/or resulted from incomplete CD80/86 blockade at the tissue level.
Materials and methods
Study design
The patient described here participated in an ongoing, randomized-controlled trial 
in kidney transplant patients and was treated with belatacept (approved by the Medical 
Ethical Committee of the Erasmus MC, University Medical Centre Rotterdam; MEC-2012-42, 
EUDRACT CT # 2012-003169-16). In this trial, a total of 40 patients were included, of which 20 
patients were randomized for treatment with belatacept and 20 patients for treatment with 
tacrolimus (the control group). Both groups were treated with basiliximab (Simulect®, Novartis, 
Basel, Switzerland) on the day of transplantation and on day 4. During the first three post-
operative days methylprednisolone was administered intravenously in a dosage of 100 mg/day. 
Subsequently prednisolone was given orally in a dose of 20 mg and tapered to 5 mg/day at 
month 3. Mycophenolate mofetil was given in a starting dose of 2000 mg/day divided in two 
doses, and then adjusted to pre-dose levels (1.5 – 3.0 mg/L). The tacrolimus-treated patients 
received tacrolimus from the day of transplantation twice a day with a starting dose of 0.2 mg/
kg/day. Thereafter, tacrolimus was adjusted to predose concentrations: 12-15 ng/mL (week 1-2), 
8-12 ng/mL (week 3-4), and 5-10 ng/mL (from week 5 onwards). Belatacept-treated patients 
received 10 mg/kg/day intravenously on the day of transplantation, and on days 4, 15, 30, 
60, and 90 after transplantation. From month 4 onwards, patients received monthly infusions 
of 5 mg/kg belatacept according to the less-intensive regimen.(4) The primary aim of this trial 
is to monitor and compare the alloreactive T-cell response during tacrolimus and belatacept 
therapy. 
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Single bead Luminex assay 
 DSA including C1q-binding capacity were determined in thawed sera before 
transplantation, 1 month after transplantation and during rejection. Twenty microliter of serum 
was incubated for 30 minutes with 2 µl Single Antigen beads mix from LABScreen Single Antigen 
class I and class II kits (One Lambda®, Canoga Park, CA). After protocol washing procedures, 
serum samples were incubated with 1 µl goat anti-human IgG-PE per well (One Lambda®). 
Microbeads were analyzed with a Luminex LabscanTM 100 analyzer using the Luminex 100IS 
software and analyzed using the HLA Fusion 3.0 software. All samples fulfilled the quality criteria 
for reactivity of the control beads.
Flow cytometric phenotyping of peripheral blood lymphocytes
 Fresh heparin whole-blood was collected from the patient one day before 
transplantation, on day 4 and month 1 after transplantation, during rejection (month 2 after 
transplantation) and 2 months after rejection (month 4 after transplantation). The following 
monoclonal antibodies were added to 100 µL of whole blood for 15 minutes on room 
temperature to determine the CD28-negative (CD28NULL) and CD28-positive (CD28POS) T-cells: 
CD3 Brilliant Violet 510 (Biolegend, San Diego, CA), CD4 Brilliant Violet 421 (Biolegend), CD8 APC-
Cy7 (Biolegend), and CD28 PerCP-Cy5 (Becton, Dickinson & company [BD], Franklin Lakes, NJ). 
Number of monocytes were determined using CD14 FITC (Serotec, Oxford, United Kingdom), 
CD45 PerCP (BD) and TruCount tubes® (BD). Erythrocytes were lysed using FACS Lysing Solution® 
(BD). 
The CD86-expression on CD14+ monocytes was determined using CD86 PE (Beckman 
Coulter, Brea, CA), which is competitive with belatacept for CD86, but binds with lower affinity, 
i.e. cannot replace belatacept from the CD86-receptor.(12) In this manner only free, non-
belatacept bound CD86 is measured. The whole-blood was incubated with the monoclonal 
antibodies for 30 minutes on ice, and thereafter erythrocytes were lysed using FACS Lysing 
Solution® (BD FACS, Franklin Lakes, NJ). Mouse IgG2B (Beckman Coulter) was used as an isotype 
control for the CD86-antibody. 
Intracellular Forkhead box P3 (FoxP3) was stained using an anti-Human Foxp3 staining 
set (eBioscience, San Diego, CA). In short, thawed PBMCs were surface stained, using the 
following monoclonal antibodies: CD3 BV510 (BioLegend), CD4 BV421 (BioLegend), CTLA4 
PeCy7 (BioLegend). Subsequently, the PBMCs were fixated and permeabilized and intracellularly 
stained for Helios (PerCP-Cy5.5, BioLegend) and FoxP3 (APC, eBioscience). Regulatory T cells 
were defined as CD3+CD4+FoxP3+ T cells. 
Immunohistochemistry of the kidney biopsy
 The renal graft biopsy and the explant were used for immunohistochemistry. The 
renal tissue was paraffin-embedded, formalin-fixed and cut into four-micrometer sections. 
Immunohistochemistry was performed by routine diagnostics on the Benchmark Ultra Stainer 
(Ventana, Basel, Switserland), using the following moAbs: CD3 (1:150 dilution, DAKO, Denmark) 
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was used to detect pan-T cells; CD4 (undiluted, Ventana, AZ) for T-helper cells; CD8 (1:50, DAKO) 
for cytotoxic T-cells; and CD20 (1:400 dilution, DAKO) for B-cells. Also CD68 (1:1600, DAKO) 
for macrophages, CD138 (undiluted, Cell Marque, Rocklin, CA) for plasma cells, and CD80 
(undiluted, R&D, Minneapolis, MN) and CD86 (undiluted, Abcam, Cambridge, UK) for the co-
stimulatory molecules on antigen-presenting cells. Incubation with antibodies was done for 30 
minutes and anti-rabbit or anti-mouse amplifiers were used. 
 Positive controls were used for immunoglobulins (lymph nodes), C4d (humoral rejection 
tissue) and CD138 (a mixture of tissue samples consisting of lymph node, bowel and pancreas). 
Positivity was required in these samples to exclude technical errors when patient material 
samples were negative. 
Flow cytometric phenotyping of explant lymphocytes 
 A section of the kidney explant was embedded in collagenase at 37ºC to detach 
the cells from the tissue. Thereafter, lymphocytes were isolated using the Ficoll density method. 
Tryptan-blue dye revealed that these cells were viable (> 90%). Explant lymphocytes were 
incubated with the following monoclonal antibodies for 30 minutes on room temperature to 
stain the cells for CD3 Brilliant Violet 510 (BioLegend, San Diego, CA), CD4 Brilliant Violet 421 
(BioLegend), CD8 APC-Cy7 (BioLegend), CD28 PerCP-Cy5 (BD, Franklin Lakes, NJ) or CD28 APC 
(BD), CCR7 PE (BD Pharm), and CD45RO Pacific Blue (BioLegend). 7-AAD PerCP (BD Biosciences, 
San José, CA) was added as viability marker. In addition, the isolated explant lymphocytes 
were stained for intracellular granzyme-B (PE, Sanquin, Amsterdam, the Netherlands) after 
permeabilization with PERM II® 1:10 (BD FACS permeabilization solution, San Jose, CA). The IFNγ-
production capacity was assessed by stimulating isolated graft lymphocytes for 4 hours with 
PMA 0.05 µg/ml and Ionomycine 1 µg/ml (Sigma-Aldrich, St. Louis, MO) at 37°C in the presence 
of Golgiplug 10 µL/mL (BD). IFNγ-FITC from BD Pharmingen (San Jose, CA) was used.
Fluorescence in-situ hybridization (FISH)
 To establish the infiltrating cells were of patient (double X-chromosomes) and not of 
donor origin (single X-chromosome), a FISH was performed as described in previous studies.(26, 
27) In short, the presence of two X-chromosomes per cell was determined using an X-probe 
(Xq13, RP11-1083G9). As a positive control a probe for chromosome 15 was used simultaneously 
(15q25, RP11-121E15). The paraffin-embedded, formalin-fixed graft tissue was first incubated with 
pepsine before the probes were added.  
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Summary
 The introduction of the currently used protocols in patient care and calcineurin inhibitor 
(CNI)-based immunosuppressive regimens improved outcomes in kidney transplantation.(1-7) 
Further progress in long-term patient and graft survival could be realized by the development 
and implementation of immunosuppressive drugs, which when compared to CNIs 1) are not 
inferior in preventing acute allograft rejection; 2) exert less severe adverse events, e.g. infections, 
malignancies, nephrotoxicity and cardiovascular events; and 3) are more efficient in preventing 
chronic graft destruction and dysfunction by inhibiting the formation of donor-specific anti-
human leukocyte antigen (HLA) antibodies (DSA). Belatacept, the CD28-CD80/86 pathway 
inhibitor,(8) might meet the second and third criteria, but violates the first criterion by increasing 
acute rejection risk.(9-11) 
 In this dissertation, we aimed to learn more about the immune mechanisms involved 
in alloreactivity in patients treated with belatacept or tacrolimus after kidney transplantation. In 
particular, we sought to explain the higher acute rejection rate in belatacept-treated patients 
by studying cytotoxic cell populations which are potentially less susceptible to co-stimulatory 
inhibition, and to explain the lower incidence of DSA in previous trials by studying the effects of 
belatacept on Tfh-B cell interaction. Additionally, we tried to characterize belatacept-resistant 
rejection clinically and immunologically, and to find a biomarker to distinguish between patients 
who will reject under belatacept-treatment and those who will not. 
In Chapter 2, we investigated if Tfh cells still mediated humoral reactivity shortly after 
kidney transplantation under the currently most prescribed immunosuppressive regimen. We 
found Tfh cells obtained from tacrolimus-treated patients can still mediate the differentiation 
of B cells into immunoglobulin-producing plasmablasts shortly after transplantation. Moreover, 
the numbers of these Tfh cells were positively correlated to pre-existent DSA, and Tfh cells co-
localized in follicular-like structures with B cells and immunoglobulins in kidney biopsies of T-cell-
mediated acute rejection. This implies Tfh-B cell interaction, which could lead to DSA formation, is 
not sufficiently inhibited by the tacrolimus-based immunosuppressive regimen. Interleukin (IL)-21 
receptor blockade in vitro demonstrated efficient inhibition of Tfh-driven plasmablast formation 
and immunoglobulin production. This emphasizes the importance of IL-21 in Tfh-B cell interaction 
and the potential of immunosuppressive compounds interfering in the IL-21 pathway.
In Chapter 3, we studied the effects of belatacept and tacrolimus on Tfh-B cell 
interaction to explain the lower incidence of DSA observed in CNI-treated patients compared to 
belatacept-treated patients.(10) In PBMCs obtained from kidney transplant patients, surprisingly, 
no superior inhibition by belatacept was observed in Tfh cell generation, IL-21 production or 
plasmablast formation when compared to tacrolimus. Even though both drugs reduced IgM 
production, only tacrolimus could prevent plasmablast formation. We hypothesized redundant 
co-stimulatory pathways, e.g. the CD40-CD40L pathway, could circumvent co-stimulation 
blockade by belatacept. Moreover, upregulation of CD86 on activated B cells was not 
completely inhibited by belatacept. The attenuated suppression by belatacept might have 
the advantage IL-10+ transitional B cells, which are potentially immune regulatory, were not 
affected, but this was not confirmed in a multivariable regression analysis. The overestimation 
of the inhibitory effects by belatacept on Tfh-B cell interaction could be because belatacept 
has always been studied in combination with other immunosuppressive drugs, which could be 
accountable for the successful suppression.
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In Chapter 4, we investigated the effect of belatacept on CD28-positive T cells, which 
in theory should be indirectly affected by costimulatory blockade. CD28-positive T cells were, 
however, capable of proliferating, differentiating and producing the cytokine IFNγ in the 
presence of belatacept. Furthermore, CD28-positive T cells could down regulate their surface 
CD28 after donor antigen stimulation and thus transform into CD28-negative T cells which are 
not susceptible to belatacept.
In Chapter 5, we tried to identify a biomarker for belatacept-resistant rejection for the 
first time in a randomized controlled trial in de novo kidney transplant patients (n = 40) comparing 
a belatacept-based to a tacrolimus-based regimen. Acute rejection rate was higher in the 
belatacept group than anticipated (50% vs. 10% in the tacrolimus group) and these rejections 
were more severe, leading to 3 graft losses in the first months after transplantation. We postulated 
that this acute rejection rate was higher than in previous trials, because mycophenolic acid 
concentrations might have differed between the study populations and because the proportion 
of pre-emptive transplantations was higher in our study. Potential biomarkers were tested and 
compared pre-transplantation between future rejectors and non-rejectors: high proportions 
and absolute numbers of CD28-negative CD8+ T cells, CD57-positive PD1-negative CD4+ T cells, 
and CD28-high positive end-stage terminally differentiated (CD28++ EMRA) CD8+ T cells were 
not predictive for belatacept-resistant rejection. CD28++ EMRA CD8+ T cells showed the most 
potential as biomarker, but these findings need to be validated in a larger prospective study. 
CD86 receptor occupancy by belatacept on circulating monocytes proved to be a feasible 
method of pharmacodynamic therapeutic drug monitoring, but could also not distinguish 
rejectors from non-rejectors.
In Chapter 6, one illustrative case of a belatacept- and steroid-resistant rejection leading 
to acute graft loss was described and immunologically analyzed in detail. The characterization 
of isolated graft-infiltrating lymphocytes, and the immunohistochemistry of graft biopsy and 
tissue revealed a severe vascular T-cell mediated rejection consisting of CD28-positive and 
CD28-negative effector-memory T cells that expressed Granzyme B and produced IFNγ. No 
signs of antibody-mediated rejection were found. ~15% of CD4+ mononuclear cells in the graft, 
morphologically classified as monocytes, still expressed CD86, which suggests an incomplete 
blockade of the CD28-CD80/86 pathway by belatacept on the tissue level.
In Figure 1, a summary is depicted of the different postulated mechanisms of the 
immune system to circumvent the effects of belatacept.   
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Figure 1. Hypothesized mechanisms of the immune system to circumvent co-stimulatory blockade by 
belatacept. 
Both cytotoxic T cells as follicular T cells (Tfh) and B cells could be less or not susceptible to belatacept. CD28-
positive T cells down-regulate surface CD28 upon repeated antigen exposure, e.g. donor antigen, and 
become anergic when only their T-cell receptor is stimulated without co-stimulatory signals. CD28-negative T 
cells can, however, be activated again by external stimulating factors like the cytokines interleukin (IL)-15 or IL-
21.(1-3) This leads to the upregulation and production of pro-inflammatory molecules and cytokines by CD28-
negative T cells, which makes them dangerous to the graft, but not susceptible to belatacept. Moreover, a 
part of the T cells that remain CD28-positive can still proliferate, differentiate and produce pro-inflammatory 
cytokines under belatacept. 
Tfh and B cells are activated by the same (donor)antigen. The formation of Tfh cells from T helper (Th) cells is 
not affected by belatacept, but the activation of Tfh cells and the consequent IL-21 production are partially 
inhibited. Tfh and B cells can still stimulate each other in the presence of belatacept by redundant CD86 on 
B cells and redundant co-stimulatory pathways, e.g. CD40-CD40L and ICOS-ICOSL. Consequently, Tfh-driven 
plasmablast formation is not prevented by belatacept. The IgM production is partially inhibited by blockade 
of the CD28-CD80/86 pathway. The inhibitory effects of belatacept on the interaction between dendritic cells 
(DCs) and Tfh or B cells is unknown.
References: (1) Traitanon et al. AJT 2014; 14: 1277–1289; (2) Alonso-Arias et al. Aging Cell 2011; 10, pp844–852; (3) Mou et al. AJT 
2014; 14: 2460–2466
Discussion - Clinical implications
 The following recommendations can be made based on this dissertation and other 
studies: 1) belatacept should not be prescribed as first-line immunosuppressive therapy in de 
novo kidney transplantation, but should be reserved to special patient populations and/or 
occasions; 2) the identification of a biomarker for belatacept-resistant rejection is important for 
the implementation of belatacept in kidney transplantation; and 3) despite the introduction of 
belatacept, the search for more efficient immunosuppressive drugs against the development of 
DSA, by targeting Tfh-B cell interaction, should be continued. 
 The first recommendation, stating belatacept should not be used as first-line 
immunosuppressant, arises from the higher than expected acute rejection rate we observed in 
kidney transplant patients with a relatively low-immunological risk profile, mostly receiving their 
first graft from a living donor (Chapter 5). Probably since not only aggressive CD28-negative 
effector-memory T cells can escape blockade by belatacept,(12-14) but also a substantial 
part of their indirect targets, CD28-positive T cells (Figure 1; Chapter 4 and 6). The severity of 
rejections under belatacept resulted in the increased necessity of using lymphocyte-depleting 
anti-rejection therapy, i.e., alemtuzumab, followed by discontinuing belatacept-treatment 
and conversion to tacrolimus (Chapter 5). As most of these rejections occurred within the first 
months after transplantation, starting with a tacrolimus-based regimen the first months after 
transplantation and switching to a belatacept-based regimen hereafter, could be an elegant 
solution to prevent early acute rejections, and benefit from the long-term effects of a CNI-free 
regimen.(11) In the only reported randomized controlled belatacept-conversion trial (and its 
extension study) tacrolimus and cyclosporine A were switched to belatacept 6 months after 
kidney transplantation, which still resulted in an increased acute rejection rate, but equal 
patient and graft survival compared to patients that remained on tacrolimus.(15, 16) Reasons 
Chapter 7
162
for conversion from CNIs to belatacept in an observational study and various case reports 
were CNI nephrotoxicity,(17-19) tacrolimus-induced microangiopathy (TMA),(20, 21) and CNI 
intolerance(22, 23) All studies that reported renal function showed an increase of glomerular 
filtration rate after conversion to belatacept.(15, 16, 19, 20, 22, 23) In some studies belatacept 
could contribute in resolving TMA.(20, 21, 23) In addition, in theory certain patient populations 
could still benefit from belatacept more than they will suffer from the down sides of belatacept-
resistant rejection, such as insulin-resistant diabetes patients and non-compliant patients.(11, 
24) The question remains if stable belatacept-treated patients could have also profited from a 
regimen containing low doses of tacrolimus or no tacrolimus at all, but only glucocorticoid and 
mycophenolate mofetil therapy.  
 The second recommendation, that a biomarker for belatacept-resistant rejection is 
imperative for the implementation of the co-stimulatory inhibitor, results from the importance to 
distinguish patients who can benefit from a CNI-free belatacept-based regimen and patients 
who will only be harmed by irreversible graft injury caused by rejection or the detrimental effects 
of lymphocyte-depleting anti-rejection therapy. No definite immunological biomarker has been 
found yet, but the absolute numbers of pre-transplantation CD28++ EMRA CD8+ T cells warrant 
further investigation in a larger randomized controlled trial than conducted here. Our study 
did not have enough power to reliably compare characteristics between rejectors and non-
rejectors. Nonetheless, belatacept is a milder immunosuppressant compared to tacrolimus. 
Thus by taking into account generally accepted risk factors for acute rejection,(25) e.g. higher 
donor age and younger recipient age, and complications caused or abrogated by CNIs like 
mentioned earlier, certain patients can be selected for belatacept-based treatment. 
 Finally, the third recommendation, that the search for a drug that effectively abrogates 
Tfh-B cell interaction should continue, comes from our in vitro studies that did not show a superior 
inhibition of this interaction by belatacept compared to tacrolimus. This was not in line with 
observations made in the BENEFIT-trial(10) and could be explained by an overestimation of the 
inhibitory effects by belatacept, because 1) it was combined with mycophenolate mofetil and 
prednisone; 2) mycophenolic acid concentrations could have been higher than usual; and 
3) the comparator was the less potent CNI ciclosporin A.(10, 26, 27) The attenuated effects 
of belatacept on Tfh-B cell interaction possibly result from inadequate saturation of CD86 
molecules on B cells and redundancy of other costimulatory pathways and cell types (Figure 
1; Chapter 3). Furthermore, in the trial presented in Chapter 5 we found that two patients in the 
belatacept group developed DSA the first year after transplantation vs. none in the tacrolimus 
group. Belatacept- (and also tacrolimus-) based regimens could be improved by the addition of 
other compounds interfering with Tfh-B cell interaction. The interleukin (IL)-21-receptor antagonist 
is a promising drug to prevent DSA formation, because the cytokine IL-21 is important for Tfh-cell-
driven differentiation into immunoglobulin-producing plasma cells (Chapter 2). A study to assess 
the safety and tolerability of an IL-21-receptor antagonist ATR-107 was, however, terminated in 
2011 due to the development of anti-drug antibodies in more than 75% of healthy volunteers, 
resulting in rapid clearance and low bioavailability of the drug.(28) Recently, a phase-I and –II 
trial have been completed about the efficacy and safety of other IL-21-receptor antagonists 
(NNC0114-0005 and -0006) in patients with rheumatoid arthritis and Crohn’s disease, respectively 
(NCT01208506 and NCT01751152). However, so far, the results of these trials are not published and 
no trials have been conducted in kidney transplant patients. Another compound, targeting the 
CD40-CD40L pathway named CFZ533, could also be an useful addition to a belatacept-based 
regimen.(8, 29, 30) Currently, a phase-II study by Novartis® is recruiting de novo kidney transplant 
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patients to assess the safety and efficacy of CFZ533.(31) A third compound, tocilizumab, used 
for the treatment of rheumatoid arthritis, interferes with Tfh-B cell interaction by blocking the IL-6 
receptor,(32, 33) and proved to be safe in a small group of highly sensitized kidney transplant 
patients.(34) Currently, kidney transplant patients are recruited in a phase-II trial to investigate 
the efficacy and safety of tocilizumab for treatment of inflammation in the graft.(35)   
 For now, belatacept does not meet the requirements to be the new corner stone in 
immunosuppression after kidney transplantation, because short-term outcomes are inferior to 
tacrolimus. However, belatacept-treatment could be beneficial and increase quality of life 
for a selected group of patients. The search for an immunosuppressive drug or combination 
of immunosuppressants, possibly including belatacept, to further improve kidney transplant 
patients’ outcomes continues.  
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Conclusions
•	 Follicular T helper cells mediate important humoral alloreactivity shortly after kidney 
transplantation under the currently used tacrolimus-based immunosuppressive 
regimen.
•	 Co-stimulation blockade by belatacept in vitro is less efficient than calcineurin inhibition 
by tacrolimus in preventing donor antigen-driven plasmablast formation resulting from 
Tfh-B cell crosstalk.
•	 Not only CD28-negative, but also CD28-positive, mostly effector-memory T cells can 
escape co-stimulatory blockade by down regulating their surface CD28 after antigen 
exposure.
•	 Belatacept-based therapy resulted in significantly higher and more severe acute 
rejection compared to tacrolimus-based therapy.
•	 Cytotoxic CD4+ and CD8+ T cells, i.e., CD4+CD57+PD1-, CD8+CD28- and CD8+CD28++ 
EMRA T cells, are no suitable immunological biomarkers for belatacept-resistant 
rejection.
•	 Measuring free CD86 molecules on circulating monocytes is a feasible method 
for pharmacodynamic therapeutic drug monitoring of belatacept, but does not 
distinguish between (future) rejectors and non-rejectors.
•	 Belatacept-resistant rejection is a classic T-cell-mediated process including CD28+ and 
CD28- effector-memory T cells, monocytes and macrophages.
•	 CD86 was not fully blocked by belatacept on CD4+ mononuclear cells during rejection 
in a kidney graft.
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Samenvatting
 De nieren zijn belangrijke organen in het menselijk lichaam en hebben de volgende 
functies: 
•	 Het vormen van urine om schadelijke stoffen of stoffen waar we teveel van hebben uit 
het bloed te filtreren
•	 Het tegenhouden van belangrijke eiwitten en het actief terughalen van belangrijke 
stoffen uit de urine die we nodig hebben in het lichaam
•	 De balans van zouten en water onderhouden in het lichaam
•	 Het reguleren van de bloeddruk
•	 Het maken van hormonen om de aanmaak van rode bloedcellen te stimuleren 
•	 Het omzetten van inactief vitamine D naar actief vitamine D
Elke minuut worden er door onze nieren 120 milliliter (mL) aan urine gevormd (dus meer 
dan 7 liter per uur), waarvan een groot deel door de nieren wordt heropgenomen naar de 
bloedbaan. Nieren kunnen beschadigd raken door hoge bloeddruk, suikerziekte, medicijnen 
en auto-immuunziektes (ziektes waarbij het immuunsysteem het eigen lichaam aanvalt, zoals 
lupus). Er wordt gesproken van chronische nierziekte wanneer de nieren nog minder dan 60 
mL urine per minuut kunnen vormen. Wanneer de nieren zo slecht zijn dat er minder dan 10 mL 
urine per minuut wordt geproduceerd, kan de patiënt niet overleven zonder medische hulp. Een 
manier om nierpatiënten te helpen is door meerdere malen per week het bloed te filtreren door 
een machine in het ziekenhuis (hemodialyse) of door het bloed te zuiveren door spoelingen 
van de buikholte te verrichten thuis of in het ziekenhuis (peritoneaal dialyse). Deze oplossingen 
zijn echter niet perfect, omdat ze niet volledig de functie van een nier kunnen vervangen. Een 
betere oplossing is een niertransplantatie. Dit is realiseerbaar, doordat het mogelijk is om met 
één nier te leven in plaats van twee zonder hier nadelen aan te ondervinden. 
 Niertransplantatiepatiënten hebben een betere kwaliteit van leven en een betere 
levensverwachting dan dialysepatiënten.(1-3) Deze kwaliteit en levensverwachting zijn echter 
nog niet gelijk aan die van gezonde personen, omdat transplantatiepatiënten levenslang 
medicijnen moeten slikken om te voorkomen dat hun donornier wordt afgestoten en deze kapot 
gaat. Een afstoting betekent dat de cellen van het immuunsysteem van de patiënt de donornier 
ingaan en aanvallen. Dit kan worden vastgesteld door de combinatie van achteruitgang van 
nierfunctie en het binnendringen van immuuncellen in de donornier. Dit laatste wordt vastgesteld 
met een nierbiopt. Een acute afstoting, in het eerste jaar na transplantatie, bestaat vaak uit T 
cellen die de donornier binnendringen. Een chronische afstoting, die meer geleidelijk en jaren na 
transplantatie plaatsvindt, wordt veroorzaakt door gespecialiseerde B cellen, plasmacellen, die 
antistoffen vormen tegen de donornier. Meestal zijn acute afstotingen te behandelen door extra 
afweerremmende medicijnen, zoals prednison, te geven waardoor het transplantaat behouden 
blijft. Voor chronische afstotingen bestaat nog geen bewezen effectieve behandeling. 
De meest gebruikte afweerremmende medicijnen die patiënten dagelijks moeten 
innemen zijn “calcineurine-remmers”, die celgroei en activatie van immuuncellen remmen, 
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in combinatie met de afweerremmers mycofenolzuur en prednison. Hierdoor treedt er veel 
minder vaak een afstoting op dan als er geen afweerremmers zouden worden gebruikt. 
Calcineurine-remmers kunnen T cellen effectief remmen, maar zijn niet goed in het voorkomen 
van antistofproductie door de plasmacellen van de patiënt.(4, 5) Hierdoor kan de nier jaren 
na transplantatie nog vernietigd worden door een chronische afstoting. Bovendien hebben 
calcineurine-remmers bijwerkingen als infecties en kanker, en zijn ze slecht voor hart en vaten.
(6-9) Ten slotte beschadigen calcineurine-remmers de donornier.(10)   
Er valt dus nog veel te verbeteren in de behandeling van niertransplantatiepatiënten. 
Het ideale afweerremmend middel voor deze patiënten zou de volgende drie eigenschappen 
bezitten:
•	 voorkomen dat de patiënt zijn donornier door een afstoting kwijtraakt;
•	 minder bijwerkingen hebben dan calcineurine-remmers;
•	 beter voorkomen dat er antistoffen worden gemaakt tegen de donornier, zodat deze 
ook op langere termijn niet beschadigd raakt.
Belatacept is nieuw afweerremmend geneesmiddel dat in 2012 geregistreerd werd voor 
niertransplantatiepatiënten en valt in de groep “co-stimulatieremmers”. Het remt, net 
als calcineurine-remmers, de immuuncellen van de patiënt, maar via blokkade van co-
stimulatiemoleculen. Het bindt op het molecuul CD86 op het oppervlak van de antigeen-
presenterende cellen (monocyten, macrofagen, dendritische cellen en B cellen), en voorkomt 
zo het co-stimulatie signaal dat door binding aan CD28 op T cellen, naast de binding van 
antigen aan de T-cel receptor, nodig is voor de activatie van T cellen.(11) Dit middel geeft 
minder bijwerkingen dan calcineurine-remmers en is mogelijk beter in het voorkomen van 
antistoffen die worden gemaakt tegen de donornier.(12-14) Het nadeel van dit geneesmiddel 
is dat het minder krachtig is dan calcineurine-remmers, waardoor er meer acute afstotingen 
plaatsvinden de eerste maanden na transplantatie.(12) 
 In dit proefschrift willen we de immuunreacties die plaatsvinden onder behandeling 
met belatacept of tacrolimus beter leren begrijpen. In het bijzonder, proberen we een 
verklaring te geven voor het hogere aantal afstotingen in patiënten die behandeld worden met 
belatacept.(12) Hiervoor hebben we verschillende subgroepen van immuuncellen bestudeerd 
die mogelijk minder gevoelig zijn voor behandeling met belatacept en daardoor een afstoting 
kunnen veroorzaken, met name “cytotoxische T cellen”. Dit zijn cellen die agressief zijn tegen 
de donornier en schadelijke stoffen maken, zoals cytokines of proteasen. Verder hebben 
we op celniveau bestudeerd hoe belatacept ervoor zorgt dat er minder antistoffen worden 
gemaakt tegen de donornier. Hierbij hebben we in het bijzonder T helper cellen en B cellen 
bestudeerd, omdat het samenspel van deze twee soorten immuuncellen zorgt voor de vorming 
van antistoffen. We hebben een uitgebreid onderzoek gedaan naar het immuunsysteem en 
de donornier van een patiënt die haar nier is kwijtgeraakt door een acute afstoting, terwijl 
ze werd behandeld met belatacept. Ten slotte, hebben we gezocht naar verschillen in het 
immuunsysteem tussen patiënten die wel en patiënten die geen acute afstoting hebben gehad 
onder behandeling met belatacept.
 In Hoofdstuk 2, hebben we onderzocht of “folliculaire T helper cellen” (T helper cellen 
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die belangrijk zijn voor het stimuleren van B cellen) kort na niertransplantatie nog steeds B 
cellen en antistofproductie kunnen activeren, terwijl de patiënten behandeld worden met een 
calcineurine-remmer genaamd tacrolimus. We hebben gevonden dat folliculaire T helper cellen 
van deze patiënten in de kweek inderdaad B cellen kunnen stimuleren om plasmacellen te 
worden die antistoffen kunnen maken tegen de donor. Wanneer patiënten voor transplantatie 
meer antistoffen hadden die schadelijk kunnen zijn voor de donornier, hadden ze ook een 
hoger aantal folliculaire T helper cellen in hun bloed na transplantatie. In biopten van patiënten 
met een afstoting werden deze T cellen gezien op dezelfde plaats in de donornier als B cellen 
en antistoffen. Al deze resultaten wijzen er op dat de calcineurine-remmer tacrolimus het 
samenspel tussen folliculaire T helper en B cellen niet goed kan remmen, waardoor antistoffen 
tegen de donornier kunnen ontstaan. Wanneer we in een kweekbakje een antistof tegen de 
interleukine 21 receptor toevoegden, werd de B cel activatie en de vorming van antistoffen 
geremd, omdat interleukine 21 belangrijk is voor het samenspel tussen T helper en B cellen. 
Dit zou kunnen betekenen dat deze anti-interleukine 21 receptor-blokker ook in patiënten de 
vorming van antistoffen kan remmen.  
 In Hoofdstuk 3, hebben we getest of belatacept inderdaad beter de samenwerking 
tussen T en B cellen remt dan tacrolimus. We bestudeerden in de kweek terwijl er belatacept 
of tacrolimus was toegevoegd of 1) immuuncellen van niertranplantatiepatiënten folliculaire T 
cellen konden vormen, 2) er interleukine 21 werd gemaakt en 3) er vorming was van plasmacellen. 
Tegen de verwachting in werd dit niet beter geremd door belatacept. Beide middelen 
konden de vorming van antistoffen verminderen, maar alleen tacrolimus kon de vorming van 
plasmacellen voorkomen. Een verklaring zou kunnen zijn dat belatacept alleen CD86 afdekt en 
de T en B cellen nog geactiveerd kunnen raken via andere moleculen. Een andere verklaring 
is dat de B cellen zoveel CD86 moleculen op hun oppervlak hebben na activatie, dat ze niet 
allemaal geblokkeerd kunnen worden door belatacept. Er was ook een voordeel aan het 
feit dat belatacept minder goed remt dan tacrolimus: namelijk dat speciale B cellen die het 
immuunsysteem onderdrukken en mogelijk de kans op afstoting verminderen (“transitionele B 
cellen” die interleukine 10 maken) ook niet werden geremd door belatacept, maar wel door 
tacrolimus. Wanneer we echter in onze analyse corrigeerden voor andere factoren, zagen we 
deze beschermende werking voor transitionele B cellen door belatacept niet meer. De reden 
dat we niet hetzelfde hebben gevonden als eerdere studies die de remming van belatacept 
op T en B cellen bestuderen, kan zijn doordat wij voor het eerst het geïsoleerde effect van 
belatacept testen. De andere studies keken naar het effect van belatacept in combinatie met 
andere middelen.
 In Hoofdstuk 4, hebben we bestudeerd wat het effect van belatacept is op T cellen 
met CD28 moleculen op hun oppervlakte. Aangezien belatacept het activerende signaal 
naar CD28 blokkeert door te binden aan CD86 moleculen van antigeen-presenterende cellen, 
moet belatacept er indirect voor zorgen dat deze CD28-positieve T cellen niet geactiveerd 
kunnen worden. Een deel van deze cellen kon na stimulatie met donormateriaal, ondanks de 
aanwezigheid van belatacept in de kweek, nog steeds delen, veranderen in gespecialiseerde 
geheugen cellen en het schadelijke cytokine Interferon-gamma produceren. Bovendien 
verdween bij een deel van de cellen de CD28 moleculen van het oppervlak door de stimulatie 
met donormateriaal. Hierdoor veranderden ze in CD28-negatieve T cellen die via andere 
manieren dan CD86 van antigeen-presenterende cellen kunnen worden geactiveerd en dus 
niet meer gevoelig zijn voor de indirecte remming door belatacept.
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In Hoofstuk 5, hebben we gezocht naar een biomarker om te voorspellen welke 
patiënten een acute afstoting zouden krijgen onder behandeling met belatacept en welke 
patiënten niet. Hierbij werden 40 patiënten at random toegewezen aan een behandeling met 
belatacept of tacrolimus (in combinatie met twee standaard gebruikte afweerremmende 
medicijnen in niertransplantatie: mycofenolaat mofetil en prednison). De helft van de 20 patiënten 
in de belatacept groep had een acute afstoting, terwijl maar 2 van de 20 patiënten in de 
tacrolimus groep een afstoting had. De afstotingen in de belatacept groep waren ook ernstiger, 
waardoor er 3 nieren verloren zijn gegaan in de eerste paar maanden na transplantatie. Het 
hogere aantal acute afstotingen dan in eerdere onderzoeken kan komen doordat de spiegels 
van de actieve vorm van mycofenolaat mofetil (mycofenolzuur) mogelijk verschilden tussen de 
studiepopulaties en doordat het aantal transplantaties bij patiënten die nog niet dialyseren in 
ons centrum hoger is (zij hebben een sterker immuunsysteem dan dialysepatiënten en dus meer 
kans op een afstoting). We hebben voor transplantatie de volgende cytotoxische T cellen getest 
als biomarkers: CD28-negatieve CD8+ T cellen, CD57-positieve PD1-negatieve CD4+ T cellen en 
CD28-hoogpositieve zeer-gedifferentieerde geheugen CD8+ T cellen (CD8+CD28++ EMRA). Geen 
van deze biomarkers kon worden gebruikt om te voorspellen welke patiënt een afstoting zou 
ontwikkelen onder belatacept behandeling. De CD8+CD28++ EMRA T cellen hadden de meeste 
potentie om een goede biomarker te zijn, maar deze resultaten moeten worden getest in een 
groter onderzoek. Het vrije aantal CD86 moleculen op monocyten kon gebruikt worden om de 
werking van belatacept te monitoren, maar niet om onderscheid te maken tussen patiënten die 
wel of geen afstoting zouden krijgen met belatacept behandeling.
In Hoofdstuk 6 is een casus beschreven over een patiënt die haar nier kwijtraakte door 
afstoting onder belatacept behandeling. Deze afstoting kon niet worden geremd met hoge 
doses prednison. We bestudeerden de immuuncellen die de donornier hadden aangevallen en 
vernietigd, en hebben ook naar het weefsel van de donornier zelf gekeken. Hieruit konden we 
concluderen dat dit een ernstige afstoting was, waarbij de bloedvaten naar de nier dicht zaten 
door de immuunreactie. Deze reactie bestond uit zowel CD28-positieve als CD28-negatieve 
T cellen die schadelijke cytokines en proteasen produceerden, genaamd Interferon-gamma 
en Granzyme B. Er werden geen antistoffen van de patiënt gevonden in de bloedbaan of 
donornier. In de kapotte donornier werden er monocyten gezien die nog steeds vrije CD86 
moleculen hadden op hun oppervlak, ondanks de patiënt met belatacept was behandeld.  
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Beschouwing – Gevolgen voor niertransplantatiepatiënten
 Op basis van dit proefschrift en andere onderzoeken kunnen de volgende 
aanbevelingen gedaan worden:
1) Belatacept is niet de eerste keus voor afweerremmende medicatie bij 
niertransplantatie, maar moet worden gebruikt in een selecte groep 
patiënten of situaties;
2) Het is belangrijk om een biomarker te vinden om te kunnen voorspellen 
welke patiënt wel en welke niet zal afstoten onder belatacept behandeling, 
voordat dit middel vaker gebruikt kan worden;
3) De zoektocht moet worden voortgezet naar een ander middel dan 
belatacept dat de vorming van antistoffen remt door het samenspel tussen 
folliculaire T helper en B cellen te verstoren.
De eerste aanbeveling, dat belatacept niet de eerste keus is als afweerremmend 
middel, is gebaseerd op het feit dat we veel meer acute afstotingen observeerden in 
niertransplantatiepatiënten die werden behandeld met belatacept. Ondanks deze patiënten 
van tevoren een laag ingeschat risico hadden op een afstoting en dat de meesten voor de 
eerste keer een nier hadden ontvangen, en deze van een levende donor was. Het hoge aantal 
afstotingen komt waarschijnlijk doordat niet alleen de agressieve CD28-negatieve geheugen T 
cellen kunnen ontsnappen aan belatacept,(15-17) maar ook een groot deel van hun indirecte 
doelwitten, CD28-positieve T cellen (Hoofdstuk 4 en 6). De afstotingen waren zodanig ernstig dat er 
aanvullende afweerremmende medicatie gegeven moest worden dat het hele immuunsysteem 
van de patiënt onderdrukt (alemtuzumab). Bovendien konden deze patiënten niet doorgaan 
met belatacept, en hebben ze tacrolimus voorgeschreven gekregen (Hoofdstuk 5). Omdat de 
meeste afstotingen in de eerste maanden na transplantatie plaatsvonden, de periode waarvan 
bekend is dat de kans op afstoting hoger is, zou een elegante oplossing kunnen zijn om de 
eerste maanden te behandelen met tacrolimus en daarna over te gaan op belatacept. Dit zou 
de vroege afstotingen voorkomen, maar als voordeel hebben dat er geen lange termijn schade 
aan de nier optreedt door tacrolimus.(14) In het enige beschreven gerandomiseerde onderzoek 
waarbij patiënten met calcineurine-remmers werden omgezet naar belatacept 6 maanden na 
transplantatie, was er een stijging in het aantal acute afstotingen, maar gelijke overleving van 
de donornier en de patiënt vergeleken met patiënten die nog steeds calcineurine-remmers 
gebruikten.(18, 19) Redenen om patiënten over te zetten van calcineurine-remmers naar 
belatacept in verschillende studies zijn nierschade,(20-22) bloedstolsels in de kleine niervaten 
(trombotische micro-angiopathie) (23, 24) of overgevoeligheid veroorzaakt door calcineurine-
remmers.(25, 26) In de studies waar de nierfunctie werd beoordeeld, werd gezien dat deze 
patiënten allemaal een betere functie van hun donornier hadden nadat ze waren overgezet 
op belatacept.(18, 19, 22, 23, 25, 26) In sommige studies waren de bloedstolsels in de niervaten 
zelfs opgelost nadat belatacept gestart en tacrolimus gestopt werd.(23, 24, 26) Verder zouden 
in theorie bepaalde patiënten meer voor- dan nadelen kunnen halen uit behandeling met 
belatacept, zoals patiënten met suikerziekte of patiënten die hun medicatie niet trouw slikken 
(belatacept wordt maandelijks via een infuus in het ziekenhuis gegeven).(14, 27) De vraag blijft 
echter of patiënten die geen afstoting hebben onder belatacept-behandeling het ook goed 
zouden doen met lagere doseringen tacrolimus of helemaal geen tacrolimus, maar alleen 
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mycofenolaat mofetil en prednison.
De tweede aanbeveling, dat de zoektocht naar een biomarker voor afstoting onder 
belatacept behandeling moet worden voortgezet, resulteert uit het feit dat het belangrijk is 
om patiënten te kunnen onderscheiden die voordeel hebben aan een behandeling zonder 
calcineurine-remmers en patiënten die alleen maar schade ondervinden aan ernstige acute 
afstotingen bij belatacept behandeling of bijwerkingen van extra anti-afstotingstherapie 
(alemtuzumab). Er is nog geen biomarker gevonden, maar het aantal CD8+CD28++ EMRA T cellen 
voor transplantatie moet verder worden onderzocht als biomarker in een groter onderzoek dan 
wij hier hebben verricht. Onze studie was niet groot genoeg om betrouwbaar patiënten die 
wel of niet afstoten met belatacept te vergelijken. Desalniettemin is belatacept een zwakker 
afweerremmend medicijn dan tacrolimus en zou daarom alleen gegeven moeten worden aan 
patiënten met een lager ingeschat risico op afstoting,(28) zoals oudere patiënten of patiënten 
die een nier ontvangen van een levende jonge donor. Hierbij moeten ook patiënten worden 
geselecteerd die duidelijke nadelen ondervinden van calcineurine-remmers, zoals eerder 
genoemd.
Ten slotte, de derde aanbeveling, dat de zoektocht moet worden voortgezet naar 
een ander middel dan belatacept dat het samenspel tussen folliculaire T helper cellen en B 
cellen verstoort, komt doordat wij hebben gezien dat belatacept dit samenspel eigenlijk niet 
beter remt dan tacrolimus in de kweek. Dit komt niet overeen met wat in een Amerikaanse 
studie (de BENEFIT-trial) gevonden is(13) en kan worden verklaard doordat de remmende 
werking van belatacept in die studie overschat is, omdat 1) het gecombineerd werd met 2 
andere afweerremmende middelen (mycofenolaat mofetil en prednison); 2) de concentraties 
van de werkzame stof van mycofenolaat mofetil (mycofenolzuur) hoger geweest konden zijn; 
en 3) belatacept werd vergeleken met een oudere en zwakkere calcineurine-remmer dan 
tacrolimus, namelijk ciclosporine A.(13, 29, 30) De verminderde werking van belatacept op het 
samenspel tussen folliculaire T helper cellen en B cellen komt waarschijnlijk doordat het niet 
alle CD86 moleculen kan afdekken op geactiveerde B cellen en doordat de activatie van de 
immuuncellen via andere moleculen kan plaatsvinden (Hoofdstuk 3). Bovendien hadden twee 
patiënten behandeld met belatacept in onze studie in Hoofdstuk 5 antistoffen tegen de donor 
gemaakt, terwijl geen patiënten behandeld met tacrolimus deze antistoffen ontwikkelden. 
Behandeling met belatacept (of tacrolimus) zou kunnen worden verbeterd door andere 
middelen toe te voegen die het samenspel tussen folliculaire T helper en B cellen remmen. 
De blokker van de interleukine-21-receptor is een veelbelovend middel om antistofvorming 
te voorkomen, omdat de cytokine interleukine-21 belangrijk is voor de samenwerking tussen 
folliculaire T helper en B cellen die leidt tot antistof-producerende plasmacellen (Hoofdstuk 2). 
Een onderzoek naar de veiligheid van zo een interleukine-21 blokker genaamd ATR-107 is echter 
vroegtijdig gestaakt, omdat meer dan driekwart van de gezonde vrijwilligers antistoffen maakten 
tegen het geneesmiddel zelf, waardoor deze werd afgebroken en niet meer werkzaam kon zijn.
(31) Onlangs zijn er twee onderzoeken verricht, waarvan nog geen resultaten zijn gepubliceerd, 
naar de veiligheid en effectiviteit van andere interleukine-21 blokkers (NNC0114-0005 en 
-0006) in patiënten met een auto-immuunziekte (trial nummers NCT01208506 en NCT01751152). 
Maar deze afweerremmers zijn nog niet onderzocht in niertransplantatiepatiënten. Een ander 
afweerremmend middel genaamd CFZ533, dat het CD40 molecuul bindt dat ook belangrijk 
is voor T en B cel samenspel, zou een goede toevoeging kunnen zijn aan behandeling met 
belatacept.(11, 32, 33) Er wordt momenteel een studie verricht door Novartis® waarbij de 
veiligheid en effectiviteit van dit middel wordt getest op patiënten die voor het eerst een 
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donornier krijgen.(34) Een derde middel genaamd tocilizumab, dat van oorsprong gebruikt 
wordt in reumapatiënten, blokkeert de interleukine-6 receptor, die ook belangrijk is voor de 
samenwerking tussen folliculaire T helper en B cellen.(35, 36) Dit middel bleek veilig te zijn in een 
kleine groep nierpatiënten die al voor transplantatie veel antistoffen hadden.(37) Er is een studie 
gaande om de effectiviteit en veiligheid van dit middel te testen in niertransplantatiepatiënten 
met een immuunreactie in hun donornier.(38)  
Vooralsnog voldoet belatacept niet aan de eisen om de nieuwe hoeksteen 
van de afweerremmende behandeling te worden na niertransplantatie, omdat de korte 
termijn uitkomsten van belatacept minder goed zijn dan die van tacrolimus. Behandeling 
met belatacept kan echter voordelen hebben en de kwaliteit van leven verbeteren voor 
een selecte groep aan patiënten. De zoektocht naar een afweerremmend middel of een 
combinatie van afweerremmende middelen, mogelijk inclusief belatacept, om de uitkomsten 
in niertransplantatiepatiënten te verbeteren, duurt voort. 
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Conclusies:
•	 Folliculaire T helper cellen reguleren belangrijke B cel processen al kort na 
niertransplantatie ondanks patiënten worden behandeld met tacrolimus.
•	 Het samenspel tussen folliculaire T helper en B cellen wordt minder goed geremd door 
belatacept dan door tacrolimus.
•	 Niet alleen CD28-negatieve, maar ook CD28-positieve geheugen T cellen kunnen 
ontsnappen aan belatacept, doordat hun oppervlakte CD28 verdwijnt na blootstelling 
aan antigenen.
•	 Behandeling met belatacept resulteert in meer en ernstigere afstotingen dan 
behandeling met tacrolimus.
•	 Cytotoxische CD4+ en CD8+ T cellen, namelijk CD4+CD57+PD1-, CD8+CD28- en 
CD8+CD28++ EMRA T cellen, zijn geen geschikte biomarkers om afstoting onder 
belatacept behandeling te voorspellen.
•	 Het meten van vrije CD86 moleculen op monocyten in de bloedbaan is een goede 
methode om het werkingsmechanisme van belatacept te bestuderen, maar niet om 
onderscheid te maken tussen patiënten die wel of niet afstoten.
•	 Bij afstoting onder belatacept zijn zowel CD28-positieve als CD28-negatieve geheugen 
T cellen betrokken die de donornier aanvallen samen met monocyten en macrofagen.
•	 CD86 was, ondanks behandeling met belatacept, niet volledig geblokkeerd op 
monocyten in de afgestoten donornier.
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omtrent de promotie en alle steun tijdens het gehele promotietraject. Lieve Marjolein, moeder 
der AIO’s en “ginger with a soul”. Ik ben blij dat ik onder jouw hoede ben geplaatst toen ik nog 
amper een pipet kon vasthouden. Met alle geduld van de wereld legde je mij alles uit over 
celletjes in welletjes en oppervlakte en intracellulaire kleurinkjes (en “poef” een wolkje op de 
FACS). Tijdens de jaren op het transplantatielab zijn we echte vriendinnen geworden en ik hoop 
dat we elkaar nog veel zullen zien in de toekomst (ik heb er alle vertrouwen in!). Lieve Sylvia, mijn 
geneeskunde BFF. Ondanks de ogenschijnlijke grote verschillen zijn we toch al langer dan 10 
jaar goede vriendinnen en hebben we zelfs even samengewoond. Heel erg bedankt dat ik bij je 
mocht klagen over afgekeurde papers en publicatiestress. Dat onze eetdates mogen doorgaan 
totdat we geen tanden meer hebben.
Mijn (te) gezellige AIO collega’s wil ik bedanken voor een onvergetelijke tijd met spelletjes- en 
SingStar-avonden, helemaal los gaan in de Coconuts en een zonnige vakantie in Córdoba in 
te strakke jurken. 
Ling, thank you for always being your happy self and making me laugh with your sharp 
remarks. I realy envy your ability to eat a lot of chocolate without getting fat. You shared some 
difficult periods in your life with me and I want to thank you for your trust in me.
Burç, we hebben samen heel wat afgelachen, bruhh, en het mysterie genaamd “de 
vrouw” uitvoerig besproken. Ook delen we de diagnose OCD. Bedankt voor het gezelliger 
maken van de kamer met jouw bulderende, aanstekelijke lach. 
Kitty, je was als een verfrissende wervelwind toen je bij ons begon. Heerlijk enthousiast 
en een tikkeltje chaotisch, maar al meteen veel inzicht (#flawless). Vanaf de eerste dag konden 
we het al goed vinden en ons hart luchten bij onze onofficiële bela-meetings bij de Doppio. 
Bedankt dat je niet gek werd van al mijn Hello Kitty spullen aan de muur en de fijne tijd samen 
in ons kantoor.
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Lin, you are a very sweet and enthusiastic lady. Good luck in the cold and rainy 
Netherlands!
Ruud, ik leerde je pas echt kennen toen we tegenover elkaar zaten in het Na-gebouw. 
Bedankt voor de onvergetelijke tijd in de Efteling en je oog voor detail. Het gaat je goed!
Nynke, met jou voelde het alsof we er een nieuw zusje bij hadden in de bela-groep. 
Samen sloegen we ons door de pittige maandagochtend meetings heen en waren we elkaars 
steun en toeverlaat tijdens cursussen en congressen. In het vliegtuig vormden we een gezellig 
koppeltje (de één met reisziekte, de ander met vliegangst). Ook jij bedankt voor de onofficiële 
bela-meetings.
Samantha, geheel tegen mijn eerste verwachtingen in, kon ik het erg goed met je 
vinden en ben je nu officieus lid van mijn “Asian Posse”. Ondanks je me regelmatig pestte met 
mijn smetvrees, zorgde je voor persoonlijke hygiëne in de groep. Bedankt hiervoor en uiteraard 
voor alle gezelligheid op en buiten het werk.
Franka, we delen onze grote passies “wijn drinken” en “TV series binge watchen”. 
Gelukkig zijn we ondanks de “Wine-throwing-gate” en de “What’s-behind-you?-You’re-
youth!-escapade” wel vrienden geworden. Bedankt voor het geven van lachstuipen en het 
beschikbaar stellen van je haar voor extensions. 
Fleur, met je befaamde knot en voetbaltalenten tegenover mijn liefde voor Hello Kitty 
en alles roze, konden we bijna niet meer verschillen. Toch heb ik veel met je gelachen wanneer 
je op een droge manier de meest hilarische verhalen vertelde. Bedankt voor het tolereren van 
mijn meisjesdingetjes. 
Jesus, you, me and your beard had lots of laughs. Keep being your funny self during 
the rest of your career!
Anusha, we kennen elkaar nog niet lang, alhoewel we al minimaal 6 keer aan elkaar 
zijn voorgesteld. Veel succes op het Transplantatielab!
Anja, Anne, Marieke, Martijn en Ramin, mijn oudere AIO-broers en zussen. We zaten 
samen in een benauwd hok en jullie hebben ervoor gezorgd dat ik niet verzoop in de PhD-stress 
de eerste periode van mijn traject. Het gaat jullie allen goed!
Ik wil ook de post-docs bedanken voor hun kennis, hulp en gezelligheid op de werkvloer. Het zou 
niet hetzelfde zijn geweest zonder jullie input.
Dr. Wu, I respect the way you adapted to the Dutch culture and that you were always 
in for a party. Sometimes you even entertained us with Chinese music in the office. Thank you for 
our talks about different cultures and good luck with the rest of your career.
Marcel.la, although you are back home now, I still think about you. With your down-to-
earth attitude, your sporty figure and yoga fitness, you’re an example to us all. Good luck with 
your family and career in Barça.
Martin, ik heb nog nooit iemand gezien met zoveel kalmte en geduld als jij. Bedankt 
voor het compenseren van alle drukte op het lab.
Nicolle, als jij iets niet weet, weet niemand het. Heel veel dank dat ik altijd naar binnen 
kon lopen om advies te vragen over protocollen, antilichamen en FACS-plaatjes. 
Ana, thank you for your Southern-Europe mentality that looks a lot like the Surinamese 
attitude. I always felt really comfortable with you and I applaud your ways to interact with the 
people around you. I hope I will see you again at the Feria Córdoba the coming years.
Karin, jij doet je nooit anders voor dan je bent en zegt gewoon waar het op staat. Als 
Rotterdammert stel ik dat zeer op prijs. Op gebied van onderzoek (te moeilijke kleuringen op 
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biopten) kon ik op je hulp rekenen. Dank hiervoor.
Nicole, de koningin van de Elispots. Succes met je nieuwe projecten en AIO’s. 
Alle analisten wil ik ook bedanken voor het opvoeden van mij tot iemand die je alleen durft 
achter te laten op een lab.
 Wenda, je wist me wel te vinden als er “iets niet goed niet was heh” aan een belatacept 
protocol of als ik mijn vrije uren weer eens verkeerd had ingevuld. Bedankt voor alle geduld en 
de lange sort-dagen.
Joke, het opperhoofd van de kweek. We hadden soms onze mini-uitbarstingen, maar 
we konden het toch goed vinden met elkaar. Je hebt me leren ficollen, terwijl we modetips aan 
elkaar uitwisselden. Ik kreeg soms zelfs mooie kleding of schoenen van je. Ik hoop dat ik er later 
half zo modieus uit zie als jij. Geniet van je vrije tijd!
 Sander, we hebben vele gezellige spelletjesavonden samen meegemaakt. Op het 
lab legde je met veel geduld onder andere uit hoe, wanneer, waarom en hoezo de centrifuges 
werkten. Ik heb veel van je geleerd.
 Mariska, de reddende engel op het lab. Je was altijd bereid een kleuring voor team 
bela te doen als wij zo nodig ergens anders moesten zijn. Ik liet met een gerust hart mijn kostbare 
samples bij je achter. Bedankt!
 Annemieke, wij hadden het vaak over mode of over je prachtige dochtertjes. Bedankt 
voor het aanwijzen waar ik spullen kon vinden op het lab.
 Ronella, we konden samen hard meezingen met de radio in de kweek. Bedankt voor 
alle kweekwijsheden die je mij hebt aangeleerd.
Derek, de nieuwe stille kracht op het transplantatielab. Succes!
 Tanja, Jeroen, Elly, Thea, Ruben en Frieda, ik vond het erg jammer toen jullie weggingen 
van het lab. Tanja, good luck abroad with your wonderful family! Jeroen, Elly en Ruben, ik heb 
met jullie gelachen om ons gedeelde sarcastische humor. Thea en Frieda, dankzij jullie kan ik nu 
ook wel eens raak prikken bij bloedafnames.
Op de D-vleugel wil ik Monique bedanken voor haar oneindige inzet voor de belataceptstudie. 
Vooral wanneer we heel de ochtend bezig waren met een inclusie of op zoek waren naar 
afgenomen samples (“mi gado”). Mi gudu, mo miss’ie. Uiteraard ook mijn dank aan Marieken 
en Nelly voor het bijspringen als Monique er niet was. Jacqueline, Joke en Marcia, bedankt voor 
het helpen met de inclusies van de belataceptstudie. Alle verpleegkundingen en artsen op 9 
Zuid en 4 Noord, bedankt voor het opvangen van alle belataceptpatiënten.
Dr. Berghout, we hebben voor het laatst samengewerkt in het Maasstad Ziekenhuis. Bedankt 
voor het extra zetje dat tot deze promotie heeft geleid.
Lieve broertjes/neefjes, Damien, Raï en Gaetano. Door jullie had ik de nodige ontspanning met 
(discussies over) films en series. Bedankt voor alle afleiding.
Lieve familie (oma’s, opa, tantes, ooms, neven, nichten, en schoonfamilie), bedankt voor jullie 
steun en interesse tijdens mijn hele opleiding en onderzoekstraject. Ik vind het erg leuk hoe 
enthousiast en trots jullie altijd zijn!
Lieve vriendjes en vriendinnetjes (van de middelbare school, geneeskundeopleiding en 
baantjes), bedankt voor alle feestjes en vakanties, en dat ik bij jullie mocht uithuilen als ik het 
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zwaar had.
Lieve mama en papa. Zonder jullie steun, vertrouwen en trots was ik nooit zo ver gekomen. 
Ik weet dat ik alles aan jullie te danken heb. Vanaf ik jong ben, stimuleren jullie me om het 
maximale uit het leven te halen. Papa, je bent niet de meest spraakzame, maar je acties 
spreken boekdelen. Bedankt dat je altijd je best doet om mij te helpen met van alles. Mama, je 
hebt een zware periode meegemaakt, maar toch wist je ons constant op de eerste plaats te 
zetten. Ik hoef je niet meer te vertellen dat je de liefste en beste moeder van de wereld bent.
Lieve Rens, net als elk sprookje begint ons verhaal met “Once upon a time…”. Je bent uiteraard 
het beste wat ik heb overgehouden aan het lab. Alhoewel we het vanaf dag 1 al goed met 
elkaar konden vinden, duurde het nog ruim 2 jaar voordat we elkaar echt gevonden hadden. 
Doordat we beiden zo handig zijn op het gebied van liefde, hebben we veel om elkaar 
heen gedraaid. Dat we uiteindelijk samen zijn geëindigd was voor niemand een verrassing, 
behalve voor ons. Het daten van de flowcytometrie-koning had uiteraard zo zijn voordelen. 
Mijn compensatiesettings waren bij elk experiment perfect en mijn gesorte populaties waren 
puurder dan ooit tevoren. Bedankt voor het nog leuker maken van mijn promotieonderzoek, 
voor je geduld en voor het zijn van mijn beste maatje en geliefde tegelijk, my sun and stars. Ik 
hou van je. 
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Abbreviations
(S)AE (Severe) Adverse event
7-AAD 7-aminoactinomycin
ABMR Antibody-mediated rejection
AF647 Alexa Fluor 647
AMR Antibody-mediated rejection
APC Antigen-presenting cell
APC Allophycocyanin
APC-Cy7 Allophycocyanin-Cyanine7
AR Acute rejection
Bcl-6 B-cell lymphoma 6
Bela Belatacept
BENEFIT (study/trial) 
Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial
BKV BK virus
BMI Body mass index
BPAR Biopsy-proven acute rejection
BSc Bachelor of Science
BV Briliant Violet
C0 Pre-dose concentration
C4d Complement factor 4d
CD Cluster of differentiation
CDC Complement-dependent cytotoxicity
CFSE Carboxyfluorescein succinimidyl ester
CMV Cytomegalovirus
CNI Calcineurin inhibitor
CsA Cyclosporin A
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4
CVA Cerebrovascular accident
CXCR5 C-X-C chemokine receptor 5
D-1 One day before transplantation
DC Dendritic cell
DSA Donor-specific anti-human leucoyte antigen antibodies
Dx x days after transplantation
EBV Epstein-Barr virus
eGFR Estimated glomerular filtration rate
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ELISA Enzyme-linked immunosorbent assay
ESRD End-stage renal disease
FACS Fluorescence-activated cell sorting
FITC Fluorescein isothiocyanate
FMO Fluorescence-minus-one
FoxP3 Forkhead box P3
FSC-A Forward scatter area
GrB Granzyme B
Gy Gray
HDL High density lipoproteins
HIGH high-positive
HIV Human immunodeficiency virus
HLA Human leukocyte antigen
HR Hazard ratio
HSV Herpes simplex virus
IC50 Half maximal (50%) inhibitory concentration
ICOS Inducible T cell co-stimulator
ICOSL Inducible T cell co-stimulator ligand
IFN Interferon
Ig Immunoglobulin
IL Interleukin
IL-21-R Interleukin-21 receptor
KT Kidney transplantation
LDL Low density lipoproteins
MCV Mean corpuscular volume
MD Medical Doctor
MFI Median fluorescense intensity
MGUS Monoclonal gammopathy of unknown significance
MLR Mixed lymphocyte reaction
MMF Mycophenolate mofetil
MPA Mycophenolic acid
mTor Mammalian target of rapamycin
Mx x months after transplantation
N/A Not applicable
NR Non-rejector
NULL Negative
PA Pathology
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PBMCs Peripheral blood mononuclear cells
PD-1 Programmed death 1
PD-L1 Programmed death ligand 1
PE Phycoerythrin
PE-Cy7 Phycoerythrin-Cyanine7
PerCP Peridinin chlorophyll
PerCP-Cy5 Peridinin chlorophyll-Cyanine 5.5
PhD Philosophical Doctor
PKH Paul Karl Horan dye
PMA Phorbol 12-myrisate 13-acetate
POS Positive
PRA Panel reactive antibodies
PTDM Post-transplant diabetes mellitus
PTLD Post-transplant lymphoproliferative disease
R Rejector
RCT Randomized controlled trial
SD Standard deviation
SDC Supplemental Digital Content
SE Standard error
SEB Superantigen Staphylococcus aureus antigen B
SPSS Statistical Package for the Social Sciences
SSC-A Sideward scatter area
Tac Tacrolimus
TCM Central-memory T cells
TCMR T-cell mediated rejection
TDM Therapeutic drug monitoring
TEM Effector-memory T cells
TEMRA
End-stage terminally differentiated effector-memory T cells 
expressing CD45RA
Tfh cell Follicular T helper cell
TIA Transient ischemic attack
TN Naïve T cells
TNF Tumor necrosis factor
Treg Regulatory T cell
VZV Varicella zoster virus


